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1.1 BACKGROUND AND OBJECTIVE 
 
What is diabetes? 
According to the Centre for Disease Control and Prevention (CDC), diabetes mellitus (DM) is 
“the condition in which the body does not properly process food for use as energy. (…) The 
pancreas, makes a hormone called insulin to help glucose get into the cells of our bodies. When 
you have diabetes, your body either doesn't make enough insulin or can't use its own insulin as 
well as it should”1.  
However, it should be noted that there are different types of diabetes mellitus and only in one 
of them ageing is a risk factor. Type 1 diabetes mellitus (T1DM) is also known as juvenile-onset 
diabetes, showing symptoms in childhood or early adulthood. It cannot be prevented and its 
prevalence represents 5 – 10% of all diabetes cases (ADA, 2017; NIDDKD, 2013). On the other 
hand, type 2 diabetes mellitus (T2DM) is commonly developed during adulthood, could be 
prevented or delayed with healthy lifestyles and represents 90 – 95% of all DM cases (ADA, 
2017; NIDDKD, 2013). Finally, gestational diabetes develops in 2 to 5% of pregnant women 
and, although gestational diabetes disappears when the baby is born, women who have had 
gestational diabetes are at greater risk of suffering from T2DM in their adulthood (NIDDKD, 
2013).     
Given the high prevalence of T2DM among total diabetes cases and the effect of ageing on its 
prevalence, in this thesis I focus on T2DM. Moreover, around one fourth of the total global 
burden of disease is due to disorders in older people, being 50% of the burden held by high-
income countries (Prince et al., 2015), and diabetes is not an exception (Prince et al., 2015; 
Murray et al., 2012). Older people represent around half of the people with diabetes and diabetes 
prevalence reaches one in every four adults aged 65 years old and above (Soriguer et al., 2012). 
Furthermore, diabetes is one of the largest factors increasing the risk of mortality, morbidity, and 
disability over the world and its economic burden demands new ways to curb diabetes health care 
expenditure (De Lagasnerie et al., 2017).  
                                                          
1 https://www.cdc.gov/media/presskits/aahd/diabetes.pdf. 
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Cost of illness (COI) and Burden of disease (BOD) studies 
Costs-of-illness (COI) studies are widespread in health economics. Their aim is to provide 
estimates about the economic burden that any disease might impose on the society (Drummond 
et al., 2015). COI studies assess the financial burden due to the corresponding condition, 
including direct and indirect expenditures that result from premature mortality, disability or injury 
(Jo, 2014; Larg and Moss, 2011). Costs might refer to the hospital costs, which in most countries 
are one of the most important types of costs (Carey, 2014), but also other cost components 
including visits to physicians and nurses, drug costs, and visits to the Emergency Room (Oliva et 
al., 2004). These costs would be called healthcare direct costs, that is, medical expenditures 
derived from diagnosis, treatment, and rehabilitation. Other direct costs, but non-healthcare 
related, might also be taken into account, such as transportation or informal care. However, COI 
studies can also refer to indirect medical costs and indirect non-medical costs, which mainly 
consist of productivity losses (Neumann et al., 2016). Productivity losses involve both the 
reduction of work productivity due to the disease and the complete cessation of work due to the 
disease-specific disability or mortality, supported by the individual, the family, the society as a 
whole or by the employer.    
True knowledge about COI is of help to implement healthcare programs and interventions 
and eventually allocate health care resources subject to budget constraints to achieve efficiency 
(Jo, 2014). COI results are useful for several reasons. Firstly, they can serve as an argument to 
inform policies on a specific disease and its related complications (Larg and Moss, 2011), which 
should be given a high priority in a policy agenda setting in light of the estimates obtained (Jo, 
2014). Secondly, they might be of help to identify target populations who could be subject to 
specific problems and policies (Drummond et al., 2015). Thirdly, their results could be used to 
determine the efficacy of any health intervention designed to reduce or eradicate the disease 
effects (Jo, 2014; Larg and Moss, 2011).  
Burden of Disease (BOD) studies focus instead on the burden of a particular disease on the 
years of life lost (YLL) due to premature death, and the years lost due to disability (YLD). These 
two categories lead to another measure, Disability-Adjusted Life Years (DALYs), which involves 
health losses resulting from premature death or disability, probably leading to larger healthcare 
costs and forgone economic or societal contribution (Jo, 2014). Those studies include analyses on 
the incidence or prevalence of a specific disease and its impact on longevity, morbidity as well as 
its effect on health status and quality of life (Jefferson et al., 2000). 
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In this thesis, I aim to assess the economic and wellbeing-related consequences of diabetes 
among older adults, looking at both direct medical (total care costs and nursing home costs) and 
indirect costs (reduction of productive activities and quality of life). 
 
Diabetes and COI / BOD studies 
Burden of Diabetes has been ranked as the seventh and eighth cause of YLL and DALYs 
respectively in Western Societies (Murray and López, 2013) and the 14th cause all over the world 
in the ranking of causes of DALYs (Murray et al., 2012), accounting for 1.9% of total DALYs 
and with an increase of more than 60% in 2010 as compared with the data obtained in 1990.  
Direct medical costs derived from diabetes represent $116 billion per year (30% of Medicare 
budget in 2007) for the US government, assessing an average expenditure per capita and per year 
for an elderly patient between $3,407 for the most-conservative estimate and $9,713 for the least 
conservative one (Anderson, 2012). The literature has already found that, for the particular case 
of diabetes in eight European countries (Belgium, France, Germany, Italy, the Netherlands, 
Spain, Sweden and the United Kingdom), the direct healthcare costs associated to hospitalization 
explain around 55% of the total costs, whereas drugs explain 30% (Jönsson, 2002). Other studies 
such as the United Kingdom Prospective Diabetes Study (UKPDS) (Alva et al., 2015) and the 
Australian work carried out by Clarke et al. (2008) have also estimated the associated costs of 
clinical complications in old patients with diabetes focusing only on inpatient hospital admission 
and primary healthcare services. Both studies show the large impact of diabetes-related 
complications on healthcare costs, not only in the first year after diagnosis, but also in the 
following years. Average glucose control has also emerged as a determinant of higher diabetes-
related costs, whose management has been found to represent more than one quarter of direct 
diabetes-related healthcare costs (Köster et al., 2014) and to avoid costs in the short and long run 
after sustained control (Baxter et al., 2016). Diabetes among older people also increases the risk 
to be institutionalized. Diabetes has been found to be significantly associated with nursing home 
placement among the frail elderly and, furthermore, older people with diabetes are 1.8 times 
more likely to be institutionalized (Matsuzawa et al., 2010). Around 30-35% of institutionalized 
older people have diabetes (Newton et al., 2013). 
Moreover, some researchers have also looked at the impact of diabetes on indirect costs. With 
respect to productivity losses, diabetes has been found to significantly reduce productivity, 
(ADA, 2013; Hex et al., 2012; Tunceli et al., 2005), even forcing an early labour-force exit 
(Rumball-Smith et al., 2014; Herquelot et al., 2011; Norlund et al., 2001) and leading to great 
economic losses in people with diabetes (Bolin et al., 2009). For example, in Spain, the total cost 
of productivity loss due to diabetes was projected to be €2.8 billion in 2009 (López-Bastida et al., 
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2013) and to account for a total of 154,214 days due to temporary disability generated by diabetes 
and its complications in 2011 (Vicente-Herrero et al., 2013).  
The existing literature has also supported the negative impact that diabetes has on quality of 
life (Vadyia et al., 2015; Schunck et al., 2012; Papadopoulos et al., 2007; Rubin and Peyrot, 1999), 
being consistent across health-related quality of life (HRQoL) instruments (Kontodimopoulos et 
al., 2012; Fu et al., 2011), signalling the relevance of micro and macrovascular diseases 
(Javanbakht et al., 2012; Redekop et al., 2002). Some authors actually state that the quality of life 
in people with diabetes worsens due to complications and not due to diabetes itself 
(Venkataraman et al., 2013).  
However, the studies aforementioned lack another component which should be part of the 
economic analyses in older people: functional status. Functional status is defined as the 
individual’s ability to perform activities of daily life, including self-care and household and 
physical activities, in order to maintain individual’s health and wellbeing (Leidy, 1994). Functional 
status is one of the most important components in determining the use of health-care systems 
(Weiss, 2011) and the annual healthcare costs in older populations (Lubitz et al., 2003), which 
increase in near three folds in people with any limitation in Activities of Daily Living (ADL) 
compared to those who remain independent. Moreover, diabetes has an increasing negative effect 
on functional autonomy as people become older (Wong et al., 2013; Kalyani et al., 2010), 
switching from the traditional focus of living longer without life-threatening complications to 
extending remaining years lived free from disability (Sinclair et al., 2015).  
 
Why this thesis? 
Although it has already been established that the economic burden of diabetes on national 
healthcare services and public expenditures is quite large (OECD/EU, 2016; Alva et al., 2015; 
ADA, 2013), as far as I am concerned, there are no relevant and comprehensive studies about the 
broader economic impact of diabetes among older adults, paying special attention to the role of 
functional status. The current defiance embraces methodological issues on how to analyse health 
costs (Wu et al., 2012), or the weight of functional impairment versus comorbidity and 
complications in the determination of the costs.  
The scenario for the next decades shows an increase in the costs associated with the 
management of people with diabetes due to the ageing of the population and the higher costs per 
capita among older adults (Waldeyer et al., 2013). Those increasing costs constitute a new 
challenge for the Health Systems that should implement models of care tailored to the needs of 
this population (Sinclair et al., 2011).  
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This thesis aims to contribute to the existing literature by bringing a new and broader insight 
on the diabetes burden among older populations by not only examining the traditional healthcare 
resource use and costs associated with diabetes in older people (costs of care for people with 
diabetes), but also other costs less frequently evaluated, such as nursing home expenditures, and 
the impact of diabetes on quality of life and productive activities. Additionally, I build on the 
existing literature by including in the analysis not only the clinical complications that might be 
suffered at the same time and due to diabetes, but also functional impairment. Diabetes has an 
increasing negative effect on functional autonomy as people become older (Wong et al., 2013; 
Kalyani et al., 2010;), having been ranked as the eighth cause of DALYs in Western societies 
(Murray and López, 2013). Moreover, I use a variety of datasets in this thesis: administrative 
(Vektis and ZODIAC data in Chapter 2) and survey datasets (the Survey of Health, Ageing and 
Retirement in Europe, SHARE, in Chapters 3 and 4; and the Toledo Study on Healthy Ageing, 
TSHA, in Chapter 5), which allow me to explore different sources of information (claims, clinical 
and self-reported data) on individuals living in different institutional settings.  
In the following section, I provide a description of the chapters that are part of my thesis and 
the specific objectives which I aim to analyse. 
 
1.2 SUMMARY AND MAIN FINDINGS 
In Chapter 2, I use Dutch claims data (Vektis) combined with a Dutch GP registry dataset 
(ZODIAC) to examine the association between average glucose control and care costs incurred 
by people with diabetes, but not necessarily due to diabetes. I additionally explore the diabetes 
diagnosis cohort effects and treatment modality. I also distinguish by cost type (total care, 
General Practitioner (GP), drugs, hospital and specialist, and devices costs). Data has been taken 
from those two linked datasets, which allows me to use administrative data on all medical 
treatments reimbursed by Dutch insurance companies within the mandatory insurance package 
and clinical measurements for a four-year time period window (2008 – 2011).  
The results show that average glucose control is significantly associated with higher care costs 
in people with diabetes, although its impact on costs is mediated by diabetes treatment modality. 
When I include oral medication and insulin as diabetes treatment variables, a 1% higher HbA1c is 
significantly associated with an increase in total care costs only if the individual is not being 
treated with insulin nor with oral medication; no significant effect of HbA1c is reported when the 
person takes oral medication or uses insulin. However, insulin does report a significant 
association with higher care costs, regardless of the covariates part of the analysis. Another 
important finding is that the positive effect of diabetes duration on care costs increases when I 
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control for year of diabetes onset cohort effects. Actually, without including cohort effects, total 
costs will increase up to a diabetes duration of 25 years and will decrease afterwards, but, when I 
include year of onset categories, the threshold at which care costs start decreasing is after 35 years 
of diabetes duration. McBrien et al. (2012) concluded that healthcare costs in people with 
diabetes always increase with time since diagnosis after the first five years, as I do, but I do find 
that the increase in costs will have a decreasing effect after 35 years lived with diabetes, which has 
not been previously reported in the literature. Lastly, correcting for treatment modality, diabetes 
duration and year of onset cohorts has led to another innovative result: age is not significantly 
related to care costs, which has traditionally been linked to increasing care costs (Trogdon and 
Hylands, 2008; Nichols and Brown, 2002). I not only look at the impact of average glucose 
control on care costs incurred by people with diabetes, but also at treatment modality, diabetes 
duration and year of onset effects, which have not been jointly assessed before. Excluding these 
factors could lead to biased estimates.  
 Chapter 3 addresses the role of diabetes and a list of clinical and functional complications on 
the probability of nursing home admission in people older than 50 years old using data from the 
Survey of Health, Ageing and Retirement in Europe (SHARE). I take data for three different 
waves: wave 1 (2004), wave 2 (2006-07) and wave 4 (2010); and twelve countries (Austria, 
Belgium, Czech Republic, Denmark, France, Germany, Greece, Italy, The Netherlands, Spain, 
Sweden and Switzerland). Moreover, I aim to analyze whether there are differences across 
European countries and other subgroups of analysis (by age or gender and by length of stay), in 
the association between nursing home placement and the main variables of interest. After 
obtaining these results, the estimates will be used to assess nursing home expenditures 
attributable to diabetes and its complications in Europe and to explore potential differences 
between European countries.  
My results confirm that diabetes is positive and significantly associated with nursing home 
placement. Diabetes increases the risk of institutionalization, although its effect decreases when 
diabetes-related clinical complications are included and especially when functional status is 
introduced. The effect of diabetes is consequently mediated by clinical and functional 
complications, reducing the impact of diabetes on the probability of being admitted to a nursing 
home. Moreover, the effect of functional impairment on the risk of institutionalization is age-
dependent, increasing the risk of nursing home placement as people become older. Total average 
nursing home costs reached $12.66 per capita over all countries, representing the several degrees 
of functional impairment 78% of the costs attributed to complications.  
Introduction 
Page | 7  
 
Although in the overall sample no interaction between diabetes and complications are 
significant, some differences across countries are indeed reported. In Belgium, France and 
Greece, diabetes and stroke are significantly related to the risk of institutionalization, whereas 
diabetes together with functional impairment rises the likelihood of being admitted to a nursing 
home in Spain. The Netherlands is the top country in nursing home expenditure for people with 
diabetes, from which more than 25% are due to mild functional impairment. The substantial 
character of functional status is also confirmed across countries, representing the greatest 
proportion of costs, especially in Spain, The Netherlands and Germany, usually followed by 
stroke. Additionally, when institutionalization costs are interpreted as percentages of Gross 
Domestic Product (GDP) per capita, Spain is the country where costs strictly attributed to 
diabetes complications show the greatest value as a proportion of GDP per capita, with 
functional impairment bearing the largest burden. The results contribute to the literature by 
showing that functional impairment not only helps to explain part of the cost, but it is the main 
driver of higher nursing home costs. Moreover, it is the first cross-countries analysis looking at 
the burden of diabetes on nursing home use and costs among older Europeans.  
Chapter 4 focuses on the relationship between diabetes and two measures of productive 
activities, being afraid health limits work for older people still in the working age (50 to 65 years 
old) and being a formal volunteer for people aged 65 and above who are already retired. For this 
analysis, I use data from waves 2, 4 and 5, corresponding to the years 2006/07, 2010 and 2013, 
respectively, and eleven European countries (Austria, Belgium, Czech Republic, Denmark, 
France, Germany, Italy, The Netherlands, Spain, Sweden and Switzerland) from SHARE. 
Observing the trends among that period could shed more light on how relevant health is with 
respect to productivity in periods of economic uncertainty. I additionally control for clinical and 
functional complications, as the effect of diabetes is generally mediated by its comorbidities.  
I show that diabetes is associated with productive activities in older adults, both paid and non-
paid. Diabetes increases the likelihood of people aged 50 to 65 years old reporting being afraid 
health limits work, suggesting a positive relationship between diabetes and the fear of health 
limiting work in people still in the working age. The fear of health limiting work increases during 
the years after the crisis, 2010 and 2013, compared to the year 2006, even after including clinical 
complications. This could reflect the increased uncertainty of the employment situation after the 
economic crisis. Moreover, the probability of being afraid health limits work significantly 
increases with the interaction between diabetes and year 2010, but no significant effects are found 
for the interaction with the year 2013. This result might be driven by the combination of the 
impairing effect of diabetes together with the fact that the economic crisis hit stronger in the 
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early years of the crisis, leading to a greater fear of health limiting the individual´s performance at 
work. With respect to volunteering engagement in people older than 65 years old, diabetes 
reduces the likelihood of doing charity work in comparison to those people without diabetes, as 
well as the frequency of carrying out such activity. Year 2010 increases the probability of doing 
charity work in a larger degree than in year 2013. The rationale behind such increase might be 
greater solidarity or greater need for charity work rather than the individual willingness to be 
productive. The interactions between having diabetes and years 2010 and 2013 are not significant 
predictors of volunteering. Moreover, some differences are observed across countries. Only in 
Denmark, a positive, but not significant, effect is reported in the association with the likelihood 
of being afraid health limited work, whereas a significant and negative relationship between Italy, 
Spain, Austria, Sweden and the Czech Republic and volunteering is shown. The results would 
contribute to the existing literature in several ways. Firstly, by filling the gap on non-paid 
activities among older people, as much has been written about productivity losses and wages in 
people with diabetes, but little is known about the relationship with volunteering. Secondly, I 
additionally control for clinical complications and mobility problems, and not only for diabetes as 
the main clinical factor. Finally, I have also assessed the influence of uncertain economic periods, 
which has not been done before, suggesting that there might be an effect of uncertain economic 
situations on both subjective (fear of health limiting work) and objective (volunteering 
participation) productivity measures.  
In Chapter 5, the aim is to build on the existing literature on Health-Related Quality of Life 
(HRQoL) and diabetes by analysing the relationship between some factors that could determine 
the differences in HRQoL among older people with and without diabetes, adding not only the 
clinical complications, but also the frailty syndrome, which worsens as age increases and leads to 
higher risk of disability, hospitalization and mortality, as a measure of functional impairment. The 
analysis is run using data from the first two waves, which correspond to the years 2006 – 2009 
(wave 1) and 2011 – 2013 (wave 2) from the Toledo Study on Healthy Ageing (TSHA). 
Moreover, the association between frailty and the number of comorbidities will be jointly 
analysed distinguishing by diabetes status to explore the existing differences between those with 
and without diabetes. 
The results confirm that diabetes is associated with lower quality of life in older people, 
compared to people without diabetes, although its effect decreases when diabetes-related clinical 
complications are included. But, if the different categories of the frailty syndrome (being pre-frail 
and frail) are part of the analysis, diabetes is no longer significantly associated with quality of life. 
Thus, the burden of diabetes on quality of life in older people is mediated by clinical 
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complications, but more importantly by frailty. When I compare the population with diabetes 
with those without diabetes, frailty bears the greatest and more negative impact on quality of life 
in both subsamples. Differences between both groups are significant, with the conditions 
included in the analysis showing a greater negative effect on the quality of life of people with 
diabetes than in those without diabetes. The results show that, after frailty, the number of 
diabetes-related conditions lead to greater reductions in quality of life in people with diabetes, 
confirming the detrimental effect of single and multiple complications on quality of life. When 
looking at the joint effect of chronic conditions and frailty, in case of people with diabetes and 
being frail, having four diabetes-related conditions reduces quality of life the most. Quality of life 
in people without diabetes is reduced the most when three non-diabetes-related chronic 
conditions are given jointly to pre-frailty. These figures could provide a valuable contribution to 
the existing literature since it is the first analysis looking at the burden of diabetes on quality of 
life in old people analyzing the impact of a list of chronic conditions, additionally comparing 
people with and without diabetes. It is also pioneer in including the frailty syndrome as one of 
the factors involved in predicting HRQoL scores, which emerges as the main mediator of the 
negative burden of diabetes on the outcome.  
 
1.3 POLICY RECOMMENDATIONS 
The above results are relevant for public policymakers and other decision makers that provide 
the society with diabetes prevention and management guidelines, as well as the introduction of 
new treatments for the disease. I will now consider the policy recommendations that follow from 
the results that have been obtained. 
 
The key influence of functional status when estimating cost of illness in ageing populations 
The main implication driven from this thesis is that the burden of diabetes among older adults 
is especially mediated by functional status. It is noteworthy that functional status not only helps 
to explain the associations between diabetes and the different outcomes studied in the thesis 
(productive activities, nursing home cost and quality of life), but it is the main one. Actually, the 
results from chapter 3 show that the relationship between functional status and healthcare use is 
age-dependent, as it is clearly shown in people older than 65, but not so evident in people with 
ages ranging from 50 to 65 years old. It has already been reported in the literature that functional 
status is one of the most important components determining the use of health-care systems 
(Weiss, 2011) and the annual healthcare costs in older people (Lubitz et al., 2003). However, no 
study has been found including functional status when assessing the economic impact of chronic 
diseases among older populations, controlling for clinical conditions.  
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Previous figures about the costs attributable to diabetes among older populations could be 
overestimating the impact of some other comorbidities that have traditionally been linked to 
diabetes, such as cerebrovascular diseases, when not controlling for functional status. 
Policymakers would have had the wrong focus when informing policies and diabetes guidelines, 
since the main surrogate of increasing costs is functional status. Even though my thesis focuses 
on one single disease, diabetes, the relevance of functional impairment among older people 
should be taken into account when measuring and evaluating the healthcare needs in this 
particular group of the population, as well as its impact on indirect costs.  
 
The scope of diabetes treatment and management among older people 
The results from this thesis suggest that the scope of diabetes treatment and management 
among older individuals should be focused on modifiable factors (diabetes treatment and average 
glucose control), but especially on the factors that lead to disability, such as functional 
impairment. Older people with a longer diabetes duration might be in need for different and 
more costly treatment, such as insulin, and at a higher risk of developing disability, as it has 
already been reported in the literature (Huang et al., 2011; Stolar, 2010). An in-depth analysis of 
those  factors could lead to the implementation of cost saving policies.  
 
Data collection, availability and suitability 
The findings presented from the third, fourth and fifth chapters show that functional status is 
a relevant variable to be considered when studying older people. However, and as it has been 
shown in Chapter 2, such information is not frequently available. Hence, I propose to collect 
more specific data covering the particularities of ageing populations and making them publicly 
accessible to researchers. Some measure of functional impairment (if not frailty status, limitations 
in the activities of daily living) should be collected in addition to chronic conditions. 
Chapter 2 also highlights the relevance of combining different datasets, as it has been 
supported that using claims administrative data reduces biases probably found in other data 
sources (self-reported data) and allowed access to laboratory, clinical and costs registries data. 
Reliable estimations on care costs per patient would then be provided to policymakers.  
 
Promote a healthy and active ageing 
Two measures of indirect costs, quality of life and productive activities, have been assessed in 
this thesis. My results show that in those aged 65 and above, diabetes reduces the likelihood of 
performing volunteering work in comparison to those people without diabetes, as well as the 
frequency of carrying out such activity. In spite of being non-paid productive activities, it might 
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be one way for older people to feel fruitful (Rumball-Smith et al., 2014; Hank, 2011). Their 
engagement into those activities report positive outcomes to them and to the society as a whole, 
so volunteering should be promoted to support a healthy and active ageing.  
Chapter 5 shows that diabetes is associated with a reduction in quality of life in people aged 65 
years old and above, although its effect is mainly mediated by functional status. Through 
prevention of chronic diseases, as it is diabetes, and prevention of disability would avoid quality 
of life losses due to these conditions, leading to a healthy ageing process.  










COSTS OF CARE IN PEOPLE WITH DIABETES IN RELATION TO 
AVERAGE GLUCOSE CONTROL:  AN EMPIRICAL APPROACH 




The number of adults with diabetes has substantially increased (OECD/EU, 2016; NCD Risk 
Factor Collaboration, 2016), affecting 4.3% and 5% of the men and women adult populations in 
1980 and getting to 9% and 7.9%, respectively, in 2014 (NCD Risk Factor Collaboration, 2016). 
In case of the Netherlands, diabetes prevalence has recently been estimated to be 5.45% 
(Kleefstra et al., 2016), and 5.13% specifically for type 2 diabetes. The substantial increase in the 
number of adults suffering from diabetes can largely be attributed to the effects of adverse 
lifestyle, the population growth and ageing and the joint effects of these factors together (NCD 
Risk Factor Collaboration, 2016; Wild et al., 2004).  
The increase in diabetes prevalence will be accompanied by an increase in diabetes-related care 
costs (OECD/EU, 2016). Diabetes expenditure in 2010 was estimated to represent, on average, 
12% among the total world health spending (1,330 US dollars per person with diabetes), with a 
considerable variation in per capita spending between countries. The average total care cost per 
Dutch individual with diabetes reached 4,000$ (Zhang et al., 2010). Moreover, those figures were 
projected to increase by 30/34% by the year 2030.  
It has already been stated in the literature that in many countries medical costs in people with 
diabetes are three times greater than in individuals without diabetes (Clarke et al., 2010), 35 – 
40% of the total care costs being due to the management of clinical complications, mainly 
cardiovascular diseases, and hospitalization costs (Bruno et al., 2008). The risk for developing 
both micro and macrovascular complications is – amongst others - associated with the degree of 
long-term glycaemic control (Huang et al., 2011; Stolar, 2010). Hence, one might expect worse 
                                                          
2 This chapter uses data from two linked datasets, Vektis and ZODIAC, for the years 2008, 2009, 2010 and 2011. 
The author would like to thank Chantal van Tilburg and Mirte van Galen for their help with the data.  
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glycaemic control to also be associated with increased care costs (Degli Esposti et al., 2013; 
Shetty et al., 2005). A 1% (1 mmol/mol) lower HbA1c level has been found to be associated with 
a 37% reduction in the prevalence of microvascular complications (Stratton et al., 2000), showing 
an association between microvascular complications, HbA1c and care costs (Gilmer et al., 2005). 
These costs might be not too outspoken, since major care costs are driven by macrovascular 
complications (Herman, 2011), which are not only related to glycaemic control, but also to blood 
pressure, cholesterol, smoking and other risk factors (Lorber, 2014). Still, impaired glucose 
tolerance has been found to increase the mortality risk due to cardiovascular diseases (Huang et 
al., 2011). Hence, an appropriate management of diabetes and glycaemic control might reduce the 
risk of developing complications and mortality, and thus limit the rise in spending on diabetes 
care (Shetty et al., 2005). Intensive glycaemic control programs have been found to be very cost-
effective in the literature (Liebl et al., 2015; Li et al., 2010; Herman et al., 2005), leading to £258 
cost reduction per patient with diabetes in the United Kingdom (Clarke et al., 2001). This was, 
however, mainly in populations with years of onset in the 1990s and may have changed for recent 
cohorts that were treated more intensively to begin with. 
Most of the available studies measuring the economic impact of glycaemic control place their 
focus on the long-term savings and lifetime medical costs (Zhuo et al., 2013), but less evidence 
has been found analysing the short-term burden of glycaemic management on care costs in 
people with diabetes. Degli Esposti et al. (2013) used data from Italian clinical and administrative 
registries on 21,586 people with diabetes to analyse the two-year diabetes-related costs according 
to their glycaemic level. People were classified into five categories according to target HbA1c 
(HbA1c ≤ 7%) values achieved: excellent (≥80%), good (60%–79%), fair (40%–59%), poor 
(20%–39%), and very poor (<20%). Authors found that costs for those with good glycaemic 
control increased mean 2-year total costs by 219.28€ compared to those with excellent HbA1c 
levels. Similarly, McBrien et al. (2012) concluded that costs for those Canadians with diabetes and 
with poor glycaemic control increased mean 5-year total costs by 1,623$ compared to those with 
good HbA1c levels. Higher costs of people with glycaemic levels above target (HbA1c level > 
7%) compared to those within target have previously been reported (Menzin et al., 2010; Shetty 
et al., 2005). These costs were larger when the individual had comorbidities. 
Diabetes duration seems to be highly related to increasing healthcare costs due to several 
reasons. Some researchers have analysed the differences in care costs according to time since 
diabetes diagnosis, stating that each additional year with diabetes increases annual medical 
expenditures by $75, when controlling for diabetes complications (Trogdon and Hylands, 2008). 
However, such increasing trend in medical care costs might be observed only after the first four 
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years of diagnosis, as some authors have already reported (Nichols and Brown, 2002). Costs were 
found to be higher during the year immediately after diagnosis. Thereafter, costs followed a U-
shaped trajectory, dropping during the first years after diagnosis, and then rising again. First of 
all, diabetes increases healthcare costs given its associated risk of developing several chronic 
conditions over time or due to the poor or incomplete control of diabetes-complications 
(Trogdon and Hylands, 2008). Secondly, glucose levels control might become more difficult over 
time (Turner et al., 1999), possibly needing multiple treatments in the long-term in order to 
achieve target glucose levels.  
However, as far as I know, no study has been found assessing the impact of glycaemic control 
on diabetes care costs by diabetes duration cohort. By assessing the diabetes onset cohort effects, 
I could infer whether there is any pattern by time of diabetes onset in care costs and how the 
cohort effects impact the associations between diabetes duration and care costs, as well as 
average glucose control and total costs.    
Hence, this study contributes to the existing literature by estimating the impact of average 
glucose control on total care costs in people with T2DM, not necessarily diabetes-related care 
costs, i) additionally controlling for diabetes treatment, as drug therapy for glycaemic control 
represents 18% of the total cost (Liebl et al., 2015) and treatment modality modifies the mean 
glucose level (Booz&Co, 2011); ii) adding diabetes duration and year of diabetes onset effects, 
which have not been jointly analysed before, by exploiting the iii) panel feature of the data. For 
doing so, I will use administrative data from the national Dutch insurance dataset on healthcare 
use and care costs incurred by people with diabetes and linked data on clinical measurements 
from ZODIAC dataset, for a four-year time period window, from the year 2008 to the year 2011. 
I will also include a list of registered clinical diagnoses in the analyses.  
In summary, I find that the effects of glucose level on total care costs is mediated by the 
treatment modality, especially in case of insulin use. Moreover, I show that if I don´t control for 
year of onset effects, different and inconsistent estimates of the duration effect are obtained.  
The chapter is structured as follows. Section 2.2 presents the data that has been used, the 
variables selected for the analysis and the empirical approach that has been followed. Section 2.3 
shows the results from the performed analyses. Section 2.4 discusses the findings, comparing 
them with the existing literature, suggesting some policy implications and mentioning the 
limitations of the study. 
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2.2 DATA AND METHODS 
2.2.1 Data 
Two datasets have been linked, Vektis and Zodiac databases, for the purpose of the study 
(Hendriks and Bilo, 2017). Vektis contains reimbursement data on all medical treatments paid for 
by Dutch insurance companies within the mandatory insurance package, including the costs for 
compulsory deductibles (Mohnen et al., 2015). Zodiac includes clinical data on subjects who were 
included in the Zwolle Outpatient Diabetes Project Integrating Available Care (ZODIAC) study, 
which started in 1998. 
 
Vektis dataset  
Vektis, the national insurance dataset on healthcare use, is an information system for 
healthcare use and costs data in the Netherlands. Individual claims data are available, categorized 
at various levels of detail. For the current study, claims were aggregated to annual care costs and 
into categories by expenditure type, such as hospitalization, specialist medical care, drugs, general 
practitioners, devices and others (obstetrics, maternity, paramedical care, dentistry, hospital 
transport, mental care and abroad costs). The Vektis database was established according to the 
Health Insurance Act implemented in 2006 (Ministry of Health, Welfare and Sport, 2012). 
Further individual information is available (year of birth and gender, socioeconomic status (SES), 
GP code, year of death) and taken from Vektis data.  
 
ZODIAC dataset 
ZODIAC data collection process started in 1998 as a prospective observational study 
examining the effect of shared care in people with type 2 diabetes mellitus in Zwolle, a city in the 
north-eastern region of the Netherlands. This shared care initiative became the standard care for 
the Zwolle region in 2002 and expanded to other regions in the Netherlands in later years, the 
extent of which has already been described elsewhere (Hendriks et al., 2015). General 
Practitioners (GPs) provide data on an annual basis to the Diabetes Centre. In 1998, 53 GPs were 
part of the project; during the years and for the sample included in the analysis, the amount of 
participating GPs increases from 317 in 2008 to 335 in 2011. ZODIAC contains all the 
information routinely gathered by GPs, as well as routine laboratory measurements.  
Clinical measurements and other sociodemographic information (ethnicity), healthy lifestyle 
factors and prevalence of selected chronic conditions according to ICPC coding, are used from 
the ZODIAC dataset in this analysis. These will be described in the following section. Table 2.A1 
in the Appendix provides a detailed description of the variables used in the analysis.  
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For the current study, data of all patients participating from year 2008 to 2011 in the Zodiac 
data were linked to the Vektis dataset to identify the healthcare costs of those patients. Linkage 
on patient level between data from the ZODIAC cohort and from Vektis was performed using 
the unique citizen service number or unique Insurance number. The privacy of all patients was 
assured by using a trusted third party (ZorgTTP) to combine the data and, subsequently, encrypt 
the personal identity number, thus creating a database with detailed information, which could not 
be traced to a known individual. 
After linkage between both datasets, 211,484 observations were merged. Selecting only the 
individuals with complete follow-up over the period 2008 – 2011, no missing value in any of the 
variables which are part of the analysis and still alive in 2011, further reduced the sample to 
22,612 observations3, grouped in 5,653 individuals. 
 
2.2.2 Variables description 
Dependent variable: care costs 
Total care costs incurred by people with diabetes, but not necessarily related to diabetes, are 
taken for the years 2008, 2009, 2010 and 2011. Those costs have been inflated or deflated, as 
appropriate, to 2010 euros, using the Consumer Price Index (CPI) found in Statistics 
Netherlands4. Costs that have not been included are uninsured care (i.e. informal care), as well as 
care from any additional insurance (extra number of treatments not covered by the insurance 
policy).   
Table 2.1 shows the distribution of total care costs incurred by people with diabetes and the 
different costs components. On average, the most important cost components are hospital and 
specialist costs and drugs costs. The number of zeros in the cost items is very small, even in 
hospital costs, with one exception: devices costs. More than half of the individuals report no 
devices costs. The distribution of all cost items is right-skewed, all of them having their mean 
above the median (p50), with some differences in the skewness across costs components. 
Hospital and specialist costs are more skewed than GP costs. The mean of the former is higher 
than the costs claimed by more than 75% (p75) of the sample, whereas in the latter, the mean 
cost of the overall sample is above the mean cost for the 50% of the sample, but below the 75%. 
This provides statistical reasons to formulate the models in terms of the logarithmic variable 
                                                          
3 From the 211,484 initial observations, 42,770 were dropped as duplicates, leading to 168,714 remaining 
observations. From these, 80,544 were further removed as they had missing data in any of the variables used in the 
analysis, leaving 88,170 observations. Then, additional 11,973 and 53,585 observations were dropped due to being 
extreme values and non being present in the four years of analysis, respectively. This would then lead to the final 
sample of 22,612 observations.   
4 Inflate the 2008 costs to 2009 costs by multiplying them times 1.012 and then the 2009 costs to 2010 costs by 
multiplying by 1.013. 2011 costs were deflated to 2010 prices by multiplying the 2010 cost data times 0.9775. 
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instead of its original form, so the data distribution approximately follows a normal distribution. 
Regression models with the natural logarithm form also have an attractive economic 
interpretation as they will measure the relative increase in spending due to changes in the 
explanatory variables. Economists are often more interested in such relative effects than in 
absolute effects. Then, since the logarithmic transformation may also reduce heteroscedasticity 
(Heij et al., 2004), I use the natural logarithm of total care costs generated by people with type 2 
diabetes mellitus as the main dependent variable.  
Table 2.1 shows that there is still some right-skewness in the logarithm (the mean of the 
logarithm of total care costs, 7.83, is slightly above the median, 7.70), but far less dramatic than 
with the original form.  
Secondary outcomes are the different types of care costs that are included in the dataset, such 
as GP, hospitalization, drugs and devices cost, for which I also use their log-transformed costs as 
the outcome.  
 
Independent variables 
I use information on a set of sociodemographic characteristics (age, gender, ethnicity and 
socioeconomic status (SES)), diabetes duration, type of medication for diabetes (oral medication 
or insulin), a lifestyle factor (smoking status), laboratory and clinical measurements (average 
glucose control, measured by HbA1c in %) and indications of chronic conditions.  
One of the main independent variables of interest in the present analysis is average glucose 
control, measured by HbA1c. It is a continuous variable expressed as a percentage of mmol/mol, 
with 5.7% as the maximum value indicating good HbA1c level in a person without diabetes and 
6.5% in case of having diabetes, according to the American Diabetes Association (ADA, 2017). 
Average glucose control will be adjusted by type of medication reimbursed for treating diabetes, 
which consists of two dichotomous variables, 1) oral medication and 2) insulin, which take value 
1 if the individual is either on diet or using oral medication or if the individual is using insulin, 
respectively, and 0 otherwise. The reason to include the interaction between average glucose 
control and treatment is that HbA1c is the representation of the efforts the individual and the 
healthcare professionals make to reach adequate metabolic control and the underlying disease 
severity. Its outcome is dependent on patient behavior (lifestyle aspects), Body Mass Index 
(BMI), treatment and treatment intensification.  
Diabetes duration cohorts are also generated using the age at diagnosis variable, which was 
registered by GPs in the dataset. I will include the time since diabetes diagnosis, as well as the 
square of diabetes duration to control for its potential decreasing marginal effect.  
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Table 2.1: Distribution of costs, n = 22,612  
 Mean (SD) Number of zeros P1 P5 P10 P25 P50 P75 P90 P95 P99 




0 470.17 677.96 816.82 1,248.36 2,214.55 4,396.38 9,536.25 15,308.57 34,558.11 
Logarithm of total 
care costs 
7.83 (0.96) 0 6.15 6.52 6.71 7.13 7.70 8.39 9.16 9.64 10.45 
GP costs (in 2010€)  
219.61 
(130.01) 
0 72.01 91.38 105.02 135.44 186.12 262.9 373.19 465.97 703.92 
Logarithm of GP 
costs 
5.26 (0.49) 0 4.28 4.52 4.65 4.91 5.23 5.57 5.92 6.14 6.56 
Drugs costs (in 
2010€)   
1,008.33 
(2,280.29) 
33 53.01 121.25 181.15 345.23 686.24 1,214.63 1,964.17 2,577.1 4,642.47 
Logarithm of drugs 
costs 
6.45 (0.95) 0 4.06 4.81 5.21 5.85 6.53 7.10 7.58 7.85 8.44 
Hospitalization 
costs (in 2010€)  
2,259.23 
(5,758.75) 
198 3.21 36 49.4 139.54 485.87 1,647.02 5,747.85 10,990.69 27,742.84 
Logarithm of 
hospitalization costs 
6.23 (1.78) 0 2.01 3.70 3.98 4.97 6.21 7.42 8.66 9.31 10.23 




11,894 0 0 0 0 0 234.92 752.31 1,271 3,341.89 




1,086 0 0 54 192.5 353.83 385 789.56 1,485 4,061.08 
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Moreover, dummy variables for three-year of diagnosis cohorts are generated to study cohort 
effects by diagnosis of diabetes. Year of diagnosis cohorts could help to explain potential 
variations in diabetes care costs over time among those individuals with shared year of onset. 
In Figure 2.1, I plot the mean of the logarithm of total care costs in the years 2008, 2009, 2010 
and 2011 for each three-year of diabetes onset cohort, represented by each coloured line. 
Assuming that there are no calendar year effects, the vertical difference between cohort lines 
measures the year of diabetes diagnosis cohort effect, whereas the difference along the same line 
exactly measures the diabetes duration effect within a cohort with same year of diabetes 
diagnosis. If the first observation of every cohort is connected, the 2008 cross-sectional 
relationship between care costs and diabetes duration would be obtained. However, it should be 
noticed that it is not possible to disentangle diabetes duration from cohort effects. When the 
cross-sectional feature is considered, the increase in the costs is smaller than when moving along 
the line of every cohort. The figure is consequently suggestive of existing year of onset cohort 
effects. By ignoring year of  diabetes onset effects, the costs- diabetes duration gradient would be 
underestimated.      
 
Figure 2.1: Mean logarithm of total care costs by diabetes duration and cohort 
 
 
The logarithm of total care costs seems to have strongly increased across cohorts up to the 
individuals being diagnosed of diabetes between 1989 and 1991. A jump between three-year of 
onset cohorts for same diabetes duration is observed. The graph indicates that the biggest cohort 
time effect is between the cohort newly diagnosed (diabetes diagnosis between years 2007 to 
2009) and the diabetes onset cohort between 2004 to 2006. The costs in those who are diagnosed 
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in years 2007 – 2009 and with a diabetes duration of four years are higher than in those who have 
been diagnosed between 2004 and 2006 at the same diabetes duration.  
The figure suggests that the diabetes duration-time effect is also large. In particular, the newly-
diagnosed individuals and those who have been diagnosed of diabetes between 1998 and 2000 
and between the years 1995 to 1997 are suspected to have experienced a sizable increase in the 
logarithm of total care costs as the number of years lived with diabetes increases.   
Such differences between year of onset cohorts can also be observed in hospital, drugs 
(although the year of onset effects are rather small, almost negligible for drugs costs, and the 
increase seems to be rather linear) and devices costs (Figure 2.A1, Appendix).  
Figure 2.2 shows a similar picture for HBA1c against duration by year of onset cohort. 
Average glucose control increases with diabetes duration, indicating a poorer control of the 
disease as the number of years lived with the disease is higher. However, the figure does not 
really suggest so clear year of onset effects. Vertical differences in average glucose control by year 
of diabetes diagnosis cohort might also reflect the different need for treatment intensification 
with its associated changes in average glucose control when diabetes duration increases.  
 
Figure 2.2: Average glucose control by year at onset cohorts 
 
 
Chronic conditions are also corrected for in the analysis by means of what are called 
Elixhauser comorbidities. Elixhauser comorbidities allow researchers to classify comorbidities 
according to the International Classification of Diseases (ICD) diagnosis codes (Elixhauser et al., 
1998). Such categorization has been widely used to assess hospital resource use and mortality 
(Menendez et al., 2014; Shaw et al., 2012). The information on chronic conditions was taken 
from the ZODIAC dataset, which did not contain the ICD diagnosis codes but the International 
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Classification of Primary Care (ICPC) codes. The ICPC codes have already been found to be able 
to be linked and, consequently, correspond to ICD codes (Jae-Yong et al., 2016). The list of 
Elixhauser comorbidities included in the current study are: cancer, congestive heart failure, acute 
myocardial infarction, peripheral vascular disease, uncomplicated hypertension, complicated 
hypertension, alcohol abuse, paralysis, stroke, any other cerebrovascular accident, dementia, 
chronic pulmonary disease, retinopathy, neuropathy, hypothyroidism, renal failure, liver disease, 
peptic ulcer, rheumatoid arthritis, weight loss, obesity, anaemia, psychosis and depression. The 
corresponding ICPC codes for each of the conditions have been listed in Table 2.A1, in the 
Appendix.   
Elixhauser comorbidities will be divided into diabetes non-related and diabetes-related 
conditions. Diabetes non-related conditions refer to cancer, alcohol abuse, paralysis, chronic 
pulmonary disease, hypothyroidism, liver disease, peptic ulcer, rheumatoid arthritis, anaemia, 
psychosis and depression. Congestive heart failure, acute myocardial infarction, peripheral 
vascular disease, uncomplicated hypertension, complicated hypertension, stroke, any other 
cerebrovascular accident, dementia, retinopathy, neuropathy, renal failure, weight loss, obesity are 
considered the diabetes-related comorbidities.  
Vektis dataset also contains the identification number of the GP that has treated every patient. 
Dummies for every GP will be added to the analysis as there might be a GP treatment effect, 
being some patients treated more efficiently depending on the GP that they go to. 
Additionally, as lifestyle factors to be part of the analysis, I will include a dichotomous variable 
for those who are currently smoking.  
I also include sociodemographic factors such as age and age-squared to additionally control 
for its potential decreasing marginal effect. For socioeconomic status, the Vektis standard 
categories were applied. SES has been created by Vektis according to postcode characteristics, 
following a normal distribution. Then, three quintiles have been generated: 1 denoting people in 
low socioeconomic status, 2 if medium and 3 in case of high SES. Dummy variables for gender 
and non-Caucasian ethnicity are also included.  
 
2.2.3 Sample characteristics 
Descriptive analyses showing the sample characteristics and by HbA1c5 are made. Continuous 
variables are presented as the mean ± the standard deviation and dichotomous variables as 
percentages. Univariate analyses will be performed to compare the means between groups using 
                                                          
5 According to the American Diabetes Association guidelines (2017), HbA1c levels are at target level if they are equal or below 
6.5%. Hence, three categories of HbA1c levels are set according to HbA1c levels: i) HbA1c ≤ 6.5%; ii) 6.5% < HbA1c ≤ 7.5%; 
and iii) HbA1c > 7.5%, which indicates uncontrolled diabetes. 
Costs of people with diabetes in relation to average glucose control: An empirical approach controlling for year of onset cohorts 
 
Page | 23  
 
the Pearson χ2 test. Characteristics of the whole study population and by average glucose control 
group are shown in Table 2.2.  
The mean total care cost incurred by people with diabetes in the whole sample is €4,361, with 
hospitalization and drugs costs as the main cost components (€2,260 and €1,008, respectively). 
52% of the sample are women, the mean age is 68.38 years old and 0.2% are non-Caucasian. 15% 
are current smokers. The mean diabetes duration is 7.69 years and the average glucose control is, 
on average, 6.77%. 85% of the sample take oral medication as their diabetes treatment, whereas 
15% use insulin. With respect to health conditions, the most prevalent conditions are 
uncomplicated hypertension, stroke and acute myocardial infarction, whose prevalence are 
10.7%, 9% and 1.4%, respectively. 
Table 2.2 suggests that there are some differences across average glucose control categories. 
Care costs are higher for those with HbA1c above 7.5% (€4,913) and HbA1c ≤ 6.5% (€4,394), 
compared to the subjects with HbA1c between 6.5% and 7.5% (€4,160). Hospitalization and 
drugs costs are also the largest costs components across average glucose control categories, 
although some variances are also observed: hospitalization costs are €2,130 in those with HbA1c 
between 6.5 and 7.5%, whereas these increase to €2,303 and €2,538 if average glucose control is 
below or equal to 6.5% and above 7.5%, respectively. With respect to drugs costs, they are 
greater for people with average glucose control up to 6.5% (€1,010) and HbA1c above 7.5% 
(€1,178), compared to individuals with HbA1c between 6.5 and 7.5% (€955). Moreover, people 
with higher average glucose control seem to be more likely to use insulin than people within 
lower average glucose control (39% if HbA1c > 7.5 vs 19% if 6.5 < HbA1c ≤ 7.5 vs 7% if 
HbA1c ≤ 6.5). Time since diabetes diagnosis is longer with higher average glucose control (9.60 
years if HbA1c > 7.5% vs 8.02 if 6.5 < HbA1c ≤ 7.5% vs 6.79 if HbA1c ≤ 6.5%). Health status 
does not seem to significantly differ between average glucose control groups, with some 
exceptions. Uncomplicated hypertension rates drop from 11% in both lower average glucose 
control categories to 9.3% in those individuals with HbA1c above 7.5%. On the contrary, 
retinopathy and stroke prevalence rates increase with average glucose control. In particular, the 
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Table 2.2: Summary statistics for the whole sample and by average glucose control 
Variables 
Whole sample                           
(N = 22,612) 
HbA1c ≤ 6.5%                       
(N = 9,845) 
6.5% < HbA1c ≤ 7.5%2                  
(N = 9,779) 
HbA1c > 7.5%2                        
(N = 2,988) 
Comparison of 
means 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD p-value 
      
Total care costs (in 2010€) 4,361.32 ± 7,173.35 4,393.47 ± 7,737.18 4,160.31 ± 6,517.51 4,913.28 ± 7,262.05 0.001*** 
Logarithm of total care costs 7.83 ± 0.96 7.79 ± 0.98 7.81 ± 0.93 7.98 ± 0.95 0.000*** 
Types of costs      
GP cost (in 2010€)  219.61 ± 130.01 216.20 ± 126.24  219.32 ± 126.90  231.78 ± 150.05  0.000*** 
Drugs cost (in 2010€)   1,008.33 ± 2,280.29 1,010.09 ± 3,147.87 954.61 ± 1,202.50 1,178.31 ± 1,390.12 0.043** 
Hospitalization cost (in 2010€)  2,259.23 ± 5,758.75 2,303.38 ± 5,878.40 2,129.51 ± 5,450.95 2,538.32 ± 6,304.91 0.057* 
Devices cost (in 2010€) 264.67 ± 698.54 218.44 ± 710.30 279.29 ± 691.02 369.16 ± 670.23 0.000*** 
Other cost (in 2010€) 532.01  ± 1,974.05 565.75 ± 2,172.21 503.86 ± 1,928.19 513.00 ± 1,330.72 0.104 
Female 0.52 0.51 0.53 0.53 0.053* 
Age (in years) 68.38 ± 10.27 68.18 ± 10.11 68.49 ± 10.25 68.71 ± 10.85 0.081* 
Non-Caucasian ethnicity   0.002 0.001 0.003 0.003 0.177 
Socioeconomic Status (SES)     0.088* 
Low 0.33 0.36 0.32 0.33  
Medium 0.34 0.35 0.36 0.38  
High 0.32 0.29 0.31 0.29  
Current smoker  0.15 0.16 0.14 0.14 0.014** 
HbA1c (in %, mmol/mol)  6.77 ± 0.79 6.12 ± 0.33 6.99 ± 0.28 8.19 ± 0.68 - 
Diabetes duration (in years) 7.69 ± 5.31 6.79 ± 4.65 8.02 ± 5.38 9.60 ± 6.39 0.000*** 
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Table 2.2: (continued) 
Variables 
Whole sample                           
(N = 22,612) 
HbA1c ≤ 6.5%                       
(N = 9,845) 
6.5% < HbA1c ≤ 7.5%2                  
(N = 9,779) 
HbA1c > 7.5%2                        
(N = 2,988) 
Comparison of 
means 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD p-value 
Type of medication      
No medication 0.11 0.14 0.10 0.06 0.003*** 
Oral medication 0.85 0.84 0.85 0.86 0.015** 
Insulin 0.16 0.07 0.19 0.39 0.000*** 
Elixhauser comorbidities      
Cancer 0.009 0.009 0.009 0.010 0.512 
Congestive heart failure 0.009 0.008 0.010 0.011 0.060* 
Acute myocardial infarction 0.014 0.013 0.014 0.014 0.624 
Peripheral vascular disease 0.007 0.008 0.008 0.006 0.429 
Hypertension, uncomplicated 0.107 0.109 0.110 0.093 0.033** 
Hypertension, complicated 0.013 0.012 0.013 0.013 0.669 
Alcohol abuse 0.001 0.002 0.001 0.002 0.811 
Paralysis 0.00004 0.0001 0.000 0.000 0.317 
Stroke 0.09 0.082 0.092 0.10 0.041** 
Any other cerebrovascular accident  0.01 0.011 0.009 0.009 0.225 
Dementia 0.002 0.001 0.002 0.002 0.649 
Chronic pulmonary disease 0.002 0.002 0.002 0.002 0.814 
Retinopathy 0.005 0.003 0.006 0.007 0.005*** 
Neuropathy 0.004 0.004 0.004 0.004 0.512 
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Table 2.2: (continued) 
Variables 
Whole sample                           
(N = 22,612) 
HbA1c ≤ 6.5%                       
(N = 9,845) 
6.5% < HbA1c ≤ 7.5%2                  
(N = 9,779) 
HbA1c > 7.5%2                        
(N = 2,988) 
Comparison of 
means 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD p-value 
Hypothyroidism 0.004 0.003 0.004 0.003 0.803 
Renal failure 0.01 0.014 0.014 0.015 0.817 
Liver disease 0.0004 0.0004 0.0005 0.000 0.412 
Peptic ulcer 0.0004 0.0005 0.0003 0.000 0.117 
Rheumatoid arthritis 0.002 0.001 0.002 0.003 0.159 
Weight loss 0.00004 0.0001 0.000 0.000 0.317 
Obesity 0.007 0.005 0.007 0.009 0.022** 
Anaemia 0.004 0.005 0.003 0.007 0.627 
Psychosis  0.0004 0.0005 0.0004 0.0003 0.544 
Depression 0.008 0.008 0.008 0.009 0.665 
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2.2.4 Statistical analyses 
Random-effects linear regression models will be applied to the data to take into account 
individual variation between the four years included in the analysis, allowing time-invariant 
factors to be associated with the outcome. Variation across individuals is assumed to be random 
and uncorrelated with the independent variables (Heij et al., 2004).  
The baseline model with random-effects is as follows: 
log(𝑡𝑜𝑡𝑎𝑙𝑐𝑎𝑟𝑒𝑐𝑜𝑠𝑡𝑖𝑡) =  𝛽1
′𝑆𝐸𝑖𝑡 +  𝛽2𝐻𝑏𝐴1𝑐𝑖𝑡 +  𝛽3𝑠𝑚𝑜𝑘𝑒𝑟𝑖𝑡 + 𝑐𝑖 +  𝑢𝑖𝑡  (1)  
where log(𝑡𝑜𝑡𝑎𝑙𝑐𝑎𝑟𝑒𝑐𝑜𝑠𝑡𝑖𝑡) is a continuous variable that represents the logarithm form of 
the total care costs claimed by individual i with type 2 diabetes mellitus in year t; 𝑆𝐸𝑖𝑡 is a vector 
of explanatory variables referring to age and its quadratic form, gender, ethnicity and 
socioeconomic status categories; 𝐻𝑏𝐴1𝑐𝑖𝑡 denotes a continuous variable referring to average 
glucose control measured in HbA1c, in %; 𝑠𝑚𝑜𝑘𝑒𝑟𝑖𝑡 refers to the fact of being a current smoker. 
𝑐𝑖 represents the random effects term, where the conditional mean of the random-effects is 
independent of the independent variables. 𝑢𝑖𝑡 denotes the idiosyncratic error term.  
In a second regression model, dummy variables for each treatment modality (oral medication 
and insulin) and the interactions between HbA1c categories and treatment are included.  
As I am also interested in evaluating the impact of time since diabetes diagnosis, the diabetes 
duration and its square will be added in a third regression model. A fourth model will also include 
the dummies for the three-year of diabetes onset cohorts. GP dummies will be added in a 
subsequent model to control for any potential GP efficiency treatment. If the GP dummies are 
jointly significant, I could infer that some GPs might treat patients more efficiently than others. 
The full model with random-effects has the following form: 
log(𝑡𝑜𝑡𝑎𝑙𝑐𝑎𝑟𝑒𝑐𝑜𝑠𝑡𝑖𝑡)
=  𝛽1
′𝑆𝐸𝑖𝑡 +  𝛽2𝐻𝑏𝐴1𝑐𝑖𝑡 +  𝛽3𝑠𝑚𝑜𝑘𝑒𝑟𝑖𝑡
+ 𝛽4
′𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖𝑡 +  𝛽2𝛽4
′(𝐻𝑏𝐴1𝑐𝑖𝑡 ∗ 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖𝑡) +  𝛽5𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑑𝑢𝑟𝑖𝑡
+  𝛽6𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑑𝑢𝑟𝑖𝑡
2 +  𝛽′7𝑦𝑒𝑎𝑟𝑜𝑓𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠𝑖𝑡 + 𝛽8
′ 𝐺𝑃𝑖𝑡 +  𝑐𝑖 +  𝑢𝑖𝑡   (2)  
 where 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖𝑡 is a vector of treatment variables referring to both dichotomous 
variables oral medication and insulin; 𝐻𝑏𝐴1𝑐𝑖𝑡 ∗ 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡𝑖𝑡 denotes the interaction term 
between average glucose control and treatment modality; 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑑𝑢𝑟𝑖𝑡 and 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑑𝑢𝑟𝑖𝑡
2 
represent the diabetes duration and diabetes duration squared, respectively. 
𝑦𝑒𝑎𝑟𝑜𝑓𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠𝑖𝑡 denotes a vector of three-year of diagnosis cohort dummy variables and 
𝐺𝑃𝑖𝑡  the vector of GP identification code dummies.  
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All the statistical analyses have been performed using STATA 14.0 software (Stata 
Corporation, College Station, TX). 
 
Sensitivity analyses6 
To test for the robustness of the results, in the above regression models, clinical complications 
have been excluded. Diabetes non-related comorbidities will be included in a sixth regression 
model and diabetes-related conditions in a seventh model.  
 
By cost component 
Model 5, which is assumed to be the full model, is estimated to assess the relationship 
between the independent variables and the different costs components (GP costs, hospital and 
specialists, and drugs costs). However, in case of devices costs, a new regression model will be 
applied, given the substantial proportion of zeros, which represent around 50% of the whole 
sample (Table 2.1). Two-part models combine a model for the binary response variable, which 
would take value 1 if the individual claims more than zero devices costs and 0 if no devices costs, 
and a model for the outcome variable that is conditioned on the binary response (Farewell et al., 
2017), conditional on having claimed devices costs.   
The first stage defines a dichotomous variable R indicating the regime into which observations 
of the dependent variable y falls (Frondel and Vance, 2011):  
𝑅 = 1, 𝑖𝑓 𝑦∗ = 𝑥1
𝑇𝜏 +  𝜖1 > 0  𝑎𝑛𝑑 𝑅 = 0 , 𝑖𝑓 𝑦
∗ ≤ 0  (3) 
y∗ is a latent variable, vector x1 denotes its determinants, τ is a vector of associated parameters, 
and 𝜖1 is an error term with a standard normal distribution. R = 1 indicates that y > 0, whereas R 
= 0 is equivalent to y = 0.  
After estimating τ using Probit estimation techniques the second stage involves a Generalized 
Linear Model (GLM) witk gamma distribution and log link regression of the parameters β that 
affect the expected value E[y|y > 0] conditional on y > 0, i. e. , R = 1:  
𝐸[𝑦 |𝑅 = 1, 𝑥2] = 𝐸[𝑦|𝑦 > 0, 𝑥2] = 𝑥2
𝑇𝛽 + 𝐸(𝜖2 |𝑌 > 0, 𝑋2)   (4) 
where x2 includes the determinants of the dependent variable y, and 𝜖2  is another error term. 
The expected value of the dependent variable y then consists of two parts, with the first part 
resulting from the first stage (3), 𝑃(𝑦 > 0) =  𝜱(𝒙𝟏
𝑻𝜏), and the second part being the 
conditional expectation E[y|y > 0] from the second stage (4).  
                                                          
6 I have also performed the same regressions including Mundlak terms (Mundlak, 1978) to relax the assumption that 
observed time-varying variables are uncorrelated with the unobserved variables by adding individual-means of 
independent variables that do vary over time within individuals. However, the Mundlak terms included are not 
significant, and the coefficients are quite similar to the ones obtained in the Random-effects linear regression models. 
Hence, results with Mundlak terms are not reported here and will be made available upon request. 
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2.3 RESULTS 
2.3.1 Regression results 
Table 2.3 shows the results obtained from the random-effects linear regression model applied 
to the overall sample. Model 1 includes socioeconomic characteristics (gender, age, ethnicity, 
socioeconomic status), being a current smoker, and average glucose control. Model 2 adds to 
Model 1 the dummy variables for treatment modalities and the interactions between HbA1c and 
type of medication (oral medication or insulin).  Model 3 adds to Model 2 diabetes duration and 
its quadratic form. Model 4 additionally includes to Model 3 the year of diabetes onset groups. 
Model 5 adds to Model 4 dummies for the General Practitioners (GPs).  
The first regression model (Column 1, Table 2.3) shows that a higher 1% HbA1c is 
significantly associated with an increase in total care costs by 2.2.% (p<0.01). Moreover, being a 
woman is related to higher total care costs, which increase by 5.7 percentage points (p<0.01), 
compared to males; as well as increasing age, with an additional year of age being associated with 
an increase in total care costs by 1.74% (p<0.1). Compared to people with high socioeconomic 
status, having low SES is related to greater total costs by 5.94% (p<0.05). Being a current smoker 
is associated with higher care costs by 5.21% (p<0.1).  
However, when the diabetes treatment dummies and the interactions between diabetes 
treatment and average glucose control are introduced (Column 2, Table 2.3), there seems to be a 
significant association between treatment and average glucose control and care costs, decreasing 
the significance of HbA1c alone. Furthermore, age is no longer significantly related to total costs. 
A higher 1% HbA1c is significantly associated with an increase in total care costs by 3.42% if 
the individual is not being treated with insulin nor with oral medication. If the person takes oral 
medication, a higher 1% HbA1c is associated with an increase in total care costs of 1.25 
percentage points (coefficient of HbA1c level alone = 0.0342 + coefficient of the interaction 
HbA1c # Oral medication = - 0.0217). However, the effect of HbA1c in people being treated 
with oral medication on total care costs is not significant (t-statistic = 1.29, p-value > 0.1). If the 
person uses insulin, a higher 1% HbA1c is related to a decrease in total care costs of 1.56 
percentage points (coefficient of HbA1c level alone = 0.0342 + coefficient of the interaction 
HbA1c # Insulin = - 0.0498). Still, the effect of a higher HbA1c is neither significantly associated 
with total costs (t-statistic = -0.67, p-value > 0.1). As diabetes treatment, taking oral medication is 
related to higher care costs, which increase by 8.23% (coefficient of oral medication alone = 
0.104 + coefficient of the interaction HbA1c # Oral medication = - 0.0217) with every additional 
unit of HbA1c, but the effect is not significant (t-statistic = 0.73, p-value > 0.1). Being treated 
with insulin is significantly associated with an increase in costs of 60.81 percentage points 
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(coefficient of insulin alone = 0.658 + coefficient of the interaction HbA1c # Insulin = - 0.0498) 
for every 1% higher HbA1c rise (t-statistic = 4.85, p-value < 0.01).  
Being a female is associated with an increase in total care costs by 4.85 percentage points 
(p<0.05), compared to males. Having low socioeconomic status is associated with a 6.51% 
(p<0.01) higher care costs, in comparison with subjects with high SES. Being a current smoker is 
related to an increase in total costs by 5.09% (p<0.1).  
In a third regression model with the diabetes duration and its square introduced in the analysis 
(Column 3, Table 2.3), HbA1c level is no longer significant individually. Age and age squared are 
not significant either.  
If the person takes oral medication, a higher 1% HbA1c is associated with an increase in total 
care costs of 0.25 percentage points, but not significant either (t-statistic = 0.26, p-value > 0.1). A 
higher 1% HbA1c and using inulin is not significantly related to total care costs of 2.32% (t-
statistic = -1.00, p-value > 0.1). Looking at the effect of diabetes treatment, taking oral 
medication is not significantly related (t-statistic = 0.43, p-value > 0.1) to higher care costs. Being 
treated with insulin is significantly associated with an increase in total costs of 49.57 percentage 
points for every 1% increase in HbA1c (t-statistic = 3.97, p-value < 0.01).  
Each additional year of time since diabetes diagnosis is associated with higher care costs, 
which are augmented by 3.68% (p<0.01), although the negative sign of the square of diabetes 
duration shows that such effect will be decreasing at some point. Being a woman is associated 
with an increase in care costs by 5.35 percentage points (p<0.01). Being in low SES is related to a 
rise in care costs by 6.27% (p<0.01), compared to high SES. 
When the set of three-year dummies for year at diabetes diagnosis are introduced (Column 4, 
Table 2.3), the same pattern as in Model 3 is followed. Average glucose control individually is not 
significantly associated with care costs. Age and age squared are not significant either.  
If the person takes oral medication as diabetes treatment, a higher 1% HbA1c is associated 
with an increase in total care costs of 0.13%, but the effect is not significant (t-statistic = 0.14, p-
value > 0.1). A higher HbA1c by 1% and using inulin is not significantly related to total care 
costs of 2.52 percentage points (t-statistic = -1.09, p-value > 0.1). With respect to diabetes 
treatment, taking oral medication is not significantly related (t-statistic = 0.57, p-value > 0.1) to 
higher care costs. Being treated with insulin is significantly associated with an increase in costs of 
52.46 percentage points by a 1% higher HbA1c (t-statistic = 4.22, p-value < 0.01).  
Each additional year of time since diabetes diagnosis is related to an increase of care costs by 
6.28% (p<0.01), although the negative sign of the square of diabetes duration shows that such 
effect will be decreasing at some point.  
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Actually, looking at Figure 2.3 and taking into account the difference in the coefficients of 
diabetes duration and its quadratic form between Model 3 and Model 4, the time point at which 
care costs start decreasing is posterior when the three-year dummies for year at diabetes diagnosis 
are part of the regression model. In case of Model 3, the beginning of decreasing costs would be 
after 25 years of diabetes duration. In Model 4, it would be after around 35 years since diabetes 
diagnosis. The figure would be suggestive of a “happy survivor” effect. If a person with diabetes 
has stayed stable after 25 – 35 years since disease diagnosis, the likelihood of developing 
complications is lower, reducing costs of total care.  
 
Figure 2.3: Diabetes duration and care costs 
 
Women are associated with higher care costs, which increase by 5.65% (p<0.01), compared to 
males. Being in low SES is also related to a rise in care costs by 6.71% (p<0.01), compared to 
high SES. Moreover, dummies for year at onset cohorts are significantly related to care costs, 
both individually and jointly, as suggested by Figure 2.1. Compared to individuals who have been 
newly diagnosed of diabetes (during the years 2007 – 2009), those whose diabetes onset has 
occurred between 2004 to 2006 are associated with a decrease in care costs by 15.7% (p<0.01) to 
70.6% (p<0.01) in case of having been diagnosed before the year 1989. 
Such trend is maintained in the fifth regression model (Column 5, Table 2.3), in which 
dichotomous variables for each GP identification number were included. GP dummies are jointly 
significant (p<0.01), suggesting a GP treatment effect. Age and age squared are not significant 
either. HbA1c individually is not significantly associated with care costs. If the effect of HbA1c is 
analysed dependent on diabetes treatment, if the person takes oral medication, the effect of 
average glucose control is not significant (t-statistic = 0.49, p-value > 0.1). A higher 1% HbA1c 
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and using inulin is not significantly related to total care costs either (t-statistic = -1.24, p-value > 
0.1).  
Looking at the effect of diabetes treatment, taking oral medication is not significantly related 
(t-statistic = 0.30, p-value > 0.1) to higher care costs. Being treated with insulin is significantly 
associated with an increase in costs of 54.49% for every 1% higher HbA1c (t-statistic = 4.36, p-
value < 0.01). 
Every additional year of time since diabetes diagnosis is related to an increase of care costs of 
6.28% (p<0.01), although such effect will be decreasing at some point, according to the negative 
sign of the square of diabetes duration. Being in low SES associated with higher total costs, 
which grow by 5.80% (p<0.1), compared to high SES individuals. Being a female is also related 
to higher care costs by 5.07% (p<0.05), compared to men. Dummies for year at onset cohorts are 
significantly related to care costs too. Those whose diabetes onset has occurred between 2004 to 
2006, care costs decrease by 12.8% (p<0.01) to 58.2% (p<0.01) in case of having been diagnosed 
before the year 1989, compared to the newly-diagnosed people. 
 
Sensitivity analysis 
Table 2.A2, in Appendix, reports the results from Models 6 and 7, which include non-diabetes 
related and diabetes-related comorbidities, respectively. 
In case of the regression model with the non-diabetes related Elixhauser comorbidities 
(Column 1, Table 2.A2, Appendix), the coefficients of gender (associated with increasing care 
costs by 5% (p<0.05)), being treated with insulin (significantly associated with increasing total 
costs by 56.05% (t-statistic = 4.45, p-value < 0.01) if HbA1c is higher by 1%), diabetes duration 
(associated with increasing care costs by 6.60% (p<0.01) and negative coefficient of diabetes 
duration squared), low SES (associated with increasing total costs by 5.83% (p<0.1)) and year of 
onset categories (associated with decreasing care costs by 13.9% (p<0.01) if diagnosis was 
between 2004 to 2006 and by 66.5% (p<0.01) in case of having been diagnosed before the year 
1989) remain as significant determinants of higher care costs. Age and age squared are not 
significant either. HbA1c, regardless of diabetes treatment, is not significantly associated with 
care costs. Taking oral medication is not significantly related to total costs either.  
Within the list of comorbidities, suffering from cancer, anaemia and depression is associated 
with increasing total care costs the most, by 62.9% (p<0.01), 18% (p<0.01) and 15.1% (p<0.05), 
respectively. On the other hand, rheumatoid arthritis is related to lower care costs, decreasing by 
39.6 percentage points (p<0.01).  
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Table 2.3:  Results from the random-effects linear regression model on the logarithm of 
total care costs  
VARIABLES Coeff. 









Female 0.0572*** 0.0485** 0.0535*** 0.0565*** 0.0507** 
 (0.0202) (0.0197) (0.0198) (0.0197) (0.0198) 
Age 0.0174* 0.0149 0.00811 0.0111 0.0130 
 (0.00996) (0.00976) (0.00971) (0.00969) (0.00988) 
Age2 2.66e-05 4.01e-05 6.55e-05 3.84e-05 2.50e-05 
 (7.27e-05) (7.12e-05) (7.08e-05) (7.06e-05) (7.20e-05) 
Non-Caucasian ethnicity 0.0453 0.0548 -0.00197 0.00914 -0.0427 
(0.198) (0.204) (0.207) (0.199) (0.173) 
Socioeconomic Status (SES) categories      
Low SES 0.0594** 0.0651*** 0.0627*** 0.0671*** 0.0580* 
 (0.0246) (0.0241) (0.0241) (0.0241) (0.0337) 
Medium SES 0.0248 0.0213 0.0181 0.0228 0.0341 
 (0.0245) (0.0238) (0.0237) (0.0236) (0.0352) 
Current smoker 0.0521* 0.0509* 0.0432 0.0365 0.0305 
 (0.0291) (0.0285) (0.0286) (0.0285) (0.0287) 
HbA1c, in % (mmol/mol) 0.0222*** 0.0342* 0.0169 0.0154 0.0145 
 (0.00835) (0.0191) (0.0190) (0.0190) (0.0193) 
Type of medication      
Oral medication  0.104 0.0631 0.0781 0.0441 
  (0.132) (0.131) (0.131) (0.133) 
Insulin  0.658*** 0.536*** 0.565*** 0.589*** 
  (0.145) (0.144) (0.144) (0.144) 
Glycaemic level # type of medication      
HbA1c  # Oral medication  -0.0217 -0.0145 -0.0141 -0.00961 
  (0.0194) (0.0193) (0.0193) (0.0196) 
HbA1c  # Insulin  -0.0498** -0.0402** -0.0406** -0.0436** 
  (0.0197) (0.0196) (0.0195) (0.0196) 
Diabetes duration   0.0368*** 0.0628*** 0.0605*** 
   (0.00367) (0.00569) (0.00597) 
Diabetes duration2   -0.000732*** -0.000911*** -0.000923*** 
   (0.000113) (0.000158) (0.000162) 
Year of onset categories      
Before 1989    -0.706*** -0.582*** 
    (0.123) (0.126) 
Year 1989 – 1991    -0.575*** -0.485*** 
    (0.0902) (0.0927) 
Year 1992 – 1994    -0.429*** -0.383*** 
    (0.0785) (0.0815) 
Year 1995 – 1997    -0.449*** -0.385*** 
    (0.0650) (0.0673) 
Year 1998 – 2000    -0.335*** -0.291*** 
    (0.0538) (0.0556) 
Year 2001 – 2003    -0.221*** -0.193*** 
    (0.0456) (0.0469) 
Year 2004 – 2006    -0.157*** -0.128*** 
    (0.0401) (0.0408) 
Constant 6.291*** 6.308*** 6.553*** 6.529*** 6.335*** 
 (0.344) (0.358) (0.356) (0.356) (0.400) 
N (Observations) 22,612 22,612 22,612 22,612 22,612 
N (Individuals) 5,653 5,653 5,653 5,653 5,653 
General Practitioner FE NO NO NO NO YES 
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Table 3.3: (continued) 
VARIABLES Coeff. 









R-squared      
Within 0.0159 0.004 0.012 0.015 0.023 
Between 0.0626 0.112 0.111 0.116 0.174 
Overall 0.0434 0.073 0.076 0.080 0.120 
σu 0.668 0.640 0.639 0.639 0.630 
σe 0.651 0.651 0.650 0.650 0.650 
ρ 0.513 0.491 0.491 0.491 0.485 
Age and age2 jointly significant (χ2) 470.00*** 464.21*** 64.35* 394.23 24.18 
Diabetes duration and diabetes 
duration2 jointly significant (χ2) 
- - 128.16*** 141.89*** 144.56*** 
Joint significance of new variables (χ2)  220.11*** 128.16*** 57.22*** 5.1e6*** 
Clustered standard errors at the individual level in parentheses. *** p<0.01, ** p<0.05, * p<0.1. 
Reference categories: men, Caucasian ethnicity, high SES, no current smokers, no medication, year of diabetes onset 2007 - 
2009. 
Model 1 includes socioeconomic characteristics (gender, age, ethnicity, socioeconomic status), being a current smoker, 
glycaemic level. Model 2 adds to Model 1 the interaction between glycaemic level and type of medication (oral medication or 
insulin).  Model 3 adds to Model 2 diabetes duration and its quadratic form. Model 4 additionally includes to Model 3 the 
year of diabetes onset groups. Model 5 adds to Model 4 dummies for the General Practitioners (GPs).  
 
In the last regression model where diabetes-related complications are included (Column 2, 
Table 2.A2, Appendix), age and age squared are not significant. HbA1c, regardless of diabetes 
treatment, is not significantly associated with care costs. Taking oral medication is not 
significantly related to total costs either.  
Being treated with insulin is significantly associated with higher care costs by 51.79 percentage 
points for every 1% higher HbA1c (t-statistic = 4.15, p-value < 0.01). Each additional year of 
time since diabetes diagnosis is associated with increasing care costs, by 7.58%, although the 
negative sign of the square of diabetes duration shows that such effect will be decreasing at some 
point. In those whose diabetes onset has occurred between 2004 to 2006, care costs decrease by 
15.4% (p<0.01) and by 81.8 (p<0.01) percentage points in case of having been diagnosed before 
the year 1989, compared to the newly-diagnosed people.  
With respect to the chronic conditions newly considered, suffering from weight loss, 
peripheral vascular disease and congestive heart failure are associated with the greatest increases 
in care costs, by 56.3 (p<0.01), 35.5 (p<0.01) and 35.4 (p<0.01), percentage points, respectively. 
Being a female is associated with higher care costs, which rise by 6.39 percentage points 
(p<0.01), compared to men. Being in low SES is related to total costs by 5.60% (p<0.1), 
compared to high SES.  
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By cost component 
Table 2.4 shows the results obtained from the random-effects linear regression model applied 
to the overall sample by cost type: GP costs, drugs costs, hospital and specialist costs; and the 
results from the two-part model on devices costs. 
 
GP costs  
The first column in Table 2.4 shows that a higher 1% HbA1c is significantly associated with 
an increase in GP costs by 3.48% if the individual is not being treated with insulin nor with oral 
medication. If the person takes oral medication, a higher 1% HbA1c is significantly associated 
with an increase in GP costs of 0.90 (t-statistic = 1.88, p-value < 0.1) percentage points. If the 
person uses insulin, a higher 1% HbA1c is related to an increase in GP costs of 1.20 percentage 
points. With respect to the diabetes treatments, taking oral medication is significantly related to 
higher GP costs, which increase by 10.12% (t-statistic = 1.66, p-value < 0.1) with every additional 
unit of HbA1c. Being treated with insulin is significantly associated with an increase in GP costs 
of 20.63 percentage points for every 1% higher HbA1c (t-statistic = 3.10, p-value < 0.01).  
Each additional year of time since diabetes diagnosis reduces GP costs by 12% (p<0.01), 
although the positive sign of the square of diabetes duration shows that such effect will be 
increasing at some point of diabetes duration7.  
Compared to individuals who have been newly diagnosed of diabetes (during the years 2007 – 
2009), those whose diabetes onset has occurred between 2004 to 2006, GP costs are higher by 
24.8% (p<0.01) to 178.6% (p<0.01) in case of having been diagnosed before the year 1989. 
Being female is related to an increase in GP costs, by 9.37 percentage points (p<0.01), 
compared to men. An additional year of age is associated with 3.17% (p<0.01) GP costs 
reduction. However, the positive sign of the square of age shows that costs will be increasing 
after some age threshold.  
Moreover, GP dummies are jointly significant (p<0.01), also suggesting a GP treatment effect 
on GP costs. 
 
Drugs costs  
The second column in Table 2.4 shows that a higher 1% HbA1c is associated with higher 
drugs costs, by 5.40% (p<0.01) if the individual is not being treated with insulin nor with oral 
medication. If the person takes oral medication, a higher 1% HbA1c is significantly associated 
with an increase in drugs costs of 2.43% (t-statistic = 3.57, p-value < 0.01). If the person uses 
                                                          
7 It has already been found in the literature that the incremental costs in the first years after diabetes diagnosis 
decrease (Nichols et al., 2000) and then start increasing again. We only have four years of data, so we do not know at 
which point of the curve the individual is. 
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insulin, a higher 1% HbA1c is related to an increase in drugs costs of 3.15 percentage points (t-
statistic = 2.06, p-value < 0.05). With respect to the diabetes treatments, taking oral medication is 
significantly related to higher drugs costs, which increase by 17.06 percentage points (t-statistic = 
2.13, p-value < 0.05) with every additional unit of HbA1c. Being treated with insulin is 
significantly associated with an increase in drugs costs of 27.76% for every 1% higher HbA1c (t-
statistic = 3.06, p-value < 0.01).   
Being female is also related to an increase in drugs costs by 10.7% (p<0.01), compared to 
males, as well as increasing age, with an additional year of age increasing drugs costs by 2.24% 
(p<0.1). Compared to high SES, being in low socioeconomic status is associated with higher 
drugs costs by 11.7% (p<0.01) and by 9.22% (p<0.05) if the individual has medium SES. Being a 
current smoker is also positively associated with drugs costs, increasing costs by 8.57% (p<0.01). 
Each additional year of time since diabetes diagnosis is related to higher drugs costs by 2.66% 
(p<0.01), although the negative sign of the square of diabetes duration shows that such effect will 
be increasing at some point of diabetes duration. 
Compared to individuals who have been newly diagnosed of diabetes (during the years 2007 – 
2009), those whose diabetes onset has occurred between 2001 to 2003 have higher drugs costs by 
13.1% (p<0.01) to 58.4% (p<0.01) in case of having been diagnosed before the year 1989. 
Moreover, GP dummies are jointly significant (p<0.01), being suggestive of a GP treatment 
effect on drugs costs. 
 
Hospital and specialist costs  
In case of hospital and specialist costs (third column, Table 2.4), HbA1c is not significantly 
related to hospital and specialist costs, regardless of whether the person receives no treatment    
(p > 0.1), oral medication (t-statistic = 0.47, p-value > 0.1), or insulin (t-statistic = -1.45, p-value 
> 0.1). Oral medication is not significantly associated with hospital costs (t-statistic = 0.27, p-
value > 0.1). Being treated with insulin is significantly associated with an increase in hospital and 
specialist costs of 81.29% (t-statistic = 3.22, p-value < 0.01) for every 1% higher HbA1c.  
An additional year of age is related to higher hospital and specialist costs by 5.62% (p<0.01), 
although the negative sign of age-squared shows that hospital and specialist costs will start 
decreasing after some age point.  
Diabetes duration, gender, socioeconomic status, being a current smoker and year of onset 
categories are not significant predictors of hospital and specialist costs.  
GP dummies are jointly significant (p<0.01), pointing to a significant GP treatment effect on 
hospital and specialist costs. 
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Devices costs  
The fourth and fifth column in Table 2.4 show the results from the probit and the GLM, 
respectively, on devices costs.  
Column four (first part two-part model: Probit results) shows that increasing HbA1c, both 
types of diabetes treatment (oral medication and insulin), diabetes duration and diabetes duration 
squared, being a female, socioeconomic status (both low and medium) are positive and 
significantly associated with the probability of incurring in devices costs. Moreover, age, having 
non-Caucasian ethnicity and some of the three-year onset categories (diabetes diagnosis before 
1989, years 1992 – 1994, years 1998 – 2000, years 2001 – 2003, years 2004 – 2006, compared to 
the newly-diagnosed cases) significantly reduce the probability of having devices costs. 
The fifth column (second part two-part model: GLM results) reports that HbA1c is not 
significantly related to devices costs, regardless of whether the person receives no treatment (p > 
0.1), oral medication (t-statistic = -1.62, p-value > 0.1), or insulin (t-statistic = -0.89, p-value > 
0.1). Oral medication is not significantly associated with devices costs (t-statistic = 0.94, p-value 
> 0.1). Being treated with insulin is significantly associated with an increase in devices costs of 
62.55% (t-statistic = 2.92, p-value < 0.01) for every one additional unit of HbA1c.  
Compared to high SES, being in low socioeconomic status is related to higher devices costs by 
23.5% (p<0.01) and by 15.1% (p<0.05) in case of medium SES.  
Diabetes duration, gender, being a current smoker and year of onset categories are not 
significant determinants of higher devices costs.  
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Table 2.4:  Results from the random-effects linear regression model on the different costs 
components  
VARIABLES 
Coeff. Model 5 
logarithm GP 
costs 
Coeff. Model 5 
logarithm 
drugs costs 
Coeff. Model 5 
logarithm 
hospital costs 
Coeff. Model 5 
devices costs   
(1st part two-part 
model: probit) 
Coeff. Model 5 
devices costs   
(2nd  part two-part 
model: GLM with 
log-link) 
      
Female 0.0937*** 0.107*** 0.00115 0.342*** -0.0318 
 (0.00925) (0.0227) (0.0347) (0.0283) (0.0423) 
Age -0.0317*** 0.0224* 0.0562*** -0.0685*** -0.00973 
 (0.00455) (0.0115) (0.0165) (0.0142) (0.0216) 
Age2 0.000324*** -5.66e-05 -0.000221* 0.000698*** 0.000186 
 (3.37e-05) (8.41e-05) (0.000122) (0.000105) (0.000154) 
Non-Caucasian ethnicity -0.0592 -0.131 0.0618 -0.524** -0.537 
(0.0849) (0.207) (0.341) (0.239) (0.526) 
Socioeconomic Status (SES) categories      
Low SES 0.00911 0.117*** 0.00482 0.117** 0.235*** 
 (0.0161) (0.0415) (0.0604) (0.0517) (0.0681) 
Medium SES -0.00183 0.0922** -0.0248 0.148*** 0.151** 
 (0.0166) (0.0413) (0.0614) (0.0529) (0.0637) 
Current smoker 0.0213 0.0857*** -0.0479 -0.0273 -0.0529 
 (0.0137) (0.0325) (0.0497) (0.0402) (0.0652) 
HbA1c, in % (mmol/mol) 0.0348*** 0.0540*** 0.0219 0.252*** 0.0173 
 (0.0103) (0.0143) (0.0399) (0.0397) (0.0374) 
Type of medication      
Oral medication 0.127* 0.200** 0.0765 0.896*** 0.274 
 (0.0712) (0.0936) (0.277) (0.274) (0.263) 
Insulin 0.229*** 0.300*** 0.904*** 2.805*** 0.675*** 
 (0.0769) (0.104) (0.292) (0.362) (0.248) 
Average glucose control # type of medication      
HbA1c  # Oral medication -0.0257** -0.0296** -0.0128 -0.153*** -0.0608* 
 (0.0106) (0.0137) (0.0407) (0.0408) (0.0366) 
HbA1c  # Insulin -0.0228** -0.0224 -0.0914** -0.142*** -0.0495 
 (0.0105) (0.0137) (0.0402) (0.0496) (0.0342) 
Diabetes duration -0.120*** 0.0266*** -0.0118 0.0622*** 0.00361 
 (0.00310) (0.00509) (0.0119) (0.0111) (0.0149) 
Diabetes duration2 0.00168*** -0.000723*** 0.000330 -0.000682** 2.30e-05 
 (0.000105) (0.000166) (0.000349) (0.000335) (0.000289) 
Year of onset categories      
Before 1989 1.786*** 0.584*** 0.120 -0.771*** -0.0447 
 (0.0659) (0.121) (0.240) (0.219) (0.243) 
Year 1989 – 1991 1.497*** 0.408*** 0.178 -0.239 -0.305 
 (0.0481) (0.0865) (0.182) (0.173) (0.205) 
Year 1992 – 1994 1.299*** 0.303*** 0.245 -0.288** -0.189 
 (0.0409) (0.0798) (0.155) (0.140) (0.183) 
Year 1995 – 1997 1.058*** 0.238*** 0.0927 -0.176 -0.191 
 (0.0321) (0.0633) (0.127) (0.113) (0.163) 
Year 1998 – 2000 0.823*** 0.198*** 0.0449 -0.178** -0.0568 
 (0.0262) (0.0554) (0.104) (0.0898) (0.140) 
Year 2001 – 2003 0.557*** 0.131*** 0.0284 -0.152** -0.0149 
 (0.0218) (0.0504) (0.0843) (0.0712) (0.117) 
Year 2004 – 2006 0.248*** 0.0483 -0.108 -0.0936* -0.134 
 (0.0181) (0.0470) (0.0696) (0.0563) (0.0984) 
Constant 5.947*** 4.160*** 3.367*** -1.002* 5.991*** 
 (0.185) (0.429) (0.663) (0.595) (0.846) 
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Table 2.4: (continued) 
VARIABLES 
Coeff. Model 5 
logarithm GP 
costs 
Coeff. Model 5 
logarithm 
drugs costs 
Coeff. Model 5 
logarithm 
hospital costs 
Coeff. Model 5 
devices costs   
(1st part two-part 
model: probit) 
Coeff. Model 5 
devices costs   
(2nd  part two-part 
model: GLM with 
log-link) 
N (Observations) 22,612 22,579 22,414 22,612 10,718 
N (Individuals) 5,653 5,653 5,653 5,653 3,862 
General Practitioner FE YES YES YES YES YES 
R-squared      
Within 0.128 0.020 0.007 - - 
Between 0.247 0.181 0.138 - - 
Overall 0.193 0.158 0.077 - - 
σu 0.271 0.771 1.036 - - 
σe 0.344 0.403 1.381 - - 
ρ 0.382 0.786 0.360 - - 
Log-pseudolikelihood - - - -11,933.96 -77,331.85 
AIC - - - - 14.486 
BIC - - - - -80,685.66 
Joint significance of GP dummies 1.6e05*** 3.5e05*** 4.3e05*** 1.9e06*** 1.9e06*** 
Clustered standard errors at the individual level in parentheses. *** p<0.01, ** p<0.05, * p<0.1. 
Reference categories: men, Caucasian ethnicity, high SES, no current smokers, no medication, year of diabetes onset 2007 - 
2009. 
Model 5 includes socioeconomic characteristics (gender, age, ethnicity, socioeconomic status), being a current smoker, 
glycaemic level, the interaction between glycaemic level and type of medication (oral medication or insulin), diabetes 
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2.4 DISCUSSION 
In this study, I aim to estimate the impact of average glucose control on total care costs 
incurred by people with type 2 diabetes mellitus, but not exclusively diabetes-related costs, in 
adult people, additionally controlling for year of onset cohort effects. I have used claims data for 
around 5,600 Dutch people with type 2 diabetes with complete data for years 2008 to 2011 
available. Diabetes claims data have been used for years to evaluate clinical care provided by 
health systems (Khan et al., 2009). The availability of very specific and detailed clinical 
information has improved the ability to have more precise diabetes registries that capture more 
accurately cohorts of people with diabetes (Brown et al., 2000). The current dataset combines 
both types of data and hence provides enriched claims data.  
The results show that care costs incurred by people with diabetes differ depending on the 
average glucose control. 4-year mean total care costs increase by €520 between people with 
HbA1c below 6.5% and people with HbA1c above 7.5%. Differences in care costs related to the 
degree of average glucose control in people with diabetes have already been reported in the 
literature (Bron et al., 2015; Degli Esposti et al., 2013; McBrien et al., 2012; Shetty et al., 2005). 
Degli Esposti et al. concluded that mean 2-year costs in Italian people with diabetes and without 
poor glucose management are higher by €219 to €565, compared to those individuals with 
diabetes with good glycaemic levels.  
Looking at the regression results, I have found that a higher 1% HbA1c is associated with 
higher total care costs by 2.2%. The incremental increase in care costs as glucose control worsens 
has also been shown in the literature. Degli Esposti et al. found that good glycaemic control 
increased 2-year care costs by 219.28€; by 264.65€ if fair and by 513.18€ if poor, compared to 
excellent control. Moreover, McBrien et al. stated that 5-year healthcare costs in the US increased 
by 1,623$ if HbA1c levels were between 8 to 9% and by 5,565$ if HbA1c > 9%. Although the 
conclusion about increasing costs due to higher average glucose control is supported by the 
findings presented here, the interpretation of the results cannot be comparable. The authors used 
the absolute value of total care costs, whereas I use the natural logarithm of total care costs. 
Hence, their interpretation is made in absolute terms and mine is made in percentages.  
I have found that the impact of average glucose control on care costs is mediated by the 
treatment modality; in my case, by whether individuals with T2DM take oral medication or use 
insulin. When diabetes treatmens are included in the analysis, a higher 1% HbA1c is significantly 
associated with an increase in total care costs by 3.42% if the individual is not being treated with 
insulin nor with oral medication. The effect of oral medication or insulin use on average glucose 
control impact is, however, not significant. Nevertheless, insulin use is significantly related to 
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higher total care costs, which will increase by 49.57 to 60.81 percentage points, depending on the 
covariates included, for every 1% higher HbA1c. One must consider that, in primary care in The 
Netherlands, mean HbA1c in people on oral medication is 6.8%, and on insulin is 7.4% 
(Booz&Co, 2011). Therefore, treatment intensity is one of the factors needed to be considered in 
this analysis. Moreover, it has already been found in the literature that care costs are higher when 
using insulin (Hendriks and Bilo, 2017; Brandle et al., 2003), but the increase in healthcare costs is 
also dependent on the type of insulin and the regime (Borah et al., 2009; van den Berghe et al., 
2006), which is not available in the data.  
With respect to the effect of diabetes duration, I have found that an additional year of diabetes 
duration is associated with higher care costs by 3.68%, reaching 6.28% when year of onset 
categories are included. This result would highlight the relevance of correcting for year of onset 
cohort effects, as not doing so would lead to biased diabetes duration estimates. Moreover, 
findings suggest that there is a strong association between diabetes duration and total costs, as 
Figure 2.1 has put forward too. I also observe that the diabetes duration point at which care costs 
start decreasing is found to be ten years later when year of onset categories are part of the 
analysis. McBrien et al. (2012) also looked at the impact of diabetes duration on healthcare 
spending, defining two categories, between one and five years since diabetes onset and greater 
than five years. Their results showed a more significant and greater effect of time since diagnosis 
over five years, increasing costs by $4,861, compared to an increase of $663 if diabetes duration 
was one to five years. They show that care costs in people with diabetes increase with time since 
diagnosis, as I do, but I do find that the increase in costs will have a decreasing effect at some 
point (particularly, after 25 to 35 years after diabetes diagnosis when year of onset effects are 
included). Trogdon and Hylands (2008) did find that annual medical expenditures increase at a 
decreasing rate as the time with diabetes increases, which would be confirmed by my results, but 
they do not report after how many years lived with diabetes the costs would be decreasing. 
The introduction of diabetes treatment, diabetes duration and year of onset cohorts has led to 
another remarkable result. I find that the effect of age is not significantly related to care costs, 
contradicting the results found by Trogdon and Hylands (2008). The authors did include age and 
age squared together with diabetes duration and diabetes duration squared, as I do in this 
analysis. However, in their case, age was significantly associated with increasing care costs, having 
age squared a negative sign, regardless of the covariates included in the regression model 
(diabetes duration, diabetes duration squared and even some comorbidities). Hence, my results 
would denote that it is diabetes duration and the complications associated with the progression of 
the disease rather than age what explain the rise in total care costs. 
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These results also suggest that diabetes complications, both non-related and diabetes-related, 
have a different impact on the effect of average glucose control and treatment and diabetes 
duration on total costs. The findings are suggestive of a mediation effect of diabetes-related 
complications on average glucose control and insulin use. In fact, being treated with insulin is 
significantly associated with an increase in total care costs, by 56.06 and 51.8 percentage points 
for every one additional unit of HbA1c, when non-related and diabetes-related complications are, 
respectively, part of the analysis. On the other hand, when chronic conditions are introduced, the 
effect of diabetes duration increases, compared to previous regression models, which would 
contradict previous findings (Trogdon and Hylands, 2008). In the current analysis, one additional 
year lived with diabetes increases total costs by 6.60% when non-diabetes related comorbidities 
are considered and by 7.58 percentage points if diabetes-related complications enter into the 
regression model. In Trogdon and Hylands (2008), before and after adjusting for comorbidities, 
the effect of one additional year since diabetes diagnosis decreased by half, from 2.4% to 1.1%.   
Moreover, I have found that the influence of average glucose control, diabetes treatment 
modality, and diabetes duration is maintained across costs components, with some minor 
exceptions. The greatest impact of HbA1c is observed on drugs (Hendriks and Bilo, 2017) and 
GP costs, whereas the greatest impact of insulin treatment is placed on devices and hospital and 
specialist costs (Brandle et al., 2003).  
Some limitations should also be mentioned. Firstly, the analyses were performed based on the 
population from the North of The Netherlands, being especially representative of the specific 
population. Although the generalizability of the results to other areas in the country might be 
limited, I expect that the relative differences in costs would be maintained in other regions of The 
Netherlands. Secondly, it would have been good to have a longer period of data and a greater 
number of complete cases to observe the same individuals for more time. Only having four-year 
data might not be enough to fully disentangle the diabetes duration effect from the year of 
diagnosis effect. The reimbursement and claims data allows to assess the association between 
care costs and diabetes, but I might not be able to completely fill in the gap in the literature and 
the clinical feature. Moreover, using ICPC codes to correct for comorbidities might be under-
reporting the prevalence and, thus, the relevance of the association between comorbidities and 
care costs in people with diabetes. For example, the obesity prevalence in the data is 0.7%, 
whereas estimates from the World Health Organization for 2008 showed that obesity prevalence 
among Dutch adults was 18.8% (WHO, 2013). In fact, the lack of information on actual 
prevalence might be the reason behind the minor change on the coefficients and significance of 
the other covariates.  
Costs of people with diabetes in relation to average glucose control: An empirical approach controlling for year of onset cohorts 
 
Page | 43  
 
These findings lead to several contributions to the existing literature. Firstly, I not only look at 
the impact of average glucose control on care costs incurred by people with diabetes, but I also 
correct for treatment modality and for diabetes duration and year of onset effects. The inclusion 
of all these factors together has not been previously done. Excluding these factors could lead to 
an overestimation of the burden of other variables. Treatment modality has been proved to be 
definitely associated with the outcome, higher care costs, and average glucose control, but it does 
not necessarily mean that improving HbA1c is related to total costs. This could have implications 
for the pharmaceutical industry when developing different treatments for older people with 
diabetes as, instead of placing the focus largely on the management of the chronic conditions, the 
scope could change to average glucose control and treatment modality, which can be modified 
and improved. Actually, the effect of diabetes duration and year at onset cohort also points to the 
relevance of diabetes treatment, as people with a longer diabetes duration might be in need for 
different and more costly treatment. Secondly, controlling for comorbidities allows to quantify 
the corrected impact of HbA1c and time since diagnosis on care costs, showing that the greatest 
variation on the effect of HbA1c, diabetes treatment and diabetes duration is shown when 
diabetes-related complications are part of the analysis. These two main contributions are of great 
relevance for policymakers when implementing diabetes management guidelines and programs. 
The results suggest that if a good management of average glucose control could be implemented 
for a whole population, the impact of diabetes duration, which is not modifiable, and the risk of 
developing associated complications could be reduced. Finally, another strength of the data is 
that using claims data reduces biases which can be derived from other data sources, such as self-
reported data. The available data allowed me to have access to laboratory, clinical and costs 
registries data. I actually show that it might be important not to rely only on reimbursement data, 
but also on clinical data to get consistent results. I then provide researchers and policymakers 
with reliable estimations on reimbursed care costs per patient. 
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Table 2.A1: Description of variables included in the analysis 
Variables Dataset of origin Coding Observations 
Total care costs (in 2010€) VEKTIS dataset 
Total care costs incurred by people with 
diabetes and reimbursed by the insurance 
Time-variant. Costs were inflated or deflated, as appropriate, 
according to the Consumer Price Index (CPI) obtained from 
Statistics Netherlands.  
GP cost (in 2010€)  VEKTIS dataset 
Total costs incurred by people with diabetes 
when visiting their General Practitioner 
(GP) and reimbursed by the insurance 
Time-variant. Costs were inflated or deflated, as appropriate, 
according to the CPI obtained from Statistics Netherlands. 
Drugs cost (in 2010€)   VEKTIS dataset 
Total drugs costs incurred by people with 
diabetes and reimbursed by the insurance 
Time-variant. Costs were inflated or deflated, as appropriate, 
according to the CPI obtained from Statistics Netherlands. 
Hospital cost (in 2010€)  VEKTIS dataset 
Total hospitalization and specialist visits 
costs incurred by people with diabetes and 
reimbursed by the insurance 
Time-variant. Costs were inflated or deflated, as appropriate, 
according to the CPI obtained from Statistics Netherlands. 
Devices cost (in 2010€) VEKTIS dataset 
Total costs incurred by people with diabetes 
covering devices and other tools reimbursed 
by the insurance 
Time-variant. Costs were inflated or deflated, as appropriate, 
according to the CPI obtained from Statistics Netherlands. 
Other cost (in 2010€) VEKTIS dataset 
Total other costs (obstetrics, maternity, 
paramedical care, dentistry, hospital 
transport, mental care and abroad costs) 
incurred by people with diabetes and 
reimbursed by the insurance 
Time-variant. Costs were inflated or deflated, as appropriate, 
according to the CPI obtained from Statistics Netherlands. 
Female VEKTIS dataset 1: individual is a woman; 0: if man Time-invariant. 
Age (in years) VEKTIS dataset 
Age of the individual in each calendar year, 
in years 
Time variant. Self-generated by subtracting the year of birth 
from the calendar year 
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Table 2.A1: (continued) 
Variables Dataset of origin Coding Observations 
Non-Caucasian ethnicity ZODIAC dataset 
1: the individual ethnicity is non-Caucasian 
(Afro-Caribbean / Black or Asian-Indian);  
0: if Caucasian ethnicity 
Time-invariant 
Socioeconomic Status (SES) VEKTIS dataset 
1: the individual SES is low; 2: the individual 
SES is medium; 3: if high 
Time-variant. Socioeconomic status by postcode and self-
divided into three quintiles 
Current smoker  ZODIAC dataset 
1: individual is currently smoking; 0: 
otherwise 
Time invariant 
Average glucose control  ZODIAC dataset HbA1c, in % (mmol/mol) Time-variant. Upper and lower bounds were applied8 
Diabetes duration  ZODIAC dataset 
Time since diabetes diagnosis in each 
calendar year, in years 
Time-invariant. Self-generated by subtracting the age at 
diagnosis diagnosis from current age 
Year of diagnosis ZODIAC dataset  
Time-invariant. Self-generated by subtracting the diabetes 
duration from the calendar year 
Type of medication    
Oral medication ZODIAC dataset 
1: individual has been told to take oral 
medication as diabetes treatment; 0: 
otherwise 
Time-variant. A low proportion of the sample undergoes 
both diabetes treatments (oral medication and insulin) 
Insulin ZODIAC dataset 
1: individual has been told to use insulin as 
diabetes treatment; 0: otherwise 
Time-variant. A low proportion of the sample undergoes 
both diabetes treatments (oral medication and insulin) 
General Practitioner (GP) code VEKTIS dataset GP identification number Time-variant 
 
 
                                                          
8 Extreme values were deleted according to the KCK DS Extreme Values report from 2016.  
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Table 2.A1: (continued) 
Variables Dataset of origin Coding Observations 
Elixhauser comorbidities    
Cancer ZODIAC dataset 
1: the individual has ever been diagnosed of 
cancer; 0: otherwise 
Time-variant. Corresponding ICPC codes: A79, B72, B72.01, 
B72.02, B74, B75, D74, D75, D76, D77, D77.01, D77.02, 
D77.03, D77.04, D78, D78.01, F74, F74.01, F74.02, H75, 
H75.01, H75.02, I71, I71.01, I71.02, K71, K71.02, K72, 
K72.01, K72.02, L88, L88.01, L88.02, N74, N75, N76, 
R83.02, R84, R85, R86, S77, S77.01, S77.02, S77.03, S78, S79, 
S79.01, S80, S80.01, S81, T71, T72, T73, U75, U76, U77, 
U78, U79, X75, X76, X76.01, X77, X77.01, X77.02, X78, 
X78.01, X79, X80, X81, Y71.01, Y77, Y78, Y78.01, Y78.02, 
Y78.03, Y79  
Congestive heart failure ZODIAC dataset 
1: the individual has ever been diagnosed of 
congestive heart failure; 0: otherwise 
Time-variant. Corresponding ICPC codes: K77, K77.01, 
K77.02 
Acute myocardial infarction ZODIAC dataset 
1: the individual has ever suffered an acute 
myocardial infarction; 0: otherwise 
Time-variant. Corresponding ICPC codes: K75, K76.02 
Peripheral vascular disease ZODIAC dataset 
1: the individual has ever been diagnosed of 
peripheral vascular disease; 0: otherwise 
Time-variant. Correspondent ICPC codes: K92, K92.01, 
K92.02, K92.03, K92.04  
Hypertension, uncomplicated ZODIAC dataset 
1: the individual has ever been diagnosed of 
uncomplicated hypertension; 0: otherwise 
Time-variant. Corresponding ICPC codes: K86 
Hypertension, complicated ZODIAC dataset 
1: the individual has ever been diagnosed of 
complicated hypertension; 0: otherwise 
Time-variant. Corresponding ICPC codes: K87 
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Table 2.A1: (continued) 
Variables Dataset of origin Coding Observations 
Alcohol abuse ZODIAC dataset 
1: the individual has ever been diagnosed of 
alcohol abuse; 0: otherwise 
Time-variant. Corresponding ICPC codes: P15, P15.01, 
P15.02, P15.03, P15.05, P15.06, P16 
Paralysis ZODIAC dataset 
1: the individual has ever been diagnosed of 
paralysis; 0: otherwise 
Time-variant. Corresponding ICPC codes: N18 
Stroke ZODIAC dataset 1: the individual has ever suffered an stroke Time-variant. Corresponding ICPC codes: K90.03 
Any other cerebrovascular accident  ZODIAC dataset 
1: the individual has ever suffered any other 
cerebrovascular accident; 0: otherwise 
Time-variant. Corresponding ICPC codes: K90, K90.01, 
K90.02 
Dementia ZODIAC dataset 
1: the individual has ever been diagnosed of 
dementia; 0: otherwise 
Time-variant. Corresponding ICPC codes: P70, P70.01, 
P70.02 
Chronic pulmonary disease ZODIAC dataset 
1: the individual has ever been diagnosed of 
chronic pulmonary disease; 0: otherwise 
Time-variant. Corresponding ICPC codes: R91, R91.01, 
R91.02, R95 
Retinopathy ZODIAC dataset 
1: the individual has ever been diagnosed of 
retinopathy; 0: otherwise 
Time-variant. Corresponding ICPC codes: F83, F83.01, 
F83.02 
Neuropathy ZODIAC dataset 
1: the individual has ever been diagnosed of 
neuropathy; 0: otherwise 
Time-variant. Corresponding ICPC codes: N94.02 
Hypothyroidism ZODIAC dataset 
1: the individual has ever been diagnosed of 
hypothyroidism; 0: otherwise 
Time-variant. Corresponding ICPC codes: T86 
Renal failure ZODIAC dataset 
1: the individual has ever been diagnosed of 
renal failure; 0: otherwise 
Time-variant. Corresponding ICPC codes: U99.01, T88 
Liver disease ZODIAC dataset 
1: the individual has ever been diagnosed of 
liver disease; 0: otherwise 
Time-variant. Corresponding ICPC codes: D72, D72.01, 
D72.02, D72.03, D96, D97, D97.04, D97.05 
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Table 2.A1: (continued) 
Variables Dataset of origin Coding Observations 
Peptic ulcer ZODIAC dataset 
1: the individual has ever been diagnosed of 
peptic ulcer; 0: otherwise 
Time-variant. Corresponding ICPC codes: D85, D86, 
D86.01 
Rheumatoid arthritis ZODIAC dataset 
1: the individual has ever been diagnosed of 
rheumatoid arthritis; 0: otherwise 
Time-variant. Corresponding ICPC codes: K71.01, K71.01, 
K71.02, L88, L88.01, L88.02 
Weight loss ZODIAC dataset 
1: the individual has ever suffered weight 
loss; 0: otherwise 
Time-variant. Corresponding ICPC codes: T06, T06.01, T08 
Obesity ZODIAC dataset 
1: the individual has ever been diagnosed of 
obesity; 0: otherwise 
Time-variant. Corresponding ICPC codes: T82 
Anaemia ZODIAC dataset 
1: the individual has ever been diagnosed of 
anaemia; 0: otherwise 
Time-variant. Corresponding ICPC codes: B78, B78.01, 
B78.02, B78.03, B79, B80, B81, B81.01, B81.02, B82 
Psychosis  ZODIAC dataset 
1: the individual has ever been diagnosed of 
psychosis; 0: otherwise 
Time-variant. Corresponding ICPC codes: P71, P72, P73, 
P73.02 
Depression ZODIAC dataset 
1: the individual has ever been diagnosed of 
depression; 0: otherwise 
Time-variant. Corresponding ICPC codes: P74, P74.01, 
P74.02, P75, P76, P76.01 
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Table 2.A2: Results from the random-effects linear regression model on the logarithm of total 
care costs. Sensitivity analysis  
VARIABLES Coeff. Model 6 Coeff. Model 7 
Female 0.0500** 0.0639*** 
 (0.0197) (0.0194) 
Age 0.0117 0.0108 
 (0.00982) (0.00973) 
Age2 3.37e-05 2.87e-05 
 (7.16e-05) (7.10e-05) 
Non-Caucasian ethnicity -0.0377 -0.0381 
(0.174) (0.173) 
Socioeconomic Status (SES) categories   
Low SES 0.0583* 0.0560* 
 (0.0335) (0.0329) 
Medium SES 0.0339 0.0301 
 (0.0349) (0.0341) 
Current smoker 0.0303 0.0209 
 (0.0285) (0.0280) 
HbA1c, in % (mmol/mol) 0.0153 0.0130 
 (0.0193) (0.0192) 
Type of medication   
Oral medication 0.0516 0.0555 
 (0.133) (0.133) 
Insulin 0.606*** 0.556*** 
 (0.146) (0.144) 
Glycaemic level # type of medication   
HbA1c  # Oral medication -0.0108 -0.0114 
 (0.0196) (0.0195) 
HbA1c  # Insulin -0.0454** -0.0380* 
 (0.0198) (0.0196) 
Diabetes duration 0.0660*** 0.0758*** 
 (0.00602) (0.00650) 
Diabetes duration2 -0.000996*** -0.00114*** 
 (0.000162) (0.000165) 
Year of onset categories   
Before 1989 -0.665*** -0.818*** 
 (0.126) (0.129) 
Year 1989 – 1991 -0.556*** -0.679*** 
 (0.0930) (0.0972) 
Year 1992 – 1994 -0.444*** -0.560*** 
 (0.0817) (0.0861) 
Year 1995 – 1997 -0.434*** -0.518*** 
 (0.0674) (0.0698) 
Year 1998 – 2000 -0.328*** -0.390*** 
 (0.0557) (0.0576) 
Year 2001 – 2003 -0.217*** -0.262*** 
 (0.0469) (0.0478) 
Year 2004 – 2006 -0.139*** -0.154*** 
 (0.0405) (0.0402) 
Diabetes non-related comorbidities   
Cancer 0.629*** 0.638*** 
 (0.0830) (0.0841) 
Alcohol abuse 0.300* 0.301* 
 (0.161) (0.159) 
Paralysis 0.0170 0.0650 
 (0.0444) (0.0481) 
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Table 2.A2: (continued) 
VARIABLES Coeff. Model 6 Coeff. Model 7 
Chronic pulmonary disease 0.177 0.144 
 (0.135) (0.139) 
Hypothyroidism 0.0948 0.0604 
 (0.0848) (0.0857) 
Liver disease 0.105 0.0356 
 (0.346) (0.336) 
Peptic ulcer 0.0195 -0.108 
 (0.183) (0.240) 
Rheumatoid arthritis -0.396*** -0.379*** 
 (0.141) (0.142) 
Anaemia 0.180*** 0.149** 
 (0.0687) (0.0684) 
Psychosis 0.393* 0.433** 
 (0.216) (0.213) 
Depression 0.151** 0.144** 
 (0.0624) (0.0614) 
Diabetes-related comorbidities   
Congestive heart failure  0.354*** 
  (0.0656) 
Acute myocardial infarction  0.349*** 
  (0.0644) 
Peripheral vascular disease  0.355*** 
  (0.0757) 
Hypertension, uncomplicated  -0.0290* 
  (0.0173) 
Hypertension, complicated  0.0363 
  (0.0503) 
Stroke  0.250*** 
  (0.0322) 
Any other cerebrovascular accident  0.322*** 
  (0.0619) 
Dementia  0.159 
  (0.143) 
Retinopathy  0.0272 
  (0.0672) 
Neuropathy  0.125 
  (0.0813) 
Renal failure  0.0671 
  (0.0480) 
Weight loss  0.563*** 
  (0.0295) 
Obesity  0.0765 
  (0.0678) 
Constant 6.367*** 6.382*** 
 (0.398) (0.396) 
N (Observations) 22,612 22,612 
N (Individuals) 5,653 5,653 
General Practitioner FE YES YES 
R-squared   
Within 0.027 0.035 
Between 0.187 0.217 
Overall 0.130 0.151 
σu 0.613 0.587 
σe 0.648 0.645 
Chapter 2   
 
Page | 52  
 
Table 2.A2: (continued) 
VARIABLES Coeff. Model 6 Coeff. Model 7 
ρ 0.472 0.453 
Joint significance of new variables (χ2) 83.87*** 578.97*** 
Clustered standard errors at the individual level in parentheses. *** p<0.01, ** p<0.05, * p<0.1. 
Reference categories: men, Caucasian ethnicity, high SES, no current smokers, no medication, year of 
diabetes onset 2007 - 2009. 
Model 6 adds to Model 5 the diabetes non-related Elixhauser comorbidities. Model 7 additionally includes the 



















DIABETES-ASSOCIATED FACTORS AS PREDICTORS OF NURSING 






The number of patients with diabetes has rapidly increased globally, being projected to near 
doubling the figures of the turn of the century (2.8%) and reaching around 380 million people by 
2025 all over the world and 4.8% of the whole population in the year 2030 (O’Shea et al., 2013). 
Older adults will lead this increase (Sloan et al., 2008), representing around 50% of the people 
with diabetes and with a prevalence of diabetes around 25% (Soriguer et al., 2012; Sloan et al., 
                                                          
9 This chapter has been published in The Journal of the American Medical Directors Association as Rodriguez-
Sanchez, B. et al., (2017): The relationship between diabetes, diabetes-related complications and productive activities 
among older Europeans. JAMDA, vol. 18, pp.: 74 – 82. 
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Netherlands, May 28-29, 2015; at the preconference workshop “Healthwise symposium on Applied Health 
Economics” in Groningen, The Netherlands, October 29, 2015; and in the SOM PhD day in Groningen, The 
Netherlands, May 15, 2016. Also, in poster form at the XXXV Jornadas Economía de la Salud in Granada, Spain, 
June 17-19, 2015. 
I thank the conference attendees for their contribution made to the manuscript; especially Maureen Rutten van 
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their advice in the revision of the manuscript.  
This chapter uses data from SHARE waves 1, 2, and 4 (DOIs: 10.6103/SHARE.w1.500, 
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00360), FP6 (SHARE-I3: RII-CT-2006- 062193, COMPARE: CIT5-CT-2005-028857, SHARELIFE: CIT4-CT-
2006-028812), and FP7 (SHARE-PREP: No. 211909, SHARE-LEAP: No. 227822, SHARE M4: No. 261982). 
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IAG_BSR06-11, OGHA_04-064), and from various national funding sources is gratefully acknowledged (see 
www.share-project.org). 
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2008). In fact, the ageing of the population, together with greater levels of obesity, will make 
diabetes becoming a pandemic (O’Shea et al., 2013). 
Traditionally, the social impact of diabetes has been linked to the use of health and social 
resources, as well as healthcare and non-healthcare costs. It has been proved that medical costs 
for patients with diabetes are up to three times higher than costs for patients without the disease 
(Clarke et al., 2010). Furthermore, a recent report from the American Diabetes Association 
(ADA, 2013) reported that due to the increase in diabetes prevalence, their estimations about use 
of healthcare resources as well as costs had increased almost one third in comparison with their 
previous analysis from 2007, increasing from $135 billion to $176 billion. Another study from the 
US concluded that direct costs derived from diabetes represent $174 billion per year for the 
government, assessing an average expenditure per capita and per year for an elderly patient 
between $3,407 for the most-conservative estimate and $9,713 for the least conservative one 
(Anderson, 2012). 
Regarding the components of the costs, associated costs typically include visits to physicians 
(GP and specialists) and nurses, drug costs, visits to the Emergency Room and hospitalization 
(Oliva et al., 2004). However, two other components usually neglected should be added into the 
calculation of costs of diabetes in the elderly: those related to impaired functional status and 
those associated with institutionalization. Functional status is one of the most important 
components in determining the use of health-care systems (Weiss, 2011) and the annual 
healthcare costs in older people (Lubitz et al., 2003), which increase in near three fold the costs in 
people with any limitation in Activities of Daily Living (ADL) compared with those who remain 
independent and by nine times in institutionalized patients. 
Diabetes among older people increases in a significant manner both risks: to be dependent 
and to be institutionalized. Some evidence from the US reported that diabetes is a determinant of 
nursing home placement among the frail elderly and, moreover, old people with diabetes are 1.8 
times more likely to be institutionalized (Matsuzawa et al., 2010). Around 30-35% of 
institutionalized older people have diabetes, a condition associated to a higher resource utilization 
(Newton et al., 2013). With all these figures in mind, the scenario for the next decades shows an 
increase in the costs associated to the management of people with diabetes due to the ageing of 
the population and the higher costs per capita with advancing age (Waldeyer et al., 2013). Those 
increasing costs constitute a new challenge for the Health Systems, who should refine broadly 
implemented procedures with non-proved benefits for the patients and costly for the Health 
System, and, at the same time, implement models of care tailored to the needs of this population 
(Sinclair et al., 2015; Sinclair et al., 2011). 
Diabetes-associated factors as predictors of nursing home admission and costs in the elderly across Europe 
Page | 55  
 
Diabetes relevance might vary between countries: in low and middle income countries, 
diabetes is becoming more important due to the diet and lifestyle factors in younger populations 
(Hanson et al., 2012; Hu, 2011); whereas in high-income countries, diabetes is becoming a 
pandemic in the elderly, as previously mentioned, due to the population ageing and the increasing 
prevalence of diabetes in this group age (O’Shea et al., 2013). Bearing in mind the effect of an 
increasing prevalence of diabetes among the elderly on a positive shift in the demand for health 
and social care and, consequently, in its costs, it seems relevant to estimate the burden of diabetes 
on both long-term care use and expenditure in developed countries, such as European countries. 
However, not many studies analyzing the drain of diabetes in old ages in Europe are currently 
available. There are reports about quality of care for people with diabetes mellitus (Gorter et al., 
2010; Sinclair, 2007), but not too much has been published about the determinants of nursing 
home admission and cost drivers within the European diabetic population. The UKPDS study, 
which is being carried out in the United Kingdom, showed that diabetes and its associated 
complications had a great impact on healthcare expenditures not only in the year of the event, 
but also in succeeding years (Alva et al., 2014). Another study carried out in the Netherlands 
showed differences in costs when people with diabetes received different kinds of care (van der 
Heijden et al., 2014). 
The main aim of this chapter is to estimate the role of diabetes and a list of clinical and 
functional complications leading to institutionalization of people older than 50 years old using 
observational data and to what extent the association between nursing home placement and the 
main variables of interest differ across Europe. A recent review on ageing in the European Union 
(Rechel et al., 2013) claimed the great need of coordination and organization of long-term 
services across Europe, where long-term care policies seem to differ substantially between 
countries. It is well-known that there are cultural differences between North and South Europe 
in terms of health and social care use, which prompts my approach. Actually, Southern European 
countries are considered to be “strong-family-ties countries”, where looking after an old and very 
old relative at home is more likely than being transferred to a nursing home, while their Northern 
counterparts are regarded as “weak-family-ties countries”, where, in comparison, the odds of 
being transferred to a nursing home are higher (Reher, 1998). After obtaining these results, I will 
use them to estimate nursing home expenditures attributable to diabetes and its complications in 
Europe. Public expenditures are likely to significantly increase in Europe from 1 – 2% to 2 – 3% 
of the GDP between 2007 and 2060 (Rechel et al., 2013). Cross-countries differences associated 
with long-term care are also found regarding public expenditures. For instance, in 2000, public 
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expenditures on long-term care as a percentage of GDP was reported to range from 2.74 in 
Sweden to 0.16 in Spain (OECD, 2005).  
So, investigating more broadly the factors that increase the risk of being institutionalized as 
well as the impact of diabetes and the problems associated with the disease on nursing home 
costs would help policy makers to a better allocation of the scarce resources and to inform 
effective policy interventions to avoid the excessive use of healthcare resources related to nursing 
home entry of people with diabetes and, consequently, reduce its associated costs. 
The chapter proceeds as follows. First, the data that have been used to run the analyses are 
presented. Second of all, the empirical methods used for both the estimation of the determinants 
of institutionalization and the costs associated with diabetes and its clinical and functional 
complications in this study will be described. Third, the results are presented. Finally, the chapter 
concludes with a discussion of the implications of my results for governments and policymakers. 
 
3.2 DATA AND METHODS 
3.2.1 Data and sample 
Data for this study have been obtained from the Survey of Health, Ageing and Retirement in 
Europe (SHARE). SHARE is a longitudinal study which includes information about health, 
socioeconomic status and family networks of a representative sample of the community-dwelling 
individuals consisting of 86,290 individuals aged fifty and over from nineteen European countries 
(Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, 
Ireland, Italy, The Netherlands, Poland, Portugal, Slovenia Spain, Sweden and Switzerland) and 
Israel. I limited my study to twelve of those countries, namely Austria, Belgium, Czech Republic, 
Denmark, France, Germany, Greece, Italy, The Netherlands, Spain, Sweden and Switzerland10. I 
have pooled data from three different waves: wave 1 (2004), wave 2 (2006-07) and wave 4 
(2010)11. SHARE contains individual level information on general characteristics (age, gender, 
country, marital status, education, etc.), health status (self-perceived health, diagnoses), functional 
impairment (number of limitations in ADLs) and health care use (being admitted into a nursing 
home (NH), being admitted to hospital, etc.). Persons in a nursing home are included when one 
of their family members is in the sample. 
                                                          
10 Estonia, Hungary, Ireland, Israel, Poland, Portugal and Slovenia have not been included due to their small size of 
sample.  
11 Wave 3 has been excluded due to a change in the questionnaire (the SHARELIFE questionnaire), which registered 
information on individuals’ childhood health and, hence, the information provided in wave 3 was not useful for the 
analysis. However, I have used Wave 3 data to drop the observations already reporting to suffer diabetes in their 
childhood. 
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Data regarding total expenditure for NHs per country have been taken from the Organization 
for Economic Co-operation and Development (OECD) Data and Statistics databases for the 
survey years (2004, 2006, 2007 and 2010). OECD Data and Statistics offers users information 
about a wide range of variables (general statistics, demography and population data, education 
and training, environment, health, labour and productivity, etc.) across OECD countries. I have 
collected information about healthcare expenditure and financing by provider, selecting data 
from services of long-term nursing care in nursing and residential care facilities. 
Institutionalization costs are not available for Italy, Sweden and Greece, so their analyses is just 
focused on finding out the predictors leading to nursing home admission. 
Finally, in order to make the results across countries more comparable, information on Gross 
Domestic Product (GDP), adjusted by Power Purchasing Parity (PPP) index for every country 
and year included in this study has been taken from the World Bank. 
 
3.2.2 Methodological framework 
By combining a logit model based on SHARE data which gives the probability of being in a 
nursing home for given diabetes and other characteristics, with information from the OECD 
database on country specific expenditure, the costs of nursing home attributable to diabetes are 
calculated as follows. 
Taking the coefficients estimated in the logit model, the etiological fraction for each of the 
clinical and functional complications associated with diabetes is calculated. This approach has 
been previously used in the reports published by the American Diabetes Association (ADA, 
2013; ADA, 2003). The main difference between those and the present study is that the former 
estimated an etiological fraction for each medical condition regardless of the healthcare resource, 
whereas I appraise a specific etiological fraction for every medical condition and for a specific 
healthcare resource (nursing home use in this analysis), which allows for more accurate 
interpretation. By doing so, I am able to estimate the excess of healthcare resource use by people 
with diabetes that would be avoided if an individual did not have diabetes. The etiological 
fraction is the excessive proportion of healthcare resource use due to a medical condition that 
affects individual’s health state, including cognitive and functional impairment, which could be 
attributable to diabetes according to the diabetes status and the probability of having diabetes 
(ADA, 2013; ADA, 2003). The formula to calculate the etiological fraction is as follows, 
                                                            𝐸𝐹𝑑 =
[𝑃𝑑  𝑥 (𝑅𝑅𝑑 − 1)]
[𝑃𝑑  𝑥 (𝑅𝑅𝑑 − 1) + 1]
                                                (1) 
where EFd is the etiological fraction of healthcare resource use, nursing home use in my study, 
for each condition d (diabetes, diabetes non-related complications and diabetes-related 
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complications) which is attributable to diabetes; Pd represents disease specific prevalence; and 
RRd denotes the adjusted relative risk of condition d for those diabetic people against people 
without diabetes. Adjusted relative risks are calculated according to Norton et al. (2014); Norton, 
et al., (2013); and Kleinman and Norton (2009). They show that previous estimations on how to 
convert odds ratio to relative risk measures are biased or overestimate the interpretation of odds 
ratio. Moreover, they show how to compute adjusted relative risks in Stata for logit models, as it 
is the case in the present analysis (Norton et al., 2014).  
Several reasons motivated the use of etiological fractions for the calculation of costs. Firstly, 
etiological fractions let the researcher make more clear judgements about causality. Secondly, they 
allow to consider the “external validity” of the results, since etiological fractions force researches, 
first of all, to examine the relevance of their results and, then, to think about the impact of their 
results in society as a whole (Steenland and Amstrong, 2006).  
Finally, costs in this study are divided into two subcategories (ADA, 2013; ADA, 2003): those 
costs incurred by people with diabetes and the costs that can be attributed to diabetes, which are 
those extra costs that governments have to face strictly due to diabetes and its complications  
(both clinical and functional complications).  
The former costs can be estimated using the following formula, 
                                                                          𝐶𝐷𝑗
𝑁𝐻 = 𝐸𝐹𝐷 𝑥 𝐶𝑗
𝑁𝐻                                                   (2) 
where 𝐶𝐷𝑗
𝑁𝐻 denotes the total nursing home costs generated by people with diabetes, EFD is the 
etiological fraction for diabetes based on Model 1 and CNH represents the total expenditure on 
nursing home care for the overall sample and by country j12. 
In order to evaluate the costs directly attributed to diabetes, the following formula is used 
running the analysis only for the subsample with diabetes13: 
                                                                          𝐶𝑑𝑗
𝑁𝐻 = 𝐸𝐹𝑑  𝑥 𝐶𝐷𝑗
𝑁𝐻                                                  (3) 
where 𝐶𝑑𝑗
𝑁𝐻 denotes the total nursing home costs attributed to condition d, EFd is the etiological 
fraction for condition d and 𝐶𝐷
𝑁𝐻 represents the total expenditure on nursing home care incurred 
by people with diabetes for the overall sample and by country j8. 
Disease specific prevalence within the sample and by country is provided in Table 3.A1 in the 
Appendix. 
                                                          
12 No data was available for nursing home expenditures in Sweden, Italy and Greece in OECD Database, so I 
couldn’t estimate nursing home expenditures attributed to diabetes in these countries. 
13 The regressions for the diabetic population could not be run for Denmark, neither for Switzerland due to data 
failures. These two countries were dropped from the costs analysis in addition to the European nations that were 
dropped due to the lack of available information on nursing home expenditures. 
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3.2.3 Statistical analyses 
First of all, univariate analyses are performed between the dependent variable and each of the 
independent variables. Only the variables that are significant in the univariate analysis are 
afterwards included in the multivariate regressions. 
Then, modelling the probability of a positive outcome with a linear probability model (LPM) 
is known to be problematic (non-sensical predictions, functional form misspecification and 
heteroskedasticity are a few of the econometric issues of the LPM). Actually, LPM are also run in 
case they are feasible, but its application to this analysis has been rejected since there are too 
many negative probabilities predicted (more than 20%). Instead, non-linear models for binary 
responses such as logistic regressions with random effects are estimated (Rabe-Hesketh and 
Skrondal, 2008; Jones, 2005; Heij et al., 2004). In order to make sure my regression model choice 
is the most appropriate, the average marginal effects from the LPM and the logit model have 
been compared. LPM marginal effects strongly differ from the ones derived from the logistic 
regression, supporting my decision. Furthermore, fixed-effects logit models are also run but the 
number of observations dramatically dropped (from 90,589 observations to 479 observations), so 
only random-effects regressions are finally used for the purpose of this study.  
In logit models, estimated coefficients capture the effects on the log-odds-ratio (see e.g. Heij 
et al., 2004). Let Λ(𝑡) = 𝑒𝑡/(1 + 𝑒𝑡) be the logistic function with values stretching between zero 
and one, and let  
𝑃𝑟[𝑁𝐻𝑃𝑖𝑐𝑡 = 1 |𝑥𝑖𝑡] =  𝛬 (𝑥𝑖𝑡
′ 𝛽)          (4) 
where i represents the individual, c country, and t  year. 𝑁𝐻𝑃𝑖𝑐𝑡 is a dummy variable indicating 
that respondent i lived in country c and either permanently or temporarily in a nursing home in 
year t. 𝑥𝑖𝑡 = (SEit, diabetesit, HIit, country dummies, time dummies)′ is a vector of 
explanatory variables. SEit, diabetesit, HIit denote the set of socioeconomic variables, having 
diabetes and chronic conditions, respectively. In other words I can rewrite model (4) as:  
𝑃𝑟[𝑁𝐻𝑃𝑖𝑐𝑡 = 1 |𝑥𝑖𝑡] = Λ( 𝛽0 +  𝛽1𝑆𝐸𝑖𝑡 +  𝛽2𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖𝑡 +  𝛽3𝐻𝐼𝑖𝑡 +  𝛾𝑐 +  𝜁𝑡)    (5) 
where 𝛾𝑐 and 𝜁𝑡 denote country and time dummy coefficients, respectively. I estimate the 
parameters of equation (5) using a panel dataset (SHARE). In order to take into account within 
individual autocorrelation, I always compute clustered standard errors at the individual level.  
In the above logistic regression model, some diseases such as cerebrovascular conditions as 
well as functional impairment have not been included due to their relationship with diabetes, the 
main disease of interest in my analysis. If these complications had been counted in, the gross 
effect of diabetes would not be measured. However, in order to evaluate the net impact of 
diabetes in institutionalization and, consequently, its costs, these variables are incorporated into 
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the vector of independent variables in a second (clinical complications) and a third (functional 
complications) regression model. In the latter model, informal care is also added to test whether 
receiving informal care at home is an alternative of nursing home care and, hence, reduces the 
odds of being institutionalized or, on the other hand, whether it is a determinant of nursing home 
placement. This third regression model also controls for smoking as a potential confounding 
variable.  
I then perform several sensitivity analyses. Firstly, in order to measure the effect of 
complications related with diabetes on the outcome, interactions between diabetes and health 
conditions, health behaviours and informal care reception are included in the vector of 
explanatory variables (model 4).  
Second, since more disaggregation of the data allows for more accurate projections of the 
overall effect and cost of diabetes, the sample has been stratified into gender (males and females) 
and age groups (50-65, 66-80 and older than 80 years) and models 1, 3 and 4 are re-estimated for 
these five subgroups.  
Third, since the survey question about nursing home use differentiates between temporary 
and permanent use, the first, third and fourth regression models are also run for the different 
types of length of stay. 
Finally, since one of the aims of this analysis is to study across countries differences, 
regression models 1, 3 and 4 detailed in this section are run by country, excluding the country 
dummies term. 
All the statistical analyses have been performed using STATA 14.0 software (Stata 
Corporation, College Station, TX). 
 
3.2.4 Variables description 
Table 3.A2, Appendix, presents all variables included in the analyses.  
Nursing home in SHARE is defined as institutions sheltering older persons who need assistance in 
activities of daily living, in an environment where they can receive nursing care, for short or long stays. Thus, the 
dependent variable takes value 1 if the respondent has been in a nursing home overnight in the 
last twelve months, either temporarily or permanently, and 0 otherwise.  
Figure 3.1 shows the idea that motivates the criteria for the inclusion of clinical and functional 
complications in the regression model. Diabetes effect on nursing home admission is expected to 
be mediated by both clinical and functional complications, which might be at the same time 
caused by other diseases and other factors.  
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Moreover, a literature review has been made on the association between nursing home 
admission and health, as well as on institutionalization and diabetes to justify the inclusion of the 
variables. Results showed that sociodemographic factors such as age (Drame et al., 2012; Luppa 
et al., 2010; Gaugler et al., 2009; Luppa et al., 2008; Gaugler et al., 2007; Andel et al., 2007; 
Russell et al., 2005; Yaffe et al., 2002; Agüero-Torres et al., 2001; Smith et al., 2001; Smith et al., 
2000; Jagger et al., 2000), gender (Gaugler et al., 2009; Habermann et al., 2009; Luppa et al., 2008; 
Gaugler et al., 2007; Russell et al., 2005; Agüero-Torres et al., 2001; Smith et al., 2001), marital 
status (Drame et al., 2012; Luppa et al., 2010; Gaugler et al., 2009; Habermann et al., 2009; Luck 
et al., 2008; Luppa et al., 2008; Gaugler et al., 2007; Andel et al., 2007; Russell et al., 2005; Yaffe 
et al., 2002; Smith et al., 2001; Smith et al., 2000; Severson et al., 1994), education (Luppa et al., 
2008; Smith et al., 2000; Severson et al., 1994), and number of children (Drame et al., 2012; 
Gaugler et al., 2007) are associated with the risk of institutionalization, either with a negative or a 
positive sign. Other factors such as employment status (Luppa et al., 2010; Banaszak-Holl et al., 
2004)  and income (Gaugler et al., 2009; Colerick and George, 1986) are also included in some of 
the studies. Previous researches have also analysed the influence of chronic conditions (Luppa et 
al., 2010; van Rensbergen and Nawrot, 2010; Gaugler et al., 2009;  Gaugler et al., 2007; Nihtila et 
al., 2007; Russell et al., 2005; Banaszak-Holl et al., 2004), functional (Drame et al., 2012; Luppa et 
al., 2010; Gaugler et al., 2009; Habermann et al., 2009; Luppa et al., 2008; Gaugler et al., 2007; 
Coehlo et al., 2007; Yaffe et al., 2002; Agüero-Torres et al., 2001; Smith et al., 2001; Hebert et al., 
2001; Smith et al., 2000; Severson et al., 1994; O’Donnell et al., 1992; Steele et al., 1990)  and 
cognitive impairment (Drame et al., 2012; Luppa et al., 2010; Gaugler et al., 2009; Habermann et 
al., 2009; Luppa et al., 2008; Gaugler et al., 2007; Russell et al., 2005; Yaffe et al., 2002; Smith et 
al., 2001; Severson et al., 1994; O’Donnell et al., 1992; Steele et al., 1990) on the risk of being 
transferred into a nursing home.  
DIABETES 
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Bearing in mind my motivation and the literature search results, the main independent 
variables of interest are diabetes, as well as the complications that might be related to it. SHARE 
includes self-reported information about doctor’s diagnosis on individuals’ chronic conditions 
and self-reported limitations in ADL. In this analysis, I use six dichotomous indicators of chronic 
medical conditions, being heart attack, stroke, chronic lung disease, cancer, ulcer and being 
cognitively impaired, in addition to diabetes. Each diagnosis (model 2) as well as their interaction 
with diabetes (model 4) are part of the regression model.  
Furthermore, SHARE contains responses to the Katz Activities of Daily Living Index. This 
index, usually referred to as the Katz ADL evaluates functional status as a measurement of the 
person’s ability to carry out six activities of daily living independently (Abizanda et al., 2014)). 
These are bathing, dressing, toileting, transferring, continence and feeding. Regarding the number 
of limitations, functional impairment is divided into four categories: i) no impairment if 
individuals report no limitation in any ADL; ii) mild functional impairment when respondents 
declare being limited in one or two ADL; iii) moderate functional impairment if participants 
describe being limited in three to five of these activities; and iv) severe functional impairment 
when the person reports having difficulties in all ADLs. The last three involved the disability 
group, whereas the former is used as the reference group. Dummy variables for the different 
severity levels of functional impairment are included (model 3), as well as their interaction with 
diabetes (model 4). 
Besides, in models 3 and 4, informal care is considered as a social support variable that might 
be a confounder in my analysis. Only smoking habits are also included in the third and fourth 
regression as health behaviours due to their expected large confounding effect. Smokers will die 
earlier and run a smaller risk of being institutionalized.  
Finally, I also include in all four regression models other variables that might be related to the 
risk of being transferred to a nursing home. These are age, gender, level of education, marital and 
employment status, household income, household size, number of children and grandchildren 
and distance of these children to the respondent’s household. 
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3.3 RESULTS 
3.3.1 Sample characteristics 
Table 3.1 shows the descriptive statistics for the overall sample divided according to the 
outcome: whether respondents have been discharged to a nursing home or not. Furthermore, the 
table shows a comparison of means test in order to find out which are the significant variables 
that lead to institutionalization within this sample.  
The results suggest that there are socioeconomic and health factors differences across both 
populations. Those who are admitted to nursing homes are older, more likely to be women, and 
retired and with lower income. In contrast, being married and high school education or higher, 
larger household size, a greater number of children and living with these children are more 
common in people who have not been institutionalized. 
Regarding the health factors, worse health status is observed in those respondents who have 
answered yes to the nursing home use question. The same trend is observed for the diseases by 
their own as well as for the functional impairment categories. Particularly, the prevalence of 
diabetes between those discharged to a nursing home and those who are not varies in seven 
percentage points, from 18.49% in the former group to 11.49% in the latter.  
The percentage of people receiving informal care is higher in the nursing home population. 
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Table 3.1: Summary statistics  
Variables 
Admitted to nursing 
home (N = 441) 
No nursing home                 
(N = 63386) 
Comparison 
of means 
p-value Mean (SD) Min  Max Mean (SD) Min  Max 
Age 75.18 (11.91) 50.1 100.1 65.08 (10.33) 50 104.3 0.000 *** 
Female (%) 62.32  0 1 56.03  0 1 0.012 ** 
High or middle education (%) 38.64  0 1 52.33  0 1 0.000 *** 
Married (%) 50.58   0 1 75.42  0 1 0.000 *** 
Low household income (%)  36.53  0 1 33.33  0 1 0.077 * 
High household income (%) 30.67  0 1 33.35  0 1 0.121 
Retired (%) 69.06  0 1 52.01  0 1 0.000 *** 
Homemaker (%) 10.43  0 1 11.65  0 1 0.99 
Household size  1.73 (0.93) 1 7 2.23 (1.03) 1 14 0.000 *** 
Number of children 2.07 (1.58) 0 11 2.23 (1.46) 0 17 0.095 * 
Number of grandchildren 3.73 (3.49) 0 20 2.87 (3.26) 0 25 0.000 *** 
Children in household (%) 23.96  0 1 37.91  0 1 0.000 *** 
Children in less than 5 km (%) 23.20  0 1 22.08  0 1 0.11 
Diabetes (%) 18.49 0 1 11.49  0 1 0.000 *** 
Heart attack (%) 24.15  0 1 12.94  0 1 0.000 *** 
Stroke (%) 19.44  0 1 3.85  0 1 0.000 *** 
Chronic lung disease (%) 8.70  0 1 5.66  0 1 0.002 *** 
Cancer (%) 7.97  0 1 4.91  0 1 0.012 *** 
Ulcer (%) 6.04 0 1 5.52  0 1 0.780 
Cognitive impairment (%) 18.63  0 1 6.61  0 1 0.000 *** 
Mild functional impairment (%) 29.38  0 1 8.84  0 1 0.000 *** 
Moderate functional impairment (%) 12.71  0 1 1.17  0 1 0.000 *** 
Severe functional impairment (%) 11.75  0 1 0.63  0 1 0.000 *** 
Current smoker (%) 12.68  0 1 19.16  0 1 0.000 *** 
Ever smoked (%) 39.69  0 1 46.50  0 1 0.003 *** 
Informal care (%) 43.82  0 1 17.74  0 1 0000 *** 
Austria (%) 6.94  0 1 6.38  0 1 0.558 
Germany (%) 6.10  0 1 5.69  0 1 0.964 
Sweden (%) 9.69  0 1 6.14  0 1 0.219 
The Netherlands (%) 9.33  0 1 6.65  0 1 0.044 ** 
Spain (%) 5.14  0 1 6.53  0 1 0.059 * 
Italy (%) 6.22  0 1 7.30  0 1 0.935 
France (%) 8.73  0 1 9.38  0 1 0.586 
Denmark (%) 6.82  0 1 5.20  0 1 0.300 
Greece (%) 7.89  0 1 4.91  0 1 0.000 *** 
Switzerland (%) 3.59 0 1 4.95  0 1 0.098 * 
Belgium (%) 11.60 0 1 9.72  0 1 0.079 * 
Czech Republic (%) 7.18 0 1 7.09  0 1 0.790 
Wave 1 (%) 35.41  0 1 24.49  0 1 0.000 *** 
Wave 2 (%) 26.79  0 1 29.16  0 1 0.080 * 
Wave 4 (%) 37.80  0 1 46.35  0 1 0.003 *** 
***: p < 0.01; **: p < 0.05; *: p < 0.10; Source: authors of this chapter using data from SHARE. Means of dichotomous variables 
are expressed as percentages 
Diabetes-associated factors as predictors of nursing home admission and costs in the elderly across Europe 
Page | 65  
 
3.3.2 Diabetes and its complications as determinants of nursing home use 
Table 2 shows the results for the overall sample from the three regression models. Model 1 
(Column 1, Table 3.2) shows that having diabetes significantly increases the risk of being 
transferred to a nursing home (OR 1.55). Diabetes ranks second in size for its odds of being 
institutionalized after cognitive impairment and followed by cancer and chronic lung disease. 
Being married (OR 0.53), lower household income14 (OR 0.81), being retired (OR 0.80) and an 
increasing number of grandchildren (OR 0.96) are the set of socioeconomic factors that are 
significantly protective against the outcome. On the other hand, increasing age (OR 1.07) 
significantly increases the risk of nursing home transit. 
When clinical (Model 2, Table 3.2) and functional complications (Model 3, Table 3.2) are 
included, diabetes is still a significant variable, but its coefficient decreases (OR 1.45 in Model 2 
and OR 1.24 in Model 3). In the former model, stroke (OR 3.50) shows the highest probability 
within the chronic diseases leading to institutionalization. Nevertheless, in Model 3, the 
complication that mostly increases the odds of nursing home placement are the several levels of 
functional impairment, with severe functional impairment having the highest odds ratio (OR 
12.53). The latter model also shows that receiving informal care (OR 1.38) is significant and 
positively associated with the dependent variable. Regarding the socioeconomic variables, the 
same pattern for most of them as in model 1 and 2 holds in model 3, with the exception of 
being retired, which is no longer a significant determinant. 
Marginal effects of the regressors on the probability of nursing home use are displayed in 
Table 3.A3 in Appendix. 
 
3.3.2.1 Sensitivity analysis 
Table 3.2 also shows the results from the interactions model (Model 4, Table 3.2). As shown 
in the table, none of the interactions between the disease of interest and clinical and functional 
complications are statistically significant. Moreover, diabetes is still positively associated with 
institutionalization, but it is no longer significant either, probably due to lack of power. 





                                                          
14 Not enough information was available to interpret the negative association between household income and 
nursing home admission. It might be due to the fact that, given their low income, those individuals cannot afford the  
institutionalization fees. However, it was not possible to identify whether the admission was in a public or a private 
instititution.  
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Table 3.2: Results from the logit regressions regarding nursing home admission for the 
overall sample 








Diabetes 1.55*** 1.45*** 1.24* 1.10 
 (1.22-1.97) (1.14-1.85) (0.98-1.62) (0.66-1.83) 
Diabetes & Chronic lung disease    0.76 
    (0.34-1.69) 
Diabetes & Cancer    0.72 
    (0.30-1.70) 
Diabetes & Ulcer    0.96 
    (0.44-2.10) 
Diabetes & Cognitive impairment    0.67 
    (0.34-1.32) 
Diabetes & Heart attack    1.05 
    (0.62-1.77) 
Diabetes & Stroke    1.04 
    (0.55-1.98) 
Diabetes & Mild functional impairment    1.00 
    (0.54-1.86) 
Diabetes & Moderate functional impairment    1.10 
    (0.46-2.61) 
Diabetes & Severe functional impairment    1.82 
    (0.68-4.87) 
Diabetes & Ever smoked    1.50 
    (0.89-2.51) 
Diabetes & Informal care    0.95 
    (0.56-1.60) 
Age 1.07*** 1.07** 1.04*** 1.04*** 
 (1.06-1.09) (1.05-1.08) (1.03-1.06) (1.03-1.05) 
Female 0.96 0.98 0.92 0.93 
 (0.78-1.18) (0.80-1.21) (0.74-1.16) (0.74-1.16) 
High or middle education  0.88 0.89 0.97 0.96 
 (0.70-1.10) (0.71-1.11) (0.77-1.23) (0.76-1.22) 
Married 0.53*** 0.53*** 0.58*** 0.57*** 
 (0.42-0.66) (0.42-0.66) (0.46-0.74) (0.45-0.73) 
Low household income 0.81* 0.80* 0.81* 0.81* 
 (0.63-1.04) (0.62-1.03) (0.65-1.08) (0.62-1.04) 
Retired 0.80* 0.80* 0.92 0.92 
 (0.64-1.02) (0.63-1.01) (0.70-1.14) (0.72-1.17) 
Household size 0.98 0.97 0.93 0.93 
 (0.84-1.15) (0.83-1.14) (0.77-1.09) (0.78-1.11) 
Number of children 1.01 1.01 1.00 0.99 
 (0.91-1.12) (0.91-1.12) (0.90-1.11) (0.90-1.10) 
Number of grandchildren 0.96* 0.96* 0.96* 0.96* 
 (0.92-1.01) (0.92-1.00) (0.92-1.00) (0.92-1.00) 
Children in household 0.81 0.81 0.77* 0.77* 
 (0.62-1.05) (0.62-1.05) (0.58-1.01) (0.59-1.01) 
Chronic lung disease 1.26 1.19 0.96 1.02 
 (0.90-1.77) (0.85-1.67) (0.68-1.37) (0.68-1.52) 
Cancer 1.42** 1.34* 1.27 1.35 
 (1.01-2.00) (0.95-1.89) (0.92-1.84) (0.92-1.99) 
Cognitive impairment 2.65*** 2.48*** 2.00*** 2.16*** 
 (2.07-3.37) (1.94-3.16) (1.60-2.68) (1.63-2.86) 
Heart attack  1.14 0.98 0.96 
  (0.90-1.44) (0.77-1.25) (0.73-1.28) 
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Table 3.2: (continued) 








Stroke  3.50*** 2.08*** 2.05*** 
  (2.72-4.49) (1.61-2.80) (1.48-2.82) 
Mild functional impairment   3.27*** 3.28*** 
   (2.60-4.19) (2.53-4.25) 
Moderate functional impairment   8.48*** 8.41*** 
   (6.02-13.09) (5.42-13.04) 
Severe functional impairment   12.53*** 10.59*** 
   (8.03-19.98) (6.27-17.91) 
Current smoker   0.88 0.89 
   (0.63-1.22) (0.64-1.23) 
Ever smoked   1.04 0.96 
   (0.81-1.31) (0.74-1.25) 
Informal care   1.38*** 1.40*** 
   (1.09-1.68) (1.10-1.77) 
Observations 90,589 90,589 90,589 90,589 
Log pseudolikelihood -2609.98 -2571.28 -2456.44 -2453.33 










Year effects YES YES YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, sex, 
education, marital status, household income, and employment status), family network, and household composition (household 
size, number of children and grandchildren, and children in household), non-diabetes-related complications (chronic lung disease, 
cancer and cognitive impairment) and country dummies. Model 2 adds to the previous model diabetes-related clinical 
complications: heart attack and stroke. Model 3 includes the above variables and different degrees of functional impairment 
according to the number of limitations in ADLs (mild, moderate, and severe), which is also related to diabetes, lifestyle (current 
smoker and ever smoked), and informal care. Model 4 adds the interactions between the main disease of interest, diabetes, and all 
the clinical and functional complications, both nonrelated and related to diabetes, as well as the interactions between diabetes and 
lifestyle variables and informal care. 
Each of the interactions measures the effect of jointly having diabetes and any of the above variables compared with not having 
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When the sample is divided into age groups (Table 3.A4, Appendix), diabetes is a determinant 
factor of higher risk of nursing home admission in later ages, from 65 years old and older. 
Furthermore, diabetes coefficients are greater in the case people’s age is over 80 years old (OR 
1.839 in Model 1, 5th Column, Table 3.A4) than in those whose age ranges between 66 and 80 
years old (OR 1.713 in Model 1, 3rd Column, Table 3.A4) when clinical and functional 
complications are omitted. However, when these are included in the regression, diabetes remains 
as a significant predictor only in the oldest subsample (OR 1.454 in Model 3, 6th Column, Table 
3.A4). For the population whose age ranges between 50 to 65 years old, diseases such as 
functional and cognitive impairment, stroke and cancer are the ones that lead to 
institutionalization (2nd Column, Table 3.A4). Furthermore, informal care is only significant for 
the oldest cohort. Such variable significantly increases the probability of being institutionalized in 
those people older than 80 years old (OR 1.710 in Model 3, 6th Column, Table 3.A4). Finally, 
when interaction terms are part of the regression, none of the interactions neither diabetes appear 
to be significant predictors of nursing home placement in the population aged 66 and older 
(Table 3.A5, Appendix). But, if one looks at the youngest age group, diabetes together with 
cancer (OR 2.472, 1st Column, Table 3.A5, Appendix) significantly increases the probability of 
being in a nursing home. Conversely, if an individual suffers from diabetes and heart attack, 
his/her likelihood of being institutionalized is significantly reduced, maybe due to the lower 
severity of such conditions in this group age. 
Tables 3.A6 and 3.A7 in Appendix show the results from the regression models for females 
and males, and the regressions including interactions for both genders, respectively. Diabetes 
stands as a significant predictor of nursing home admission for males across the regression 
models without interactions, although its OR decreases from 1.994 (3rd Column, Table 3.A6) in 
the baseline model to 1.556 (4th Column, Table 3.A6) when both clinical and functional 
complications are included in the regression. Conversely, for women, diabetes never emerges as a 
determinant factor of the measured outcome. For females, the different degrees of functional 
impairment severity, stroke and cognitive impairment are the most determinant health factors of 
institutionalization (2nd Column, Table 3.A6). Informal care is never significant neither smoking 
habits for women. Equally, severity levels of functional impairment are highly significant for 
males (4th Column, Table 3.A6), being the impact of severe functional impairment greater than 
for females, but moderate and mild report lower odds ratios for men. Informal care (OR 1.897) 
does appear to be significant and positively associated with increasing odds of nursing home 
placement (4th Column, Table 3.A6). As a final point, jointly having diabetes and stroke are 
interaction terms (Table 3.A7, Appendix) commonly significant for both genders, but with 
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contrary interpretations: women with diabetes and stroke are more prone to be institutionalized 
(OR 2.415, 1st Column, Table 3.A7), whereas men who suffer from both diseases are less likely to 
be placed in a nursing home (OR 0.362, 2nd Column, Table 3.A7) compared to those without any 
of both. Also, severe (OR 5.784) functional impairment interaction with diabetes does 
significantly predict higher odds of being admitted into a nursing home for males. Diabetes is not 
significant for any of the genders (Table 3.A7, Appendix) when interactions are part of the 
analysis. 
Length of stay results are shown in Table 3.A8, Appendix, for permanent and temporary use 
of nursing homes, respectively, and in Table 3.A9, Appendix, with the results from the regression 
with interactions. Diabetes  is a significant factor of nursing home transit when the respondent 
stays either permanent or temporarily (OR 1.435 in Model 1 for permanent stay, 1st Column, 
Table 3.A8; OR 1.819 in Model 1 for temporary stay, 3rd Column, Table 3.A8) as long as 
diabetes-related complications and functional impairment indicators are not included in the 
regression. When they are introduced, diabetes is no longer significant. Cognitive impairment, 
heart attack, stroke and functional impairment are statistically significant and always positively 
associated with the outcome, regardless of the length of stay (2nd and 4th Columns, Table 3.A8). 
However, heart attack is statistically significant in both subsamples, but with opposite 
interpretation between length of stays. Moreover, informal care follows the same trend as heart 
attack, but it is only significant for temporary admissions. Eventually, no interaction term is 
reported to be significant, irrespective of the length of stay (Table 3.A9, Appendix). Diabetes is 
not a determinant of nursing home placement anymore in Model 4. 
Finally, results by country without interaction terms are shown in Table 3.3. When looking at 
models 1 and 3, diabetes is only significant in three countries: Sweden, The Netherlands and 
Spain. In Sweden and in the Netherlands, diabetes is significantly associated with an increasing 
probability of being institutionalized only in Model 1. Conversely, in the case of Spain, diabetes is 
a determinant of nursing home regardless of the covariates that are included. Actually, within the 
Spanish population, when related clinical and functional complications are part of the regression 
model, diabetes coefficient reduces from OR 3.496 (Model 1) to OR 3.184 (Model 3). Results 
regarding other diseases and complications vary quite a lot across countries, although some 
agreement seems to be reached about greater severity of functional impairment, cognitive 
impairment and, in a shorter majority, about heart attack and stroke. 
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Results from the regression models with interactions are shown in Table 3.A10, in the 
Appendix15. Spain, France, Denmark, Greece, Belgium and Czech Republic report significant 
results for some of the interactions. Diabetes together with stroke is the most common 
interactions highly increasing the likelihood of being institutionalized in France, Greece and 
Belgium.  
Increasing age is always a factor leading to institutionalization, apart from Belgium and Czech 
Republic, where age is not a significant variable. Being a woman only significantly increases the 
risk of nursing home placement in the Netherlands. High household income only appears as a 
protective factor against institutionalization in Sweden. In the rest of the countries, income is not 

































                                                          
15 Only four countries (Sweden, The Netherlands, Italy and Switzerland) do not allow for the calculation of the 
model with interactions (Model 4) due to their sample size. 
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Diabetes 1.675 1.189 1.626 1.297 
 (0.837) (0.704) (0.784) (0.716) 
Age 1.082*** 1.039* 1.107*** 1.069** 
 (0.0191) (0.0214) (0.0274) (0.0331) 
Female 0.520* 0.545 1.237 1.333 
 (0.192) (0.216) (0.637) (0.666) 
High or middle education 0.672 0.743 0.933 0.877 
 (0.179) (0.211) (0.227) (0.252) 
Married 1.938** 1.987** 1.043 0.955 
 (0.503) (0.594) (0.259) (0.272) 
Retired 0.507 0.541 0.572 0.447 
 (0.217) (0.247) (0.271) (0.229) 
Household size 1.137 1.056 0.594 0.575 
 (0.366) (0.421) (0.222) (0.227) 
Number of children 0.826 0.795 0.779 0.650* 
 (0.204) (0.209) (0.137) (0.167) 
Number of grandchildren 0.906 0.926 1.084 1.084 
 (0.0809) (0.0857) (0.0911) (0.115) 
Children in household 0.640 0.617 1.086 0.858 
 (0.344) (0.324) (0.542) (0.494) 
Chronic lung disease 0.507 0.341 3.588*** 3.528** 
 (0.522) (0.400) (1.747) (2.000) 
Cancer 2.593 1.941 2.166 2.058 
 (1.642) (1.314) (1.247) (1.057) 
Cognitive impairment 2.696* 3.487** 2.518** 1.681 
 (1.513) (1.882) (1.130) (0.726) 
Heart attack  2.276*  1.156 
  (1.087)  (0.537) 
Stroke  2.278  3.041** 
  (1.276)  (1.715) 
Mild functional impairment  1.980  3.214** 
  (1.033)  (1.649) 
Moderate functional impairment  1.554  42.35*** 
  (1.886)  (23.35) 
Severe functional impairment  31.79***  5.201 
  (24.35)  (6.091) 
Current smoker  0.195  3.229* 
  (0.205)  (2.192) 
Ever smoked  1.318  0.486 
  (0.575)  (0.249) 
Informal care  1.126  2.209** 
  (0.539)  (0.884) 
Observations 5,924 5,924 5,102 5,102 
Log pseudolikelihood -160.20 -145.34 -138.01 -112.91 
Year effects YES YES YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, sex, 
education, marital status, household income, and employment status), family network, and household composition (household 
size, number of children and grandchildren, and children in household) and non-diabetes-related complications (chronic lung 
disease, cancer and cognitive impairment). Model 2 adds to the previous model diabetes-related clinical complications: heart attack 
and stroke. Model 3 includes the above variables and different degrees of functional impairment according to the number of 
limitations in ADLs (mild, moderate, and severe), which is also related to diabetes, lifestyle (current smoker and ever smoked), 
and informal care.  
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Table 3.3: (continued) 
VARIABLES 
OR Model 1 
Sweden 
OR Model 3 
Sweden 
OR Model 1 
Netherlands 
OR Model 3 
Netherlands 
Diabetes 2.645** 1.441 2.188** 1.785 
 (1.077) (0.493) (0.860) (0.916) 
Age 1.127*** 1.053* 1.106*** 1.073*** 
 (0.0276) (0.0301) (0.0197) (0.0228) 
Female 0.822 0.665 2.101* 2.509* 
 (0.302) (0.299) (0.894) (1.392) 
High or middle education 0.997 0.850 0.472*** 0.521** 
 (0.296) (0.292) (0.112) (0.132) 
Married 0.629 0.520 0.768 0.890 
 (0.219) (0.240) (0.298) (0.344) 
Low household income 0.808 0.721 1.058 1.109 
 (0.381) (0.456) (0.483) (0.564) 
High household income 0.141* 0.0721*** 1.121 0.988 
 (0.153) (0.0559) (0.622) (0.650) 
Retired 0.739 1.255 0.690 0.719 
 (0.552) (1.181) (0.247) (0.322) 
Household size 0.254** 0.129** 0.186** 0.230** 
 (0.177) (0.124) (0.141) (0.148) 
Number of children 1.044 1.050 1.126 1.060 
 (0.188) (0.225) (0.122) (0.124) 
Number of grandchildren 0.918 0.883 0.947 1.025 
 (0.0673) (0.0800) (0.0442) (0.0547) 
Children in household - - 3.322** 4.028** 
   (1.562) (2.350) 
Chronic lung disease 2.952** 2.587 0.947 0.524 
 (1.570) (1.786) (0.512) (0.436) 
Cancer 0.769 0.494 0.401 0.448 
 (0.497) (0.459) (0.422) (0.486) 
Cognitive impairment 2.846** 2.646* 3.066*** 1.374 
 (1.169) (1.410) (1.164) (0.698) 
Heart attack  1.186  1.046 
  (0.508)  (0.464) 
Stroke  7.697***  0.864 
  (3.753)  (0.522) 
Mild functional impairment  4.839***  8.534*** 
  (2.591)  (3.581) 
Moderate functional impairment  52.51***  52.46*** 
  (33.23)  (37.45) 
Severe functional impairment  174.0***  143.1*** 
  (119.1)  (113.7) 
Current smoker  0.871  0.342 
  (0.839)  (0.246) 
Ever smoked  1.056  2.501* 
  (0.565)  (1.239) 
Informal care  1.624  0.791 
  (0.749)  (0.321) 
Observations 4,863 4,863 5,913 5,913 
Log pseudolikelihood -171.80 -115.03 -185.72 -153.65 
Year effects YES YES YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, sex, 
education, marital status, household income, and employment status), family network, and household composition 
(household size, number of children and grandchildren, and children in household) and non-diabetes-related complications 
(chronic lung disease, cancer and cognitive impairment). Model 2 adds to the previous model diabetes-related clinical 
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complications: heart attack and stroke. Model 3 includes the above variables and different degrees of functional impairment 
according to the number of limitations in ADLs (mild, moderate, and severe), which is also related to diabetes, lifestyle 
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Table 3.3: (continued) 
VARIABLES 
OR Model 1 
Spain 
OR Model 3 
Spain 
OR Model 1 
Italy 
OR Model 3 
Italy 
Diabetes 3.496** 3.184** 1.564 1.434 
 (1.734) (1.664) (0.659) (0.565) 
Age 1.048* 1.039 1.027 1.016 
 (0.0292) (0.0360) (0.0219) (0.0217) 
Female 0.467 0.726 0.609 0.547 
 (0.334) (0.546) (0.213) (0.210) 
High or middle education 1.195 1.207 1.207 1.238 
 (0.343) (0.352) (0.317) (0.327) 
Married 0.953 0.966 0.818 0.788 
 (0.218) (0.246) (0.211) (0.208) 
Retired 0.214* 0.187* 1.009 1.101 
 (0.186) (0.179) (0.362) (0.409) 
Household size 0.580** 0.544** 0.907 0.867 
 (0.160) (0.162) (0.207) (0.206) 
Number of children 0.712 0.731 1.040 1.046 
 (0.257) (0.253) (0.217) (0.223) 
Number of grandchildren 1.084 1.067 0.990 0.983 
 (0.180) (0.178) (0.0742) (0.0752) 
Children in household 1.950 1.846 1.187 1.174 
 (0.980) (0.905) (0.500) (0.501) 
Chronic lung disease 0.647 0.463 1.451 1.362 
 (0.656) (0.359) (0.814) (0.766) 
Cancer 1.023 1.006 1.310 1.141 
 (1.099) (0.823) (0.975) (0.808) 
Cognitive impairment 2.567* 1.831 1.506 1.307 
 (1.348) (1.176) (1.120) (1.030) 
Heart attack  0.820  0.609 
  (0.497)  (0.385) 
Stroke  2.559  0.823 
  (2.104)  (0.887) 
Mild functional impairment  2.001  2.235 
  (1.378)  (1.188) 
Moderate functional impairment  4.651  3.177 
  (5.084)  (4.213) 
Severe functional impairment  7.027*  10.41** 
  (7.364)  (11.19) 
Current smoker  0.804  1.510 
  (0.651)  (0.816) 
Ever smoked  2.885  0.781 
  (1.915)  (0.367) 
Informal care  0.852  0.762 
  (0.653)  (0.436) 
Observations 5,867 5,867 6,860 6,860 
Log pseudolikelihood -125.41 -119.98 -207.18 -203.34 
Year effects YES YES YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, sex, 
education, marital status, household income, and employment status), family network, and household composition 
(household size, number of children and grandchildren, and children in household) and non-diabetes-related 
complications (chronic lung disease, cancer and cognitive impairment). Model 2 adds to the previous model diabetes-
related clinical complications: heart attack and stroke. Model 3 includes the above variables and different degrees of 
functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), which is also related 
to diabetes, lifestyle (current smoker and ever smoked), and informal care.  
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Table 3.3: (continued) 
VARIABLES OR Model 1 
France 
OR Model 3 
France 
OR Model 1 
Denmark 
OR Model 3 
Denmark 
Diabetes 1.263 1.207 1.009 1.089 
 (0.551) (0.557) (0.671) (0.974) 
Age 1.044*** 1.012 1.125*** 1.039 
 (0.0164) (0.0190) (0.0262) (0.0298) 
Female 1.022 0.990 0.408** 0.345 
 (0.334) (0.416) (0.162) (0.253) 
High or middle education 1.104 1.196 0.631 1.072 
 (0.183) (0.211) (0.195) (0.400) 
Married 0.994 0.996 1.984 2.127 
 (0.197) (0.210) (1.457) (1.860) 
Low household income - - 0.918 1.201 
   (0.454) (0.763) 
High household income 0.740 0.753 2.286 1.250 
 (0.320) (0.327) (1.872) (1.054) 
Retired 3.686*** 4.565*** 0.477 0.664 
 (1.658) (2.064) (0.373) (0.619) 
Household size 0.974 0.972 0.151 0.107 
 (0.210) (0.229) (0.217) (0.188) 
Number of children 0.965 0.958 1.219 1.053 
 (0.138) (0.147) (0.181) (0.290) 
Number of grandchildren 0.989 0.989 0.958 1.107 
 (0.0583) (0.0608) (0.0657) (0.104) 
Children in household 1.738 1.648 - - 
 (0.820) (0.818)   
Chronic lung disease 1.806 1.553 0.297 0.223 
 (0.891) (0.836) (0.332) (0.226) 
Cancer 1.632 1.534 1.296 0.877 
 (0.810) (0.767) (0.848) (0.723) 
Cognitive impairment 2.263** 2.452** 5.483*** 6.142*** 
 (0.877) (0.963) (2.378) (3.382) 
Heart attack  1.033  1.877 
  (0.462)  (1.083) 
Stroke  2.675*  5.142** 
  (1.358)  (3.688) 
Mild functional impairment  2.382*  12.97*** 
  (1.117)  (7.258) 
Moderate functional impairment  2.121  498.2*** 
  (2.536)  (575.8) 
Severe functional impairment  11.83**  19.32* 
  (13.34)  (32.36) 
Current smoker  0.189  0.250* 
  (0.198)  (0.200) 
Ever smoked  1.093  0.687 
  (0.438)  (0.472) 
Informal care  1.577  1.922 
  (0.590)  (0.903) 
Observations  8,313 8,313 4,083 4,083 
Log pseudolikelihood -244.54 -233.53 -122.19 -79.55 
Year effects YES YES YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, sex, 
education, marital status, household income, and employment status), family network, and household composition 
(household size, number of children and grandchildren, and children in household) and non-diabetes-related 
complications (chronic lung disease, cancer and cognitive impairment). Model 2 adds to the previous model diabetes-
Chapter 3  
 
Page | 76  
 
related clinical complications: heart attack and stroke. Model 3 includes the above variables and different degrees of 
functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), which is also related 
to diabetes, lifestyle (current smoker and ever smoked), and informal care.  
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Table 3.3: (continued) 
VARIABLES OR Model 1 
Greece 
OR Model 3 
Greece 
OR Model 1 
Switzerland 
OR Model 3 
Switzerland 
Diabetes 1.094 1.123 1.931 2.957 
 (0.478) (0.500) (1.870) (2.310) 
Age 1.030 1.021 1.047 1.008 
 (0.0230) (0.0224) (0.0470) (0.0398) 
Female 1.256 0.915 1.053 0.969 
 (0.418) (0.279) (0.810) (0.821) 
High or middle education 1.336 1.337 0.581 1.025 
 (0.298) (0.301) (0.342) (0.624) 
Married 1.389** 1.410** 0.393* 0.237** 
 (0.211) (0.214) (0.207) (0.138) 
Low household income - - 0.491 0.361 
   (0.425) (0.229) 
High household income - - 1.122 0.823 
   (0.842) (0.582) 
Retired 0.917 0.924 3.425 4.197* 
 (0.343) (0.350) (2.777) (3.658) 
Household size 1.502** 1.573*** 0.118** 0.0482*** 
 (0.238) (0.275) (0.102) (0.0511) 
Number of children 0.930 0.856 1.011 1.153 
 (0.176) (0.166) (0.220) (0.275) 
Number of grandchildren 0.979 0.994 0.860 0.847 
 (0.0780) (0.0837) (0.0862) (0.0985) 
Children in household 0.341*** 0.333*** 1.180 0.686 
 (0.110) (0.112) (0.941) (0.619) 
Chronic lung disease 0.443 0.466 2.002 1.278 
 (0.462) (0.503) (2.435) (1.676) 
Cancer 3.068* 3.173* 2.452 2.346 
 (2.054) (2.119) (2.293) (2.211) 
Cognitive impairment 1.341 1.363 2.451 2.940 
 (0.851) (0.867) (2.248) (2.447) 
Heart attack  0.249*  0.601 
  (0.206)  (0.704) 
Stroke  1.218  1.161 
  (0.877)  (1.221) 
Mild functional impairment  1.786  12.76*** 
  (0.835)  (8.782) 
Moderate functional impairment  2.520  82.69*** 
  (2.678)  (103.9) 
Severe functional impairment  -  - 
     
Current smoker  0.841  2.055 
  (0.408)  (1.990) 
Ever smoked  0.519*  0.799 
  (0.206)  (0.559) 
Informal care  1.160  6.988** 
  (0.488)  (5.432) 
Observations 5,167 5,147 4,385 4,383 
Log pseudolikelihood -271.81 -265.50 -74.53 -60.09 
Year effects YES YES YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, sex, 
education, marital status, household income, and employment status), family network, and household composition (household 
size, number of children and grandchildren, and children in household) and non-diabetes-related complications (chronic lung 
disease, cancer and cognitive impairment). Model 2 adds to the previous model diabetes-related clinical complications: heart 
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attack and stroke. Model 3 includes the above variables and different degrees of functional impairment according to the 
number of limitations in ADLs (mild, moderate, and severe), which is also related to diabetes, lifestyle (current smoker and 
ever smoked), and informal care.  
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Table 3.3: (continued) 
VARIABLES OR Model 1 
Belgium 
OR Model 3 
Belgium 
OR Model 1 
Czech Republic 
OR Model 3 
Czech Republic 
Diabetes 1.291 0.866 1.108 0.885 
 (0.500) (0.352) (0.472) (0.362) 
Age 1.108*** 1.089*** 1.020 0.991 
 (0.0170) (0.0165) (0.0254) (0.0242) 
Female 1.191 1.273 0.508* 0.517* 
 (0.375) (0.494) (0.184) (0.187) 
High or middle education 1.131 1.202 0.853 0.899 
 (0.194) (0.211) (0.243) (0.262) 
Married 1.417* 1.406* 1.310 1.333 
 (0.269) (0.282) (0.244) (0.261) 
Low household income 0.761 0.784 - - 
 (0.258) (0.254)   
Mid household income - - 0.651 0.604 
   (0.293) (0.270) 
High household income 0.546 0.560 - - 
 (0.250) (0.264)   
Retired 0.868 0.980 1.134 1.156 
 (0.283) (0.314) (0.582) (0.595) 
Household size 0.953 0.958 1.009 0.982 
 (0.289) (0.310) (0.213) (0.243) 
Number of children 1.256** 1.200 0.986 0.974 
 (0.144) (0.137) (0.205) (0.215) 
Number of grandchildren 0.893** 0.899** 1.036 1.035 
 (0.0445) (0.0455) (0.0875) (0.0811) 
Children in household 0.715 0.692 0.691 0.630 
 (0.323) (0.327) (0.281) (0.275) 
Chronic lung disease 1.336 1.177 1.619 1.216 
 (0.653) (0.588) (0.916) (0.657) 
Cancer 1.277 1.002 1.341 1.124 
 (0.604) (0.481) (0.797) (0.770) 
Cognitive impairment 2.032* 2.010* 4.877*** 3.339*** 
 (0.779) (0.769) (2.015) (1.472) 
Heart attack  1.041  1.436 
  (0.393)  (0.527) 
Stroke  2.021  2.266* 
  (0.867)  (1.032) 
Mild functional impairment  2.502***  2.585** 
  (0.748)  (1.019) 
Moderate functional impairment  1.546  5.490** 
  (1.135)  (4.419) 
Severe functional impairment  30.39***  18.73*** 
  (20.68)  (15.13) 
Current smoker  1.066  0.638 
  (0.485)  (0.321) 
Ever smoked  1.390  1.373 
  (0.507)  (0.499) 
Informal care  1.453  1.444 
  (0.455)  (0.513) 
Observations 8,947 8,947 6,721 6,721 
Log pseudolikelihood -285.39 -270.50 -225.39 -211.49 
Year effects YES YES YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
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Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, sex, 
education, marital status, household income, and employment status), family network, and household composition (household 
size, number of children and grandchildren, and children in household) and non-diabetes-related complications (chronic lung 
disease, cancer and cognitive impairment). Model 2 adds to the previous model diabetes-related clinical complications: heart 
attack and stroke. Model 3 includes the above variables and different degrees of functional impairment according to the number 
of limitations in ADLs (mild, moderate, and severe), which is also related to diabetes, lifestyle (current smoker and ever smoked), 
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3.3.3 The cost of diabetes and its complications 
The methods to estimate the costs have already been discussed in section 3.2. Table 3.4 shows 
the results for the Adjusted Relative Risks and the Etiological Fractions. Table 3.4 shows that 
without estimating the adjusted relative risks, my estimation could be overestimating the impact 
of diabetes and its non-related and related clinical and functional complications if I had used the 
Odds Ratio directly from the regressions output.  
Results of nursing home costs are shown in Figure 3.2. Information about total nursing home 
costs per capita per country and year can be found in Table 3.A11 in the Appendix. Monetary 
values are in current international US dollars and adjusted by Purchasing Power Parity (PPP) 
index. Gross Domestic Product (GDP) per capita per country and year, which has been used to 
calculate the expenditures per capita as a percentage of  country GDP, is shown in Table 3.A12, 
Appendix. 
Figure 3.2 shows that total average costs per capita incurred by people with diabetes within 
the SHARE sample and along the years of the three waves reach $12.66, with one third of them 
attributed to its complications. The complications associated with diabetes that generate the 
greatest burden to cross-countries nursing home expenditures are functional impairment ($3.17 
in total) and stroke ($0.45). Functinal impairment represent 78% of the total costs attributed to 
diabetes complications in overall countries. 
Costs incurred by people with diabetes by country level range from $61.34 per capita in the 
Netherlands to $0.35 in Czech Republic. Figure 3.2 also reports nursing home expenditures per 
capita attributed to diabetes by country as a percentage of country Gross Domestic Product 
(GDP), adjusted by Power Purchasing Parity (PPP) index. When interpreting nursing home costs 
attributed to diabetes as percentages of GDP, Spain is again the country which reports the 
highest figures. Within Spanish’ results, the main drivers of increasing costs are the several levels 
of severity of functional impairment (0.058% and 0.038% of the GDP in Spain for moderate and 
severe functional impairment, respectively), and heart attack (0.017% of Spanish GDP). 
Across countries, the main drivers of costs attributed to diabetes vary in some way, as Figure 
3.2 shows. Severity of functional impairment seems to be the main determinant of increasing 
nursing home costs attributed to diabetes, especially when the severity of functional impairment 
is mild. After functional impairment, stroke is the complication with a higher burden on 
institutionalization costs, especially in France, Belgium and Czech Republic.  
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Table 3.4: Odds Ratio (OR), Adjusted Relative Risks (RR) and Etiological Fractions (EF) for diabetes and diabetes non-related and 













































- - - 
Chronic lung disease 1.26 1.26  0.88 0.89 -0.006 0.51 0.513  - - - 
Cancer 1.42 1.41  1.04 1.04 0.002 2.59 2.516  5.77 3.25 0.097 
Cognitive impairment 2.65 2.60  1.38 1.34 0.022 2.70 2.621  19.19 5.94 0.225 
Heart attack    1.05 1.04 0.005    86.55 23.96 0.717 
Stroke    2.23 2.08 0.036    0.22 0.35 -0.029 
Mild functional 
impairment 
   
3.69 3.12 0.144 
   
2.15 1.77 0.061 
Moderate functional 
impairment 
   
8.82 6.52 0.046 
   
- - - 
Severe functional 
impairment 
   
25.81 15.18 0.060 
   

























































- - - 
Chronic lung disease 3.59 3.366  7.68 4.39 0.16 0.95 0.95  0.03 0.21 -0.053 
Cancer 2.17 2.073  2.30 1.92 0.050 0.40 0.43  - - - 
Cognitive impairment 2.52 2.410  - - - 3.067 2.76  0.79 0.88 -0.007 
Heart attack    0.22 0.32 -0.089    1.78 1.37 0.038 
Stroke    0.22 0.32 -0.026    0.01 0.10 -0.034 
Mild functional 
impairment 
   
6.06 3.78 0.174 
   
8.85 3.82 0.132 
Moderate functional 
impairment 
   
150.67 28.41 0.208 
   
96.85 8.49 0.037 
Severe functional 
impairment 
   
- - - 
   
- - - 
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- - - 
Chronic lung disease 0.65 0.65  - - - 1.81 1.78  - - - 
Cancer 1.02 1.02  - - - 1.63 1.62  - - - 
Cognitive impairment 2.57 2.52  - - - 2.26 2.23  0.62 0.75 -0.023 
Heart attack    0.03 0.09 -0.117    0.07 0.18 -0.116 
Stroke    - - -    248.59 12.70 0.253 
Mild functional 
impairment 
   
0.57 0.63 -0.035 
   
9.26 3.22 0.176 
Moderate functional 
impairment 
   
1,308.07 35.69 0.392 
   
- - - 
Severe functional 
impairment 
   
467.39 23.75 0.257 
   

























































- - - 
Chronic lung disease 1.34 1.32  3.64 1.74 0.0391 1.62 1.61  1.58 3.80 0.14 
Cancer 1.28 1.27  4.21 1.84 0.0448 1.34 1.34  - - - 
Cognitive impairment 2.03 1.98  10.78 2.62 0.1084 4.88 4.74  1.07 2.36 0.062 
Heart attack    0.05 040 -0.0799    0.36 1.35 0.05 
Stroke    41785.38 24.28 0.4330    0.93 2.26 0.057 
Mild functional 
impairment 
   
12.31 2.75 0.1627 
   
1.29 2.72 0.114 
Moderate functional 
impairment 
   
2774.87 9.43 0.0720 
   
- - - 
Severe functional 
impairment 
   
11227.4 12.29 0.0253 
   
4.01 24.23 0.057 
OR: Odds Ratio; RR: Relative Risk; EF: Etiological Fraction 
a Odds ratio obtained from logit regressions controlling for age, gender, education, marital status, household income, employment status, household size, number of children and 
grandchildren, whether any children lives in respondent’s household, smoking status and informal care. b Adjusted relative risks estimated after running logit regressions using 
the Stata command adjrr (Norton et al., 2013).c Etiological fractions estimated using formula (1). 
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Figure 3.2: Components of costs per capita and per year attributed to diabetes complications. Costs per capita incurred by people with diabetes in 
brackets adjusted by PPP, current international $, followed by % of nursing home costs over GDP per capita 
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Figure 3.2: (continued) 
 
 
Costs attributed to diabetes complications are estimated using formula (3), multiplying the EF corresponding for each disease (Table 3, Model 3) times the costs incurred by people 
with diabetes. So, for example, for the whole sample, the costs attributed to mild functional impairment are calculated as follows: 0.1437 x $12.66 = $1.82.  
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3.3. DISCUSSION 
This analysis assesses the main drivers of nursing home entry among a representative sample 
of the European people older than 50 years old, focusing on one disease and its related 
complications: diabetes. Furthermore, taking the values obtained from the logistic regressions, 
estimates about expenditures on diabetic institutionalized people are calculated.  
It has been found in the literature that diabetes among older people increases in a significant 
manner the risk to be institutionalized. One study developed in the US shows that diabetes is a 
determinant of nursing home placement among the frail elderly, increasing the risk of nursing 
home placement of old adults by 1.8 (Matsuzawa et al., 2010). My results confirm that diabetes is 
a predictor of nursing home placement. Diabetes increases the risk of institutionalization in the 
overall sample by 1.552 OR when compared with people without diabetes, being ranked second 
in size of its odds. However, when clinical and functional complications are included in the 
regression, diabetes is still significant, but its coefficient decreases till OR 1.240, showing that the 
variables remaining in the model explain part of the effect of diabetes as a risk factor for 
admission in a nursing home. Remarkably, the major factor explaining this association is 
functional impairment. Hence, it could be concluded that the effect of diabetes is mediated by 
the clinical and functional complications included in the regression, reducing its impact on 
healthcare resources use. 
Newton et al. (2013) also reported that around 30-35% of institutionalized older people have 
diabetes, a condition associated to a higher resource utilization. In my data, the rates of diabetes 
among institutionalized adults are lower, affecting around 20% of the overall sample who are in a 
nursing home and reaching 22% when people are 75 and older. 
It might be expected that some diseases when linked with diabetes, such as stroke or 
functional impairment, increase the odds of being placed into a nursing home, as some previous 
studies have already showed (Abizanda et al., 2014; Rechel et al., 2013; Russell et al., 2005; 
Banaszak-Holl et al., 2004). However, my results from the overall sample contradict this 
assumption since none of the interactions between diabetes and clinical and functional 
complications are statistically significant. Still, in some countries, such as Belgium, France and 
Greece, diabetes and stroke do significantly increase the risk of institutionalization, whereas 
diabetes linked to functional impairment rises the likelihood of being admitted to a nursing home 
in Spain. 
Overall, total nursing home costs per capita due to diabetes reach $12.66 within the whole 
sample and the time period analyzed in this study. Moreover, when costs attributed to diabetes 
complications are calculated, the greatest burden of the disease is due to the different categories 
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of functional impairment ($3.17 per capita in total), whose effect is quite larger than the next 
complication with the highest costs, stroke, which accounts for $0.45 per capita. 
Diabetes remains in the adjusted model as a determinant of nursing home admission only in 
three countries: Sweden, The Netherlands and Spain, suggesting that other factors added to the 
ones included in my adjusted models may contribute to explain the relationship between diabetes 
and admission to nursing home. The latter country reports the highest increasing risk of 
institutionalization, even when complications are part of the regression model.  
The Netherlands is the top country in nursing home expenditure for people with diabetes, 
whose expenses on nursing home care are about $61.34 per capita, from which around one third 
are due to mild functional impairment. The substantial character of functional status is confirmed 
across countries analysis, as it bares the greatest proportion of costs, usually followed by stroke. 
This result is driven mainly by one single factor: the relevance of functional status inside the 
complications caused by diabetes, which has been consistently ascertained in this analysis. 
Additionally, when comparing the results across countries as percentages of GDP per capita, 
Spain is the country where costs strictly attributed to diabetes complications show the greatest 
value16.  
The methods used to estimate nursing home costs attributable to each disease are similar to 
the methods used by the American Diabetes Association diabetes reports (ADA, 2013; ADA, 
2003). However, in this study, I have adjusted for potential bias in the estimation of relative risk 
parameters and, consequently, in the values of etiological fractions. As it can be seen in Table 3.4, 
if I hadn’t estimated the adjusted relative risks, my estimation could be overestimating the impact 
of diabetes and its non-related and related clinical and functional complications.  
These figures could provide a valuable contribution to the existing literature since it is the first 
cross-countries analysis looking at the burden of diabetes on nursing home use and costs. It is 
also pioneer in including functional impairment as one of the factors involved in predicting costs 
associated with diabetes. It is noteworthy that this factor not only helps to explain part of the 
cost, but it is the main one. Moreover, this relationship between functional status, risk for 
admission in nursing home and its associated costs are age-dependent, as they are clearly shown 
in people older than 65, but not so evident in people with ages ranging from 50 to 65. These 
results would be important for two main reasons: firstly, previous estimates about the costs and 
                                                          
16 Although there might be differences between countries due to the country-specific market liberization of 
healthcare, especially after the 2008 economic crisis, Reeves et al. (2014) concluded that it was borrowing money 
from international institutions, budget cuts and the (decreases in) tax revenues what led to changes in healthcare 
expenditures, rather than the ideological orientation or the magnitude of economic recessions. However, it was not 
possible to control for these parameters (or their changes) in this analysis. Hence, differences between countries 
estimations should be interpreted with caution, as nursing home financing might be influenced by those 
aforementioned factors leading to variations in healthcare expenditures.  
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institutionalization estimates attributable to diabetes could be overestimating the impact of some 
other comorbidities that have traditionally been linked to diabetes, such as cerebrovascular 
diseases. Secondly, and due to the first reason, policymakers would have had the wrong focus 
when informing policies and diabetes guidelines, since the main surrogate of increasing costs is 
functional status. 
Another remarkable results is the one related to informal care, which could also explain the 
existing differences across countries mentioned before. Traditionally, informal care has been 
regarded as a substitute of nursing home (Greene, 1983; Cantor, 1979). Actually, a study using 
data from SHARE showed that informal and formal care are substitutes as long as the elderly’s 
disability is low (Bonsang, 2009). However, my results contradict this assumption. My estimation 
shows that informal care increases the risk of transit to nursing home in the total sample, as well 
as in most of the European countries. The Netherlands, Denmark and Czech Republic are the 
only countries that report the opposite results, although the coefficients are not statistically 
significant. Substitutability or complementarity between informal care and formal care outside the 
household have been largely discussed, highlighting that differences can be found regarding the 
disease, the services provided and the degree of disability of the care recipient (Jiménez and 
Vilaplana, 2012; Muramatsu et al., 2007; Viitanen, 2007; Chappel and Blandford, 1991; Greene, 
1983). Furthermore, variation within use of informal care services is quite large within European 
countries, not only due to the population distribution and population ageing, but also due to the 
design of welfare programs in Europe, and the existing programs and the availability of support 
to these caregivers. For example, in Mediterranean countries, where informal care tradition is 
common, the benefits and support that informal caregivers receive for their services are quite 
low. On the other hand, in Northern European countries, informal care is not so extended, but 
social benefits and support are higher. Finally, in Central Europe, caregivers are provided with 
widely spread social support programs, benefits that vary within and across regions, but informal 
care is not so relevant (Mot et al., 2012; Kraus et al., 2010). Hence, the consequences behind this 
result can be ambiguous and probably vary across countries. Another noteworthy result regarding 
the association between nursing home admission and informal care is that the latter variable is 
only statistically significant in temporary admissions. In-depth analysis could try to investigate 
whether temporary nursing home admissions prevent from permanent placements, which could 
have implications for policy makers. So, further analysis about the interpretation of the 
coefficient of informal care should be made in order to analyze its potential endogeneity with my 
dependent variable and to establish a conclusion. One approach could be the inclusion of 
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instrumental variables in the regression model, as Bolin et al. did in their analysis (2008), in which 
they also used SHARE data. 
Previous researchers have already analyzed the factors associated with nursing home 
admission in the elderly after adjusting for functional disability. Tomiak et al. (2000) concluded 
that chronic diseases, such as mental disorders, significantly raised such risk. Nevertheless, 
analyzing the determinants of institutionalization after adjusting for functional disability could 
have underestimated the effect of some chronic conditions that potentially lead to functional 
disability, as it is the case of diabetes. Still, a more recent report showed that the effect of diabetes 
or stroke on institutionalization disappears after controlling for functional status (Banaszak-Holl 
et al., 2004), which is consistent with my results. Furthermore, my expenditure figures are reliable 
when compared to the estimation provided in the report by the American Diabetes Association 
(2013). They concluded that, within the US population, 57% of the total costs incurred by people 
with diabetes are attributed to diabetes, which is higher than my estimate (37.27%), but still 
showing the great relevance of comorbidities when analyzing the economic burden of diabetes.  
Some limitations should also be mentioned. Firstly, nursing home residents were not 
interviewed in SHARE, so only people who did not live in nursing home prior to the interview 
are part of the survey. Moreover, if an individual moves from home to a nursing home during the 
survey period, no additional information is registered, unless nursing home placement is 
temporary. Hence, the results that are reported here might be underestimating the effect of 
diabetes and its clinical and functional complications on institutionalization. Second of all, due to 
data restrictions, I have excluded seven countries from the analysis from the nineteen countries 
that SHARE provides information from. However, the results reported in this study are still 
accurate since I include a representative sample of the European population. Another caveat 
derived from data limitations is the costs imputation. Although SHARE includes one question 
about costs and care services, it has not been possible to use this information in the present 
analysis due to the great number of missing values and the inclusion of many care services, not 
exclusively nursing home care. However, values for national healthcare expenditure on nursing 
homes are obtained for most countries and all the years included in the survey period. Yet, no 
data was available for three of the countries included in my study (Sweden, Italy and Greece), so I 
have not been able to estimate the costs for these populations. In addition, interaction terms to 
measure the joint effect of diabetes and its complications and regressions by diabetes status could 
not be run for all the countries. Finally, the self-reported feature of the data , especially about 
health conditions, could bias the results, since it could lead to recall bias and, hence, the results 
here could over or underestimate the true impact of diabetes. Nevertheless, this possibility looks 
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unlikely as the data comes from three different waves of the study, showing a strong consistency 
among them. In addition, there are several findings showing the reliability of data from health 
conditions collected using self-reporting information (Dal Grande et al., 2012; Goebeler et al., 
2007).  
Overall, these findings have direct consequences for policy makers and governments. Deep 
knowledge of the economic drain of the disease, regarding the medical costs, is an essential 
matter in the healthcare policy making process. Diabetes prevalence is increasing and, together 
with the population ageing, its associated costs are highly likely to noticeably grow in the 
subsequent years. Some general European guidelines have already considered diabetic patients in 
nursing homes, but most of them are largely focused on individual’s clinical management and not 
on functional dependency (IDF, 2013; EDWPOP, 2011). These results show for the first time 
that higher nursing home care expenditure due to diabetes all over Europe is mainly caused by 
functional impairment, which, in addition, increases the risk of institutionalization for older 
people with diabetes. Further analysis could assess the use of other healthcare resources by the 
population with diabetes in order to look at possible differences across Europe in terms of 
diabetes management and access to healthcare services. By doing so, an in-depth research would 
be carried out and efficient guidelines about diabetes and its complications could be written so as 
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APPENDIX CHAPTER 3 










Whole sample 0.1181 0.054 0.049 0.0674 0.117 
By country           
Austria  0.1064 0.0484 0.0477 0.0586 0.1103 
Germany  0.1218 0.0561 0.0561 0.1122 0.1191 
Sweden 0.0911 0.0327 0.0645 0.0907 0.158 
The Netherlands  0.09 0.0641 0.0521 0.0596 0.1063 
Spain 0.1588 0.0624 0.0328 0.0644 0.1157 
Italy 0.1211 0.0731 0.0393 0.0356 0.1072 
France 0.1008 0.054 0.0551 0.0888 0.1261 
Denmark 0.0735 0.0633 0.0573 0.0647 0.0898 
Greece 0.0976 0.0333 0.0188 0.0513 0.1065 
Switzerland 0.0631 0.0357 0.0556 0.0578 0.0698 
Belgium 0.0924 0.0551 0.0556 0.0752 0.1225 












Whole sample 0.0344 0.0792 0.0088 0.0045 
By country         
Austria  0.0431 0.0838 0.0079 0.0046 
Germany  0.0368 0.0759 0.0096 0.0054 
Sweden 0.0392 0.0723 0.0064 0.0036 
The Netherlands  0.0359 0.0539 0.0051 0.0021 
Spain 0.0216 0.0926 0.0186 0.0152 
Italy 0.0321 0.0785 0.0141 0.0082 
France 0.0289 0.0962 0.0068 0.003 
Denmark 0.0415 0.0635 0.0066 0.0033 
Greece 0.0271 0.0542 0.0077 0.004 
Switzerland 0.0245 0.0571 0.002 0.0007 
Belgium 0.0328 0.1111 0.0092 0.0023 
Czechia  0.0479 0.0751 0.0086 0.0026 
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Table 3.A2: List of variables and coding 
Variable Label Coding 
Nursing home admission 
“During the last twelve months, have you 
been in a nursing home overnight?” 
1: respondent has been to a nursing home in the 
last twelve months, temporary or permanently; 
0: otherwise 
Age Age of respondent   
Female Gender of respondent  1: female; 0: male 
Education ISCED-97 coding of education 
0: no education; 1: low education; 2: medium 
education; 3: high education 
Marital status Current marital status 
1: married or with a registered partner; 2: never 
married; 3: separated, divorced or widowed 
Low household income 
Lowest income quintile when sample was split 
into three groups according to income 
1: respondent’s income is in the lowest quintile 
group; 0: otherwise 
Medium household 
income 
Medium income quintile when sample was 
split into three groups according to income 
1: respondent’s income is in the medium 
quintile group; 0: otherwise 
High household income 
Highest income quintile when sample was 
split into three groups according to income 
1: respondent’s income is in the highest quintile 
group; 0: otherwise 
Retired 
“How would you describe your current 
situation?” 
1: respondent is retired; 0: otherwise  
Homemaker 
“How would you describe your current 
situation?” 
1: respondent works as homemaker; 0: 
otherwise 
Household size 
Number of people living in the respondents’ 
household 
  
Number of children Number of children that are still alive   
Number of grandchildren Number of respondents’ grandchildren   
Children in household 
Whether at least one child lives in the same 
household or the same building as respondent 
1: child lives in the same household or building 
as respondent; 0: otherwise 
Heart attack 
Whether the respondent has been told by a 
doctor s/he has had a heart attack 
 1: respondent has had a heart attack; 0: 
otherwise 
Hypertension 
Whether the respondent has been told by a 
doctor s/he has hypertension 
 1: respondent has hypertension; 0: otherwise 
Stroke 
Whether the respondent has been told by a 
doctor s/he has had a stroke 
 1: respondent has had a stroke; 0: otherwise 
Chronic lung disease 
Whether the respondent has been told by a 
doctor s/he has any chronic lung disease 
 1: respondent has any chronic lung disease; 0: 
otherwise 
Cancer  
Whether the respondent has been told by a 
doctor s/he has cancer 
 1: respondent has cancer; 0: otherwise 
Ulcer 
Whether the respondent has been told by a 
doctor s/he has an ulcer 
 1: respondent has an ulcer; 0: otherwise 
Cognitive impairment 
Whether the respondent’s performance has 
been impaired by some cognitive factors 
 1: some cognitive factors may have impaired 
respondent’s performance; 0: otherwise 
No functional impairment 
Individuals reported no limitation in any 
ADLs 
1: no limitation was present when performing 
ADLs; 0: otherwise 
Mild functional 
impairment 
Respondents declared being limited in one or 
two ADLs 
1: there were some limitations when performing 
one or two ADLs; 0: otherwise 
Moderate functional 
impairment 
Respondents declared being limited in three 
to five ADLs 
1: there were some limitations when performing 
three to five ADLs; 0: otherwise 
Severe functional 
impairment 
Respondents declared being limited in all 
ADLs 
1: there were some limitations when performing 
all ADLs; 0: otherwise 
Currently smoking Smoking at the present time  1: respondent smokes currently; 0: otherwise 
Ever smoked Whether respondent has ever smoked daily 
 1: respondent has ever smoked daily; 0: 
otherwise 
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Table 3.A2: (continued) 
Variable Label Coding 
Informal care 
“Have you received care from any person 
within or outside the household?” 
1: respondent received care from household’s 
members or from relatives or friends outside 
the household; 0: otherwise  
Austria  Whether the respondent lives in Austria   1: respondent lives in Austria; 0: otherwise 
Germany  Whether the respondent lives in Germany  1: respondent lives in Germany; 0: otherwise 
Sweden  Whether the respondent lives in Sweden  1: respondent lives in Sweden; 0: otherwise 
The Netherlands 
 Whether the respondent lives in The 
Netherlands 
 1: respondent lives in The Netherlands; 0: 
otherwise 
Spain  Whether the respondent lives in Spain  1: respondent lives in Spain; 0: otherwise 
Italy   Whether the respondent lives in Italy  1: respondent lives in Italy; 0: otherwise 
France  Whether the respondent lives in France  1: respondent lives in France; 0: otherwise 
Denmark  Whether the respondent lives in Denmark  1: respondent lives in Denmark; 0: otherwise 
Greece  Whether the respondent lives in Greece  1: respondent lives in Greece; 0: otherwise 
Switzerland  Whether the respondent lives in Switzerland  1: respondent lives in Switzerland; 0: otherwise 
Belgium  Whether the respondent lives in Belgium  1: respondent lives in Belgium; 0: otherwise 
Czech Republic 
 Whether the respondent lives in Czech 
Republic 
 1: respondent lives in Czech Republic; 0: 
otherwise 
Wave 1  Whether the data collected belongs to wave 1  1: data was collected from wave 1; 0: otherwise 
Wave 2  Whether the data collected belongs to wave 2  1: data was collected from wave 2; 0: otherwise 
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Table 3.A3: Average marginal effects from the regression models for the overall sample 
VARIABLES 
Average marginal 
effects Model 1 
Average marginal 
effects Model 2 
Average marginal 
effects Model 3 
Average marginal 
effects Model 4 
Diabetes 0.00218*** 0.00184*** 0.00104* 0.000923 
 (0.000615) (0.000612) (0.000616) (0.000656) 
Age 0.000351*** 0.000321*** 0.000198*** 0.000198*** 
 (3.24e-05) (3.24e-05) (3.07e-05) (3.07e-05) 
Female -0.000201 -8.38e-05 -0.000382 -0.000351 
 (0.000524) (0.000526) (0.000549) (0.000551) 
High or middle education -0.000494 -0.000473 -0.000143 -0.000131 
 (0.000320) (0.000320) (0.000317) (0.000319) 
Married 0.00151*** 0.00151*** 0.00124*** 0.00125*** 
 (0.000302) (0.000302) (0.000309) (0.000310) 
Low household income -0.00104* -0.00111* -0.00104* -0.00105* 
 (0.000629) (0.000631) (0.000626) (0.000630) 
Retired -0.00108* -0.00110* -0.000391 -0.000405 
 (0.000595) (0.000595) (0.000590) (0.000592) 
Household size -9.66e-05 -0.000142 -0.000343 -0.000346 
 (0.000401) (0.000407) (0.000431) (0.000431) 
Number of children 4.08e-05 3.03e-05 -1.85e-05 -2.85e-05 
 (0.000259) (0.000262) (0.000255) (0.000256) 
Number of grandchildren -0.000187* -0.000192* -0.000186* -0.000187* 
 (0.000109) (0.000109) (0.000105) (0.000104) 
Children in household -0.00106 -0.00105 -0.00130* -0.00126* 
 (0.000670) (0.000672) (0.000679) (0.000677) 
Chronic lung disease 0.00116 0.000872 -0.000205 -0.000150 
 (0.000850) (0.000852) (0.000862) (0.000868) 
Cancer 0.00172* 0.00144 0.00117 0.00118 
 (0.000881) (0.000874) (0.000857) (0.000854) 
Cognitive impairment 0.00483*** 0.00448*** 0.00336*** 0.00338*** 
 (0.000649) (0.000640) (0.000655) (0.000652) 
Heart attack  0.000639 -0.000124 -0.000138 
  (0.000591) (0.000596) (0.000608) 
Stroke  0.00618*** 0.00354*** 0.00350*** 
  (0.000686) (0.000701) (0.000712) 
Mild functional impairment   0.00574*** 0.00576*** 
   (0.000635) (0.000635) 
Moderate functional impairment   0.0104*** 0.0104*** 
   (0.00104) (0.00106) 
Severe functional impairment   0.0123*** 0.0120*** 
   (0.00121) (0.00124) 
Current smoker   -0.000615 -0.000580 
   (0.000809) (0.000811) 
Ever smoked   0.000177 0.000161 
   (0.000595) (0.000600) 
Informal care   0.00156*** 0.00158*** 
   (0.000539) (0.000537) 
Observations 90,589 90,589 90,589 90,589 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, sex, education, marital status, 
household income, and employment status), family network, and household composition (household size, number of children and 
grandchildren, and children in household), non-diabetes-related complications (chronic lung disease, cancer and cognitive impairment) and 
country dummies. Model 2 adds to the previous model diabetes-related clinical complications: heart attack and stroke. Model 3 includes the 
above variables and different degrees of functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), 
which is also related to diabetes, lifestyle (current smoker and ever smoked), and informal care. Model 4 adds the interactions between the main 
disease of interest, diabetes, and all the clinical and functional complications, both nonrelated and related to diabetes, as well as the interactions 
between diabetes and lifestyle variables and informal care. 
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Table 3.A4: Regression models from the sensitivity analysis: by age group  
VARIABLES OR Model 1 
Age 50 to 65 
OR Model 3 
Age 50 to 65 
OR Model 1 
Age 66 to 80 
OR Model 3 
Age 66 to 80 
OR Model 1 
Age > 80 
OR Model 3 
Age > 80 
       
Diabetes 1.139 0.928 1.713*** 1.287 1.839*** 1.454* 
 (0.320) (0.281) (0.318) (0.246) (0.388) (0.322) 
Age 1.031 1.027 1.070*** 1.033* 1.067*** 1.018 
 (0.0282) (0.0276) (0.0189) (0.0184) (0.0221) (0.0225) 
Female 0.976 0.939 0.710* 0.709* 1.138 1.150 
 (0.172) (0.173) (0.129) (0.143) (0.235) (0.258) 
High or middle education 1.051 1.088 0.770** 0.825* 0.937 1.040 
 (0.121) (0.126) (0.0805) (0.0866) (0.123) (0.141) 
Married 0.964 0.950 1.420*** 1.386*** 1.543*** 1.508*** 
 (0.121) (0.121) (0.153) (0.161) (0.216) (0.224) 
Low household income 1.078 1.007 0.810 0.802 0.822 0.805 
 (0.226) (0.214) (0.158) (0.162) (0.193) (0.192) 
Retired 1.136 1.067 0.804 0.929 0.652* 0.650* 
 (0.262) (0.239) (0.180) (0.208) (0.150) (0.153) 
Household size 0.950 0.923 0.942 0.897 0.890 0.842 
 (0.133) (0.130) (0.141) (0.154) (0.196) (0.201) 
Number of children 0.791* 0.788* 1.097 1.074 1.005 1.000 
 (0.110) (0.108) (0.0707) (0.0678) (0.0904) (0.0942) 
Number of grandchildren 1.003 0.994 0.954* 0.952* 0.966 0.961 
(0.0723) (0.0711) (0.0267) (0.0266) (0.0336) (0.0342) 
Children in household 0.906 0.913 0.769 0.744 0.601 0.538* 
 (0.224) (0.228) (0.169) (0.168) (0.193) (0.182) 
Chronic lung disease 1.556 1.271 0.985 0.715 1.527 1.210 
 (0.584) (0.476) (0.281) (0.209) (0.408) (0.344) 
Cancer 2.373*** 2.135** 1.101 1.019 1.369 1.146 
 (0.765) (0.683) (0.320) (0.286) (0.423) (0.369) 
Cognitive impairment 2.311*** 1.961** 2.703*** 2.068*** 2.966*** 2.230*** 
 (0.631) (0.545) (0.552) (0.435) (0.606) (0.488) 
Heart attack  1.196  1.142  0.741 
  (0.355)  (0.214)  (0.148) 
Stroke  2.466**  1.748**  2.319*** 
  (0.935)  (0.409)  (0.499) 
Mild functional 
impairment 
 2.013**  3.094***  3.960*** 
 (0.644)  (0.608)  (0.908) 
Moderate functional 
impairment 
 16.78***  11.03***  7.480*** 
 (7.573)  (3.193)  (2.348) 
Severe functional 
impairment 
 17.51***  16.76***  11.67*** 
 (10.49)  (5.762)  (4.396) 
Current smoker  1.180  0.748  0.748 
  (0.301)  (0.218)  (0.347) 
Ever smoked  0.685*  1.135  1.322 
  (0.151)  (0.231)  (0.290) 
Informal care  1.013  1.330  1.710*** 
  (0.276)  (0.236)  (0.339) 
Observations 48,177 48,177 31,422 31,422 6,170 6,170 
Log pseudolikelihood -871.85 -843.91 -1013.25 -940.72 -624.15 -560.44 
Country dummies YES YES YES YES YES YES 
Year dummies YES YES YES YES YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, sex, education, 
marital status, household income, and employment status), family network, and household composition (household size, number of 
children and grandchildren, and children in household) and non-diabetes-related complications (chronic lung disease, cancer and 
cognitive impairment). Model 3 adds to the previous model diabetes-related clinical complications (heart attack and stroke) and the 
Chapter 3  
 
Page | 96  
 
different degrees of functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), lifestyle 
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Table 3.A5: Regression models from the sensitivity analysis: Results from the regression with 
interaction terms by age group 
VARIABLES 
OR Model 4 
Age 50 to 65 
OR Model 4 
Age 66 to 80 
OR Model 4 
Age > 80 
Diabetes 0.637 1.482 1.169 
 (0.391) (0.551) (0.672) 
Diabetes#Chronic lung disease 0.589 0.955 0.470 
 (0.521) (0.612) (0.301) 
Diabetes#Cancer 2.472*** 1.066 1.158 
 (0.797) (0.342) (0.426) 
Diabetes#Ulcer 1.000 0.526 2.349 
 (1.119) (0.349) (1.519) 
Diabetes#Cognitive impairment 0.315 0.689 0.756 
 (0.431) (0.353) (0.402) 
Diabetes#Heart attack 0.178** 1.299 0.954 
 (0.143) (0.514) (0.444) 
Diabetes#Stroke 0.519 1.263 1.017 
 (0.569) (0.671) (0.493) 
Diabetes#Mild functional impairment 1.907 1.041 0.739 
 (1.770) (0.479) (0.447) 
Diabetes#Moderate functional impairment 0.566 0.828 1.433 
 (0.914) (0.535) (1.020) 
Diabetes#Severe functional impairment 3.522 2.245 1.476 
 (4.735) (1.654) (1.192) 
Diabetes#Ever smoked 3.237* 1.136 1.426 
 (2.153) (0.438) (0.710) 
Diabetes#Informal care 2.023 0.436* 1.314 
 (1.439) (0.189) (0.657) 
Age 1.026 1.034* 1.016 
 (0.0278) (0.0184) (0.0227) 
Female 0.948 0.718 1.157 
 (0.176) (0.145) (0.262) 
High or middle education 1.084 0.833* 1.034 
 (0.127) (0.0886) (0.140) 
Married 0.957 1.378*** 1.499*** 
 (0.121) (0.161) (0.226) 
Low household income 0.991 0.799 0.802 
 (0.211) (0.163) (0.193) 
Retired 1.061 0.938 0.679 
 (0.240) (0.214) (0.161) 
Household size 0.918 0.892 0.836 
 (0.129) (0.156) (0.207) 
Number of children 0.790* 1.077 1.006 
 (0.109) (0.0701) (0.0942) 
Number of grandchildren 0.994 0.953* 0.962 
 (0.0714) (0.0264) (0.0338) 
Children in household 0.913 0.751 0.556* 
 (0.227) (0.169) (0.189) 
Chronic lung disease 1.391 0.736 1.287 
 (0.560) (0.252) (0.426) 
Cancer 2.472*** 1.066 1.158 
 (0.797) (0.342) (0.426) 
Cognitive impairment 2.159*** 2.274*** 2.390*** 
 (0.609) (0.527) (0.585) 
Heart attack 1.494 1.086 0.742 
 (0.454) (0.243) (0.172) 
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Table 3.A5: (Continued) 
VARIABLES 
OR Model 4 
Age 50 to 65 
OR Model 4 
Age 66 to 80 
OR Model 4 
Age > 80 
Stroke 2.727** 1.623* 2.306*** 
 (1.105) (0.446) (0.583) 
Mild functional impairment 1.792* 3.068*** 4.284*** 
 (0.630) (0.687) (1.061) 
Moderate functional impairment 19.40*** 12.14*** 7.196*** 
 (9.049) (4.068) (2.566) 
Severe functional impairment 15.69*** 12.81*** 10.85*** 
 (10.96) (5.192) (4.578) 
Current smoker 1.209 0.765 0.732 
 (0.309) (0.223) (0.335) 
Ever smoked 0.603** 1.093 1.250 
 (0.143) (0.245) (0.314) 
Informal care 0.913 1.610** 1.599** 
 (0.278) (0.308) (0.348) 
Observations 47,990 31,422 6,083 
Log-pseudolikelihood -836.92 -936.57 -553.86 
Country effects YES YES YES 
Year effects YES YES YES 
Prob > chi2 interactions 0.0000  0.6072 0.9383 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Regression model includes diabetes, sociodemographic characteristics (age, 
sex, education, marital status, household income, and employment status), family network, and household composition 
(household size, number of children and grandchildren, and children in household), non-diabetes-related complications 
(chronic lung disease, cancer and cognitive impairment), diabetes-related clinical complications (heart attack and stroke), the 
different degrees of functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), 
lifestyle factors (current smoker and ever smoked), informal care and country dummies. It also includes the interactions 
between the main disease of interest, diabetes, and all the clinical and functional complications, both nonrelated and related to 
diabetes, as well as the interactions between diabetes and lifestyle variables and informal care. 
Each of the interactions measures the effect of jointly having diabetes and any of the above variables compared with not 
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Table 3.A6: Regression models from the sensitivity analysis: by gender 
VARIABLES OR Model 1 
Females 
OR Model 3 
Females 
OR Model 1 
Males 
OR Model 3 
Males 
     
Diabetes 1.252 1.012 1.994*** 1.554** 
 (0.213) (0.176) (0.359) (0.294) 
Age 1.073*** 1.042*** 1.074*** 1.041*** 
 (0.00773) (0.00797) (0.0114) (0.0113) 
High or middle education 0.858* 0.922 0.964 1.039 
 (0.0721) (0.0792) (0.0990) (0.110) 
Married 1.338*** 1.274*** 1.361*** 1.326*** 
 (0.111) (0.112) (0.123) (0.127) 
Low household income 0.889 0.896 0.703* 0.669* 
 (0.148) (0.151) (0.139) (0.138) 
Retired 0.927 1.012 0.690 0.891 
 (0.130) (0.146) (0.173) (0.220) 
Household size 0.946 0.871 1.025 1.019 
 (0.107) (0.110) (0.118) (0.123) 
Number of children 0.981 0.973 1.041 1.019 
 (0.0693) (0.0683) (0.0806) (0.0802) 
Number of grandchildren 0.966 0.970 0.962 0.953 
 (0.0283) (0.0275) (0.0309) (0.0316) 
Children in household 0.803 0.755 0.825 0.788 
 (0.146) (0.142) (0.167) (0.167) 
Chronic lung disease 1.209 0.914 1.360 1.026 
 (0.279) (0.221) (0.347) (0.272) 
Cancer 1.602** 1.440* 1.128 1.017 
 (0.351) (0.313) (0.342) (0.308) 
Cognitive impairment 2.604*** 2.006*** 2.709*** 1.984*** 
 (0.408) (0.333) (0.546) (0.433) 
Heart attack  1.036  0.918 
  (0.165)  (0.177) 
Stroke  2.065***  1.997*** 
  (0.379)  (0.448) 
Mild functional impairment  3.488***  2.924*** 
  (0.543)  (0.581) 
Moderate functional impairment  8.075***  9.346*** 
  (2.065)  (2.845) 
Severe functional impairment  12.08***  13.54*** 
  (3.514)  (4.992) 
Current smoker  0.760  0.962 
  (0.197)  (0.209) 
Ever smoked  1.076  1.052 
  (0.187)  (0.184) 
Informal care  1.112  1.897*** 
  (0.153)  (0.335) 
Observations 51,152 51,152 38,234 38,234 
Log pseudolikelihood -1515.84 -1430.24 -1079.01 -1007.97 
Country effects YES YES YES YES 
Year effects YES YES YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, education, 
marital status, household income, and employment status), family network, and household composition (household size, number of 
children and grandchildren, and children in household) and non-diabetes-related complications (chronic lung disease, cancer and 
cognitive impairment). Model 3 adds to the previous model diabetes-related clinical complications (heart attack and stroke) and the 
different degrees of functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), lifestyle 
factors (current smoker and ever smoked), and informal care.  
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Table 3.A7: Regression models from the sensitivity analysis: Results from the regression with 
interaction terms by gender 
VARIABLES OR Model 4 Females OR Model 4 Males 
   
Diabetes 0.962 1.389 
 (0.336) (0.567) 
Diabetes#Chronic lung disease 1.082 0.463 
 (0.624) (0.285) 
Diabetes#Cancer 0.604 0.835 
 (0.383) (0.515) 
Diabetes#Ulcer 0.922 0.962 
 (0.472) (0.587) 
Diabetes#Cognitive impairment 0.852 0.474 
 (0.366) (0.282) 
Diabetes#Heart attack 1.169 0.932 
 (0.438) (0.376) 
Diabetes#Stroke 2.415** 0.362** 
 (1.063) (0.181) 
Diabetes#Mild functional impairment 0.811 1.475 
 (0.334) (0.734) 
Diabetes#Moderate functional impairment 1.006 1.085 
 (0.639) (0.661) 
Diabetes#Severe functional impairment 0.741 5.784** 
 (0.533) (4.293) 
Diabetes#Ever smoked 0.906 1.653 
 (0.389) (0.658) 
Diabetes#Informal care 0.973 0.833 
 (0.353) (0.327) 
Age 1.042*** 1.041*** 
 (0.00798) (0.0112) 
High or middle education 0.918 1.049 
 (0.0789) (0.113) 
Married 1.276*** 1.329*** 
 (0.112) (0.128) 
Low household income 0.892 0.664** 
 (0.151) (0.138) 
Retired 1.019 0.870 
 (0.148) (0.215) 
Household size 0.872 1.020 
 (0.111) (0.123) 
Number of children 0.972 1.018 
 (0.0682) (0.0840) 
Number of grandchildren 0.969 0.950 
 (0.0274) (0.0321) 
Children in household 0.755 0.799 
 (0.142) (0.169) 
Chronic lung disease 0.881 1.285 
 (0.248) (0.383) 
Cancer 1.548* 1.059 
 (0.363) (0.378) 
Cognitive impairment 2.068*** 2.345*** 
 (0.375) (0.551) 
Heart attack 1.006 0.951 
 (0.186) (0.216) 
Stroke 1.682** 2.614*** 
 (0.370) (0.640) 
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Table 3.A7: (Continued) 
VARIABLES OR Model 4 Females OR Model 4 Males 
Mild functional impairment 3.615*** 2.640*** 
 (0.604) (0.588) 
Moderate functional impairment 7.871*** 9.656*** 
 (2.254) (3.373) 
Severe functional impairment 12.63*** 7.255*** 
 (4.022) (3.600) 
Current smoker 0.752 0.969 
 (0.197) (0.212) 
Ever smoked 1.086 0.932 
 (0.205) (0.184) 
Informal care 1.120 1.979*** 
 (0.167) (0.390) 
Observations 51,152 38,234 
Log pseudolikelihood -1427.53 -1001.33 
Country effects YES YES 
Year effects YES YES 
Prob > chi2 interactions 0.7390 0.5382 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Regression model includes diabetes, sociodemographic characteristics (age, 
education, marital status, household income, and employment status), family network, and household composition (household 
size, number of children and grandchildren, and children in household), non-diabetes-related complications (chronic lung 
disease, cancer and cognitive impairment), diabetes-related clinical complications (heart attack and stroke), the different 
degrees of functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), lifestyle 
factors (current smoker and ever smoked), informal care and country dummies. It also includes the interactions between the 
main disease of interest, diabetes, and all the clinical and functional complications, both nonrelated and related to diabetes, as 
well as the interactions between diabetes and lifestyle variables and informal care. 
Each of the interactions measures the effect of jointly having diabetes and any of the above variables compared with not 
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Table 3.A8: Regression models from the sensitivity analysis: by length of stay  
VARIABLES OR Model 1 
Permanent 
OR Model 3 
Permanent 
OR Model 1 
Temporary 
OR Model 3 
Temporary 
     
Diabetes 1.435** 1.292 1.706*** 1.176 
 (0.244) (0.226) (0.304) (0.220) 
Age 1.060*** 1.041*** 1.090*** 1.043*** 
 (0.00871) (0.00874) (0.00879) (0.00950) 
Female 1.048 0.960 0.864 0.874 
 (0.151) (0.143) (0.132) (0.151) 
High or middle education 0.866* 0.909 0.946 1.040 
 (0.0758) (0.0799) (0.0875) (0.0993) 
Married 1.354*** 1.312*** 1.333*** 1.256** 
 (0.101) (0.103) (0.133) (0.132) 
Low household income 0.701** 0.718** 0.984 0.955 
 (0.117) (0.121) (0.187) (0.187) 
Retired 0.704** 0.778 1.001 1.183 
 (0.109) (0.121) (0.196) (0.238) 
Household size 1.060 1.010 0.872 0.827 
 (0.100) (0.104) (0.129) (0.134) 
Number of children 0.999 0.989 1.013 0.996 
 (0.0729) (0.0736) (0.0749) (0.0720) 
Number of grandchildren 0.948 0.949 0.981 0.979 
 (0.0312) (0.0309) (0.0283) (0.0275) 
Children in household 0.609*** 0.575*** 1.127 1.076 
 (0.108) (0.106) (0.227) (0.224) 
Chronic lung disease 1.171 1.030 1.362 0.910 
 (0.283) (0.259) (0.331) (0.229) 
Cancer 1.035 1.001 1.816*** 1.524* 
 (0.291) (0.280) (0.414) (0.351) 
Cognitive impairment 2.628*** 2.021*** 2.598*** 1.900*** 
 (0.440) (0.356) (0.480) (0.375) 
Heart attack  0.543***  1.516** 
  (0.108)  (0.254) 
Stroke  1.647**  2.432*** 
  (0.342)  (0.470) 
Mild functional impairment  2.128***  4.846*** 
  (0.367)  (0.922) 
Moderate functional impairment  7.525***  9.867*** 
  (2.010)  (2.876) 
Severe functional impairment  13.55***  11.46*** 
  (3.953)  (4.098) 
Current smoker  1.105  0.602* 
  (0.238)  (0.170) 
Ever smoked  0.884  1.250 
  (0.153)  (0.223) 
Informal care  0.997  1.949*** 
  (0.149)  (0.332) 
Observations 90,589 90,589 87,654 87,654 
Log pseudolikelihood -1603.83 -1543.58 -1281.07 -1162.99 
Country effects YES YES YES YES 
Year effects YES YES YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Model 1 includes diabetes, sociodemographic characteristics (age, sex, education, 
marital status, household income, and employment status), family network, and household composition (household size, number of 
children and grandchildren, and children in household) and non-diabetes-related complications (chronic lung disease, cancer and 
cognitive impairment). Model 3 adds to the previous model diabetes-related clinical complications (heart attack and stroke) and the 
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different degrees of functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), lifestyle 
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Table 3.A9: Regression models from the sensitivity analysis: Results from the regression with 
interaction terms by length of stay 
VARIABLES OR Model 4 Permanent OR Model 4 Temporary 
   
Diabetes 0.887 1.678 
 (0.333) (0.709) 
Diabetes#Chronic lung disease 1.276 0.433 
 (0.696) (0.258) 
Diabetes#Cancer 0.286 0.992 
 (0.288) (0.517) 
Diabetes#Ulcer 0.925 1.036 
 (0.530) (0.592) 
Diabetes#Cognitive impairment 1.022 0.452 
 (0.449) (0.246) 
Diabetes#Heart attack 1.054 1.068 
 (0.439) (0.401) 
Diabetes#Hypertension 1.235 0.687 
 (0.412) (0.218) 
Diabetes#Stroke 1.012 1.064 
 (0.503) (0.472) 
Diabetes#Mild functional impairment 1.775 0.603 
 (0.774) (0.287) 
Diabetes#Moderate functional impairment 0.773 1.217 
 (0.518) (0.732) 
Diabetes#Severe functional impairment 0.989 2.997 
 (0.728) (2.168) 
Diabetes#Ever smoked 1.331 1.574 
 (0.491) (0.595) 
Diabetes#Informal care 1.115 0.791 
 (0.423) (0.305) 
Age 1.041*** 1.042*** 
 (0.00881) (0.00950) 
Female 0.954 0.903 
 (0.143) (0.158) 
High or middle education 0.906 1.046 
 (0.0804) (0.101) 
Married 1.314*** 1.254** 
 (0.104) (0.132) 
Low household income 0.713** 0.949 
 (0.121) (0.187) 
Retired 0.776 1.178 
 (0.122) (0.237) 
Household size 1.010 0.826 
 (0.104) (0.133) 
Number of children 0.990 0.990 
 (0.0742) (0.0703) 
Number of grandchildren 0.949 0.980 
 (0.0308) (0.0269) 
Children in household 0.572*** 1.102 
 (0.105) (0.229) 
Chronic lung disease 0.962 1.113 
 (0.289) (0.307) 
Cancer 1.178 1.531 
 (0.346) (0.402) 
Cognitive impairment 2.015*** 2.267*** 
 (0.392) (0.475) 
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Table 3.A9: (continued) 
VARIABLES OR Model 4 Permanent OR Model 4 Temporary 
Heart attack 0.529*** 1.515** 
 (0.127) (0.287) 
Stroke 1.635** 2.397*** 
 (0.383) (0.534) 
Mild functional impairment 1.865*** 5.287*** 
 (0.370) (1.093) 
Moderate functional impairment 8.082*** 9.319*** 
 (2.312) (3.219) 
Severe functional impairment 13.71*** 7.580*** 
 (4.348) (3.492) 
Current smoker 1.117 0.595* 
 (0.242) (0.169) 
Ever smoked 0.839 1.145 
 (0.155) (0.230) 
Informal care 0.980 2.069*** 
 (0.162) (0.390) 
Observations 90,589 87,654 
Log pseudolikelihood -1540.74 -1155.73 
Prob > chi2 interactions 0.8936 0.1586 
Country effects YES YES 
Year effects YES YES 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Regression model includes diabetes, sociodemographic characteristics (age, 
sex, education, marital status, household income, and employment status), family network, and household composition 
(household size, number of children and grandchildren, and children in household), non-diabetes-related complications 
(chronic lung disease, cancer and cognitive impairment), diabetes-related clinical complications (heart attack and stroke), the 
different degrees of functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), 
lifestyle factors (current smoker and ever smoked), informal care and country dummies. It also includes the interactions 
between the main disease of interest, diabetes, and all the clinical and functional complications, both nonrelated and related to 
diabetes, as well as the interactions between diabetes and lifestyle variables and informal care. 
Each of the interactions measures the effect of jointly having diabetes and any of the above variables compared with not 
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Table 3.A10: Regression models from the sensitivity analysis: Results from the regression with 
interaction terms by country 
VARIABLES 
OR Model 4 
Austria 
OR Model 4 
Germany 
OR Model 4 
Spain 
OR Model 4 
France 
Diabetes 0.716 4.799 3.869 0.180 
 (1.024) (4.923) (4.115) (0.199) 
Diabetes#Chronic lung disease - 1.306 - - 
  (1.814)   
Diabetes#Cancer 2.314 1.679 - - 
 (2.794) (1.680)   
Diabetes#Cognitive impairment 2.179 - - 1.269 
 (2.527)   (1.049) 
Diabetes#Heart attack 12.34 0.501 0.0522** 0.204 
 (19.22) (0.418) (0.0626) (0.206) 
Diabetes#Hypertension 0.868 1.818 0.823 0.802 
 (0.854) (1.708) (0.776) (0.605) 
Diabetes#Stroke 0.271 0.148 - 11.06*** 
 (0.228) (0.225)  (9.731) 
Diabetes#Mild functional impairment 0.469 0.377 0.619 2.572 
 (0.430) (0.646) (0.993) (2.790) 
Diabetes#Moderate functional impairment - 1.062 2.051e+07*** - 
  (1.223) (2.718e+07)  
Diabetes#Severe functional impairment - - 13.95 - 
   (27.68)  
Diabetes#Ever smoked 0.344 0.597 3.712 27.74*** 
 (0.458) (0.843) (4.276) (21.09) 
Diabetes#Informal care 1.631 0.330 1.415 - 
 (1.451) (0.366) (2.253)  
Age 1.039* 1.062* 1.038 1.007 
 (0.0223) (0.0334) (0.0319) (0.0203) 
Female 0.502* 1.448 0.663 1.004 
 (0.204) (0.740) (0.500) (0.439) 
High or middle education 0.696 0.840 1.185 1.177 
 (0.198) (0.250) (0.376) (0.209) 
Married 2.017** 0.928 1.070 1.002 
 (0.657) (0.290) (0.267) (0.221) 
High household income - - - 0.802 
    (0.360) 
Retired 0.566 0.419* 0.172** 4.845*** 
 (0.253) (0.218) (0.143) (2.325) 
Household size 1.020 0.544 0.621* 0.995 
 (0.456) (0.242) (0.169) (0.256) 
Number of children 0.775 0.668 0.695 0.969 
 (0.195) (0.173) (0.270) (0.150) 
Number of grandchildren 0.922 1.061 1.082 0.989 
 (0.0830) (0.122) (0.181) (0.0654) 
Children in household 0.592 0.790 1.593 1.630 
 (0.328) (0.472) (0.808) (0.831) 
Chronic lung disease 0.356 3.359* 0.879 2.058 
 (0.460) (2.177) (0.540) (1.157) 
Cancer 1.778 1.924 0.610 1.928 
 (1.510) (1.143) (0.552) (0.985) 
Cognitive impairment 3.373** 2.003 4.844** 2.325* 
 (2.009) (0.978) (3.292) (1.004) 
Heart attack 1.690 1.246 1.508 1.173 
 (0.968) (0.669) (1.089) (0.570) 
Diabetes-associated factors as predictors of nursing home admission and costs in the elderly across Europe 
Page | 107  
 
Table 3.A10: (continued) 
VARIABLES 
OR Model 4 
Austria 
OR Model 4 
Germany 
OR Model 4 
Spain 
OR Model 4 
France 
Stroke 2.701 4.311** 4.600* 1.823 
 (1.767) (2.555) (3.767) (1.144) 
Mild functional impairment 2.128 4.191*** 1.939 2.395* 
 (1.316) (2.115) (1.484) (1.237) 
Moderate functional impairment 1.934 50.50*** 4.02e-06*** 3.291 
 (2.396) (33.11) (2.67e-06) (3.977) 
Severe functional impairment 53.62*** 6.145 3.238 12.96** 
 (37.12) (8.055) (2.763) (16.09) 
Current smoker 0.198 2.813 0.767 0.133* 
 (0.209) (1.953) (0.657) (0.157) 
Ever smoked 1.359 0.562 1.982 0.781 
 (0.659) (0.328) (1.474) (0.346) 
Informal care 0.958 2.551* 1.016 1.951* 
 (0.499) (1.221) (0.943) (0.762) 
Observations 5,854 5,014 5,648 8,112 
Log pseudolikelihood -139.94 -109.47 -107.76 -223.02 
Year effects YES YES YES YES 
Prob > chi2 interactions 0.2653 0.0335 0.0000 0.0000 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Regression model includes diabetes, sociodemographic characteristics (age, 
sex, education, marital status, household income, and employment status), family network, and household composition 
(household size, number of children and grandchildren, and children in household), non-diabetes-related complications 
(chronic lung disease, cancer and cognitive impairment), diabetes-related clinical complications (heart attack and stroke), the 
different degrees of functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), 
lifestyle factors (current smoker and ever smoked), informal care. It also includes the interactions between the main disease of 
interest, diabetes, and all the clinical and functional complications, both nonrelated and related to diabetes, as well as the 
interactions between diabetes and lifestyle variables and informal care. 
Each of the interactions measures the effect of jointly having diabetes and any of the above variables compared with not 
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Table 3.A10: (continued) 
VARIABLES 
OR Model 4 
Denmark 
OR Model 4 
Greece 
OR Model 4 
Belgium 
OR Model 4 
Czech 
Republic 
     
Diabetes 1.68e-06*** 0.387 0.437 0.171 
 (1.88e-06) (0.274) (0.570) (0.231) 
Diabetes#Chronic lung disease - - 0.842 13.64** 
   (0.775) (16.48) 
Diabetes#Ulcer 9.867 - 2.698 0.711 
 (0)  (3.224) (0.823) 
Diabetes#Cognitive impairment - 4.631 3.703 0.657 
  (5.060) (3.521) (0.991) 
Diabetes#Heart attack 0.409 - 0.707 0.769 
 (0)  (0.918) (0.562) 
Diabetes#Stroke 1.167e+13 50.11** 23.83*** 1.680 
 (0) (85.93) (27.48) (1.584) 
Diabetes#Mild functional impairment 1.904e+14*** 5.394 1.296 1.673 
 (3.505e+14) (6.354) (1.528) (1.725) 
Diabetes#Moderate functional impairment - - 3.651 - 
   (5.667)  
Diabetes#Severe functional impairment - - 0.219 6.073 
   (0.262) (12.46) 
Diabetes#Ever smoked - 0.282 0.680 1.252 
  (0.476) (0.657) (1.151) 
Diabetes#Informal care - 0.983 0.953 2.935 
  (1.026) (0.826) (2.886) 
Age 1.045 1.020 1.094*** 0.999 
 (0.0350) (0.0234) (0.0169) (0.0239) 
Female 0.302* 0.923 1.236 0.513* 
 (0.202) (0.294) (0.478) (0.186) 
High or middle education 1.141 1.359 1.204 0.890 
 (0.419) (0.310) (0.218) (0.254) 
Married 0.853 1.458** 1.481* 1.356 
 (0.389) (0.223) (0.297) (0.266) 
Low household income 1.829 - 0.802 - 
 (1.283)  (0.268)  
Mid household income - - - 0.587 
    (0.284) 
High household income 0.556 - 0.564 - 
 (0.543)  (0.274)  
Retired 0.445 0.901 0.958 1.124 
 (0.447) (0.352) (0.311) (0.580) 
Household size 0.0160*** 1.593*** 1.017 1.005 
 (0.0164) (0.278) (0.305) (0.252) 
Number of children 1.153 0.870 1.160 0.991 
 (0.345) (0.166) (0.122) (0.226) 
Number of grandchildren 1.096 0.982 0.905* 1.044 
 (0.120) (0.0831) (0.0470) (0.0833) 
Children in household - 0.324*** 0.654 0.707 
  (0.109) (0.301) (0.303) 
Chronic lung disease 0.214 0.641 1.100 0.351 
 (0.205) (0.685) (0.623) (0.377) 
Cancer 0.822 3.935** 1.138 1.626 
 (0.770) (2.640) (0.596) (1.124) 
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Table 3.A10: (continued) 
VARIABLES 
OR Model 4 
Denmark 
OR Model 4 
Greece 
OR Model 4 
Belgium 
OR Model 4 
Czech 
Republic 
Cognitive impairment 7.927*** 1.048 1.760 4.051*** 
 (4.489) (0.792) (0.800) (1.805) 
Heart attack 1.723 0.306 1.063 1.358 
 (1.227) (0.272) (0.450) (0.618) 
Stroke 7.408** 0.660 0.955 1.639 
 (5.771) (0.595) (0.610) (1.058) 
Mild functional impairment 10.26*** 1.508 2.447*** 2.242* 
 (6.242) (0.857) (0.789) (1.058) 
Moderate functional impairment 887.1*** 3.764 0.892 9.175*** 
 (1,457) (4.178) (0.996) (7.708) 
Severe functional impairment 4.786 - 42.83*** 8.182 
 (7.383)  (34.95) (11.42) 
Current smoker 0.191* 0.805 1.076 0.645 
 (0.181) (0.413) (0.488) (0.341) 
Ever smoked 0.645 0.566 1.373 1.290 
 (0.387) (0.245) (0.523) (0.537) 
Informal care 3.279** 1.225 1.379 1.141 
 (1.622) (0.570) (0.465) (0.462) 
Observations 3,851 5,005 8,947 6,643 
Log pseudolikelihood -64.73 -259.10 -264.00 -205.72 
Year effects YES YES YES YES 
Prob > chi2 interactions 0.0000 0.0820 0.2476 0.1654 
*** p<0.01, ** p<0.05, * p<0.1 Source: authors of this chapter using data from SHARE. 
Standard errors were clustered at individual level. Regression model includes diabetes, sociodemographic characteristics (age, 
sex, education, marital status, household income, and employment status), family network, and household composition 
(household size, number of children and grandchildren, and children in household), non-diabetes-related complications 
(chronic lung disease, cancer and cognitive impairment), diabetes-related clinical complications (heart attack and stroke), the 
different degrees of functional impairment according to the number of limitations in ADLs (mild, moderate, and severe), 
lifestyle factors (current smoker and ever smoked), informal care. It also includes the interactions between the main disease of 
interest, diabetes, and all the clinical and functional complications, both nonrelated and related to diabetes, as well as the 
interactions between diabetes and lifestyle variables and informal care. 
Each of the interactions measures the effect of jointly having diabetes and any of the above variables compared with not 
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Table 3.A11: Nursing home expenditures per capita by country and year, adjusted by PPP 
(current international $) 
 
 
2004 2006/07 2010 AVERAGE 
Austria 204.7604 230.5729 313.7079 249.6804 
Germany 236.0971 231.7317 330.5710 266.1333 
The Netherlands 299.9008 853.2611 994.6301 715.9307 
Spain 118.7421 155.4664 213.2555 162.4880 
France 146.7926 183.1528 251.0871 193.6775 
Denmark 367.5769 443.7908 551.6237 454.3305 
Switzerland 669.6459 759.8198 915.9817 781.8158 
Belgium 348.3664 457.4916 539.3053 448.3878 
Czech Republic 15.5109 19.4042 27.9781 20.9644 
 
Source: Self-generated using OECD Data and Statistics and World Bank dat.a 
 
 
Table 3.A12: GDP per capita by country and year, adjusted by PPP (current international $) 
 
 
Wave 1 Wave 2 Wave 4 
 
2004 2006 2007 2010 
Austria 33,809.8 37,649.5 39,238.3 41,804.2 
Germany 30,662 34,667.6 36,735.8 39,553.2 
The Netherlands 35,167 40,434.1 43,339.6 44,743 
Spain 26,445 30,879.9 32,806.7 32,350.5 
France 29,037.3 32,288.8 34,039.8 35,868.9 
Denmark 33,152.6 37,189.7 38,674.4 41,806.9 
Switzerland 37,771 43,377.8 47,409.5 51,321.5 
Belgium 31,946.2 35,169 36,621.1 39,211.3 
Czech Republic 20,990.3 24,415.9 26,683.2 27,051 
 




















THE RELATIONSHIP BETWEEN DIABETES, DIABETES-RELATED 





A number of studies have analysed the impact of health on productivity (Grossmeier et al., 
2015; Lenneman et al., 2011; van den Heuvel et al., 2010; Bergstrom et al., 2009; Pauly et al., 
2008; Burton et al., 2005) concluding that worse health status increases both measures of 
productivity impairment, absenteeism and presenteeism, forcing early labour-market exit (Rice et 
al., 2011). In this analysis, I aim to measure the effect that diabetes, a disease that mainly affects 
people in advanced age and more specifically, one in every four people aged 65 and above 
(Soriguer et al., 2012; Sloan et al., 2008), has on productivity through two different measures 
depending on the age group: being afraid health limits work for those who are still in the working 
age (up to 65) and being a formal volunteer in case people are in the retirement age (above 65 
                                                          
17 This chapter has been published in The European Journal of Health Economics as Rodriguez-Sanchez, B. et 
al., (2017): The relationship between diabetes, diabetes-related complications and productive activities among older 
Europeans. Eur J Health Econ, doi: 10.1007/s10198-017-0911-9. 
Parts of this chapter have been presented in oral form at the LolaHESG congress 2016 in Ghent, Belgium, 26-27 
May 2016; at the XXXVI Jornadas Economía de la Salud in Murcia, Spain, 15-17 June 2016, where the prize to the 
best oral communication was awarded; and at the EuHEA congress in Hamburg, Germany, 16-18 July 2016.  
I thank the contribution that conference attendants have made to the manuscript, especially to Gimon de Graaf 
for his appreciated input as discussant. 
This chapter uses data from SHARE Waves 2, 4 and 5 (DOIs: 10.6103/SHARE.w2.500, 
10.6103/SHARE.w4.500, 10.6103/SHARE.w5.500), see Börsch-Supan et al. (2013) for methodological details. The 
SHARE data collection has been primarily funded by the European Commission through FP5 (QLK6-CT-2001-
00360), FP6 (SHARE-I3: RII-CT-2006-062193, COMPARE: CIT5-CT-2005-028857, SHARELIFE: CIT4-CT-2006-
028812) and FP7 (SHARE-PREP: N°211909, SHARE-LEAP: N°227822, SHARE M4: N°261982). Additional 
funding from the German Ministry of Education and Research, the U.S. National Institute on Aging 
(U01_AG09740-13S2, P01_AG005842, P01_AG08291, P30_AG12815, R21_AG025169, Y1-AG-4553-01, 
IAG_BSR06-11, OGHA_04-064) and from various national funding sources is gratefully acknowledged (see 
www.share-project.org). 
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years old). In case of the former outcome, only a few studies have looked into the burden of 
diabetes in terms of productivity impairment (Rumball-Smith et al., 2014; ADA, 2013; Hex et al., 
2012; Herquelot et al., 2011; Tunceli et al., 2005; Norlund et al., 2001; Songer et al., 1989); and 
when talking about the latter, considerably less research has been conducted (Leitjen et al., 2014; 
Di Gessa and Grundy, 2014; Hank, 2011; Hank and Erlinghagen, 2010; Hank and Erlinghagen, 
2009; Hank and Stuck, 2007; Börsch-Supan et al., 2005), only self-perceived health has been 
supported to reduce volunteering rates (Komp et al., 2012).  
Such a gap in the literature could be due to the difficulty in measuring the impact of diabetes 
on productivity, since it is a disease that does not impair individual’s health itself, but through the 
complications that it generates. Actually, diabetes can impact productivity in several ways. Firstly, 
diabetes complications might impair the ability to work completely (Rumball-Smith et al., 2014; 
Herquelot et al., 2011; Norlund et al., 2001), increase the number of days absent from work due 
to health problems (ADA, 2013; Hex et al., 2012; Tunceli et al., 2005) or reduce productivity at 
work (ADA, 2013; Hex et al., 2012). Secondly, individuals with diabetes could be discriminated at 
work by their employers due to their concerns about low productivity (Songer et al., 1989), 
limiting the type of work they can do. While direct effects on actual productivity are hard to 
measure, perceptions of patients concerning productivity loss might be another related measure 
that is affected before actual job loss takes place. Especially in uncertain economic circumstances, 
such perceptions maybe importantly affected by diseases such as diabetes. I thus also aim to 
assess the relationship of diabetes and these two productivity measures during the crisis period 
that recently hit Europe, from 2006 to 2013, which has not been taken into account in any of the 
studies previously mentioned. During an economic crisis, both insecurity and solidarity might rise 
due to the instability of employment in case of the former and need for helping those who have 
been heavily affected by the crisis when talking about the latter. Observing the trends among that 
period of time could provide evidence of how relevant health is with respect to productivity in 
periods of economic uncertainty.  
Bearing in mind that the effect of diabetes is generally mediated by its comorbidities, it seems 
sensible to assess the impact of diabetes on the individual´s perception to perform their work due 
to health problems and their commitment into volunteering, controlling for diabetes-related 
complications.  
This chapter therefore proposes to take a cross-sectional perspective from some European 
countries to analyse the role of such a prevalent disease in old adults as well as a set of clinical 
and functional complications in determining individual’s commitment with both paid and non-
paid work. Having a cross-country dataset allows me to control for differences in labour market 
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regulations, which potentially affect the enrolment of people into productive activities, but also 
country-specific cultural differences.  
My findings could be of special relevance in order to better determine how programs and 
policies should be designed and implemented to ensure and maximize the engagement of old 
people, in who diabetes is highly prevalent (Soriguer et al., 2012; Sloan et al., 2008), into 
productive activities. 
The following section proposes six hypotheses about the link between diabetes and some 
diabetes-related and non-related clinical and functional complications with the measures I use to 
address self-commitment to productive activities. Then, I present the data and methods I use, 
followed by the analysis of the descriptive and multivariate results. Finally, I discuss the results 
and mention the limitations and implications derived from the study. 
 
4.2 HYPOTHESES 
As it has been previously mentioned and according to Figure 4.1, diabetes could potentially 
impair the individual´s participation on both paid, that is, job for which s/he receives a salary; 
and non-paid activities, such as volunteering.  
 
Figure 4.1: Impact of diabetes on participation (modified from “Towards a common language for functioning, 













Some studies have already analysed the association between diabetes and lower productivity, 
concluding that people with diabetes reported higher numbers of disability days (Hank, 2011; von 
Korf et al., 2005; Yassin et al., 2002; Valdmanis et al., 2011), lost productivity time (Di Gessa and 
Grundy, 2014; Lavigne et al., 2003) and unemployment rates (Leijten et al., 2014; Hank, 2011; 
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al., 2005; Valdmanis et al., 2001). However, they used as outcome measure either the number of 
working days lost due to diabetes or employment transitions, that is, changing from being 
employed to be retired or disabled. Not so much analysis evaluated the potential impact of 
diabetes on work limitations. The study closest to my aim of analysis is the one by Tunceli et al. 
(2005), who used US data on 7,055 employees aged 51 – 61 years old from the first two waves 
(1992 and 1994) of the Health & Retirement Study (HRS). Individuals were asked if they had any 
impairments or health problems at the time of the interview that limited the kind or amount of 
paid work they could do, which is quite similar to the survey question I am using in this study. 
Authors concluded that, compared with individuals without diabetes, US men and women with 
diabetes were 5.4 and 6 percentage points, respectively, more likely to have work limitations. 
They controlled for health status using two self-reported measures: BMI and the number of other 
chronic conditions in addition to diabetes (hypertension, heart disease, chronic lung disease, 
stroke, cancer, arthritis and psychiatric problems). In my analysis I aim to assess the impact of 
diabetes and a list of clinical complications not on productivity losses or unemployment, but on 
the fear of health limiting work that people might feel. This leads to the first hypothesis:   
Hypothesis 1: Diabetes increases the likelihood of people aged 50 to 65 years old being afraid 
health limits their work, although the magnitude of the effect will be reduced when diabetes-
related complications are included in the regression. 
 
Moreover, the aforementioned works tested their hypotheses using data prior to the economic 
crisis that took place in 2008. In fact, none of them looked at the relevance of time variables. 
Conversely, I am using data from the time before (2006), during (2010) and after (2013) that time 
threshold. Due to the uncertain situation, I expect people to be more afraid to lose their job 
during and after the crisis than before. One of the factors that could impair individual’s ability to 
carry out his/her job appropriately could be health. The economic crisis might force employers 
to become stricter with regards to the job requirements and employees could experience more 
pressure while they are in their job position. Hence, people could expect that the fewer 
limitations they have in their working performance derived from their health status, the less likely 
it will be them to lose their job. Thus, the second hypothesis is: 
Hypothesis 2: The fear of health limiting work of people between ages 50 and 65 will increase 
during 2010 and 2013 with respect to 2006.  
 
As shown in the previous two hypotheses, I expect both diabetes and time variables to be 
positively associated with being afraid health limits work, I consequently presume the joint effect 
of both variables will lead to greater risk of being afraid health limits work. Given the effect of 
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the crisis, which is expected to become apparent in later years, and the impact of diabetes, 
especially high in old age groups and impairing individuals´ functioning, I establish the third 
hypothesis: 
Hypothesis 3: Having diabetes will increase the perception of the individuals aged 50 to 65 
years old being afraid health limits work more during the crisis years 2010 and 2013 with respect 
to 2006. 
 
Furthermore, non-paid productive activities could be a useful tool to measure productivity in 
advanced ages, especially when individuals are retired. According to the existing literature, the 
likelihood of taking-up volunteering seems to be lower in higher ages (Rumball-Smith et al., 2014; 
ADA, 2013; Tunceli et al., 2005), due to their health status, also leading to withdrawals in those 
who were already performing non-paid work (Tunceli et al., 2005). Nevertheless, not so much 
literature has been found taking diabetes as the main health measure (ADA, 2008), leading me to 
the fourth hypothesis: 
Hypothesis 4: Diabetes will significantly reduce the likelihood of being a formal volunteer 
(doing charity work), as well as the amount of time dedicated to this task in people aged 65 and 
older18. 
 
Moreover, as a consequence of the economic crisis, rates of volunteering have increased 
(Rumball-Smith et al., 2014; ADA, 2013; Hex et al., 2012; Herquelot et al., 2011; Tunceli et al., 
2005), showing great differences within European countries (Hex et al., 2012; Herquelot et al., 
2011; Tunceli et al., 2005). The rationale behind such increase could be due to a willingness to 
help people given the unstable situation rather than a self-decision to perform some productive 
activities as a real work could be. Moreover, individuals might do charity work because, due to 
the hit of the crisis, governments could have cut budgets and subsidies on this kind of social 
services, so someone else should do it instead. So, I settle the fifth hypothesis: 
Hypothesis 5: Volunteering will increase during the years 2010 and 2013 with respect to 2006. 
 
Finally, I aim to analyse the interaction between both independent variables, having diabetes 
and time, and to be a formal volunteer. I expect the interaction term to be significantly related 
with volunteering, although the sign of its coefficient is uncertain given the opposite 
interpretations of these variables separately. 
Hypothesis 6: The association between diabetes and volunteering will be different during and 
after the crisis period for those older than 65 years old, that is, years 2010 and 2013.  
                                                          
18 I did not include the individuals younger than 65 in the analysis of volunteering since it could be considered as a 
substitute of a paid job, which would complicate the analysis. 
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4.3 METHODS AND DATA 
4.3.1 Sample data 
The data are drawn from waves 2, 4 and 519, corresponding to the years 2006/07, 2010 and 
2013, respectively, from the Survey of Health, Ageing and Retirement in Europe (SHARE). The 
survey is a longitudinal survey that aims to provide comprehensive data on socioeconomic 
characteristics, health and healthcare use, and family networks from multiple European countries 
and Israel (Börsch-Supan et al., 2005). 
I have limited the analysis to eleven of these countries: Austria, Belgium, Czech Republic, 
Denmark, France, Germany, Italy, The Netherlands, Spain, Sweden and Switzerland. Other 
countries are excluded from the analysis either because they only appear in one of the three 
waves or due to their small sample size. I then split the sample by age: given that the most 
common retirement age in Europe is 65 years old, I distinguish between those still in the working 
age (from 50 to 65 years old) and retired individuals20 (above 65 years old).  
Thus, the population of analysis consists on 53,631 observations between the ages 50 to 65 
clustered in 34,393 individuals when the outcome is being afraid health limits their work and 
45,384 figures grouped in 29,104 individuals when assessing volunteering and age is above 65 
years old, that is, those who are already retired.  
 
4.3.2 Selection of variables 
Outcome variables 
In order to evaluate the fear of health limiting work, I take the information from SHARE on 
the following question: “Are you afraid health limits the kind or amount of work you do?”, to which 
respondents could choose between “yes” or “no”. 
Data on respondents’ commitment in volunteering is based on a question from SHARE that 
is formulated as follows: 
“Have you done any of the following activities in the last month? 
1. Done voluntary or charity work 
2. Cared for a sick or a disabled adult 
3. Provided help to family, friends or neighbours” 
 
                                                          
19 Wave 3 was excluded due to a change in the questionnaire (the SHARELIFE questionnaire), which registered 
information on individuals’ childhood health and, hence, the information provided in wave 3 was not useful for the 
analysis. However, I have used Wave 3 data to drop the observations already reporting to suffer diabetes in their 
childhood. 
20 According to the responses to the employment status question from the survey, only 2% of the people aged 65+ 
are employed or self-employed, whereas almost 85% are retired and another 11.5% declared to be homemakers. 
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According to Hank and Stuck (2007), volunteering could be divided into three categories: 
formal volunteering (having done voluntary or charity work), informal care (care for a sick or 
disabled adult) and carer (provided help to family, friends or neighbours). However, waves 4 and 
5 do not include the latter two. Hence, I decide to take the more strict definition of volunteering: 
formal volunteering. 
I then focus on whether respondents have been actively performing volunteering activities, 
instead of looking at, for example, membership of charity associations. The latter measure, 
although commonly used, might overestimate the actual engagement, whereas my chosen variable 
will likely give a more accurate estimation of the real volunteering figures across Europe (Hank 
and Erlinghagen, 2009) since respondents are asked about the volunteering made in the last 
month instead of longer time periods. 
I also looked at the frequency of charity work, which could be i) daily, ii) weekly, and iii) less 
often than weekly. 
 
Independent variables 
Since the main independent variable is diabetes, I take self-reported information from SHARE 
about doctor’s diagnosis on diabetes. Moreover, as I also want to evaluate the impact of 
comorbidities on both outcome measures, I also use information on individuals’ other chronic 
conditions: heart attack, stroke, chronic lung disease, cancer, ulcer, hypertension, hip fracture. 
These are the main chronic conditions that are available in SHARE across all waves, as well as all 
diabetes related conditions that are available in SHARE. I consider the following conditions to be 
diabetes related: heart attack, stroke, ulcer, and hypertension. 
Furthermore, SHARE contains data on the number of mobility problems that individuals 
might report, ranging from 0, that is, no mobility problems at all, to a maximum of 10. I then 
generate a dummy variable that takes value 1 if any number of mobility problems had been 
reported by the respondent and 0 otherwise. This variable is only included when assessing 
individual´s engagement in volunteering activities. Mobility problems can be regarded as a health 
limitation, so its consideration in the analysis of the fear health limited work could lead to 
estimation problems.   
The second main variable of interest is time, so dummy variables for wave 4 (year 2010) and 
wave 5 (year 2013) are included in the analysis, being wave 2 (years 2006/07) the reference group. 
Moreover, I include sociodemographic factors such as age. In case of the working age people, 
I generate dichotomous variables for age groups 50 – 55, 56 – 60 and 61 to 65, being the former 
the reference group. I do so to control for differences across group ages, since the oldest one 
might not perceive health as a big problem as the younger subpopulations, due to their proximity 
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to retirement. On the other hand, I include six age groups, age 65 – 70, 71 – 75, 76 – 80, 81 – 85, 
86 – 90 and older than 90 years old, in the volunteering analysis21. Common to both analyses is 
the natural logarithm of household income, which is actually my only continuous variable. I also 
incorporate dummy variables for gender, marital status, and education categories. A detailed 
explanation can be found in Appendix, 4.A1. Finally, I include country dummy variables so I 
control for potential differences across countries.  
 
4.3.3 Statistical analyses 
In a first step of analysis, I have estimated univariate logit models for the list of covariates and 
the two binary dependent variables: being afraid health limits work and doing formal 
volunteering activities. By doing so, I will be able to evaluate the relevance of the association 
between each independent variable and both outcome measures.  
Then, I estimate a multivariate logistic regression with clustered standard errors, which is 
actually convenient when using data from different waves as I do, at the individual level to take 
into account within individual autocorrelation in the analysis of being afraid health limits work 
and at the household level when analyzing volunteering, so I take into account correlation 
between household members’ decisions (Rabe-Hesketh and Skrondal, 2008; Heij et al., 2004).  
In logit models, estimated coefficients capture the effects on the log-odds-ratio (see e.g. Heij, 
C. et al., 2004). Let Λ(𝑡) = 𝑒𝑡/(1 + 𝑒𝑡) be the logistic function with values stretching between 
zero and one, and let: 
 𝑃𝑟[𝐴𝐻𝐿𝑊𝑖𝑐𝑡 = 1 |𝑥𝑖𝑡] = Λ( 𝛽0 + 𝛽1𝑆𝐸𝑖𝑡 +  𝛽2𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖𝑡 +  𝛽3𝐻𝐼𝑖𝑡 +  𝛾𝑐 +  𝜁𝑡)    (1) 
where i represents the individual, c country, and t  year. 𝐴𝐻𝐿𝑊𝑖𝑐𝑡 is a dummy variable indicating 
that respondent i is afraid health limits his/her work in country c in year t. 𝑥𝑖𝑡 = (SEit,
diabetesit, HIit, country dummies, time dummies)′ is a vector of explanatory variables. SEit, 
diabetesit, HIit denote the set of socioeconomic variables, having diabetes and chronic conditions, 
respectively.  
Model A adjusts for demographic characteristics, socioeconomic status, chronic conditions 
not related to diabetes, time and country dummies. In this model some diseases such as 
cerebrovascular conditions are not included due to their relationship with diabetes. However, in 
order to evaluate the net impact of diabetes on being afraid health limit, I include diabetes-related 
clinical complications in model B. Moreover, and in order to measure the effect of diabetes 
                                                          
21 Although the retirment age is not fixed at the age of 65 across European countries, it is the mean retirement age in 
Europe. Moreover, only 2% of the people aged 65+ in the sample are employed or self-employed, whereas almost 
85% are retired and another 11.5% declared to be homemakers. 
The relationship between diabetes, diabetes-related complications and productive activities among older Europeans 
Page | 119  
 
together with the time dummy on the outcome according to the third and sixth hypotheses, the 
interaction between these two is included in a last regression (model C).  
Same procedure has been followed for the second outcome of interest, to be a formal 
volunteer, but with an additional inclusion. In model B, I also look at the impact of having 
mobility problems.  
After running these three regression models, I test which model better fits the data using Wald 
tests and the Akaike’s (AIC) and Schwarz’s Bayesian (BIC) information criteria. The Wald test 
compares the null hypothesis that a set of parameters is equal to zero, so, if the test fails to reject 
the null hypothesis, removing those variables from the model will not substantially damage the fit 
of such model. AIC and BIC provide information which model fits data better. When comparing 
AIC and BIC, models need to be nested. Both smaller AIC and BIC indicate a better fitting 
model. I compare Model B against Model A, as the former adds clinical complications and 
mobility problems in case of volunteering to the latter model, and Model C against Model B, 
testing for the statistical and explanatory relevance of the interactions between diabetes and years 
2010 and 2013.  
Besides, the aim is also to see how the independent variables affect the different intensities of 
volunteering. In order to do so, I will run Model C as an ordered logit model. As this kind of 
models are easier to estimate and interpret than multinomial logit models, it is advantageous to 
exploit the order nature of the outcomes of the dependent variable (Heij et al., 2004). 




4.4.1 Descriptive statistics 
Characteristics of the study population by productive outcome are shown in Table 4.1. 
Moreover, the table shows a comparison of means test between the two groups. 
With regards to those being afraid health limits their work, there seems to be meaningful 
differences between those with such fear and the ones without. First of all, diabetes prevalence 
more than doubles in the former with comparison to the latter (16.45% vs 6.79%). The same 
pattern holds for the other chronic conditions. For example, 11.72%, 14.15%, 38.61% and 6.32% 
of those being afraid suffer from chronic lung disease, heart attack, hypertension or stroke, 
respectively, in contrast with their comparison group, for who these rates drop to 3.27%, 3.71%, 
27.66% and 0.97%, respectively. 
In addition, there are differences regarding the time variable, but no wave is significant. The 
trend in the percentage of people answering they were afraid health limits work varies between 
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waves, since in wave 5 the percentage of people perceiving such fear was higher than those who 
did not (47.09% vs 46.76%), opposite to what is shown in waves 2 and 4, as 16.57% and 36.33% 
reported being afraid against the 16.35 and 36.89 who were not, respectively. Those who are 
afraid health limits their work are slightly older, with lower education level, with no current 
partner, and with lower income.  
In terms of volunteering, significant differences have also been found between those doing 
charity work and those not. Those not being formal volunteers had higher rates of diabetes 
prevalence than their counterparts (16.12% vs 10.76%). The same pattern holds for the other 
chronic conditions and mobility problems. For example, 16.54%, 46.87% and 62.36% of the 
non-volunteers have heart attack, hypertension or mobility problems, respectively, in comparison 
to the volunteers, whose ratios decrease to 13.37%, 40.45% and 47.06%, respectively. In addition, 
the three time variables report no significant relationship with volunteering. Those who do not 
provide charity work are older, more likely to be women, with lower education, with no current 
partner, and with lower income.  
Regarding both outcomes, country dummies also capture differences in reporting styles, which 
are likely to differ across countries. With respect to diabetes prevalence, some differences can 
also be observed between countries (Table 4.2). It can be seen that diabetes prevalence is the 
highest in the Czech Republic and Spain, with percentages of 20 - 23% of the population older 
than 65 years old. The lowest diabetes prevalence can be observed in Denmark and Switzerland, 
which barely get to 10% for people above 65 years old.  
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Table 4.1: Descriptive statistics22 
Variables 
Whole 
sample                           
(N = 53,631) 
Afraid health 
limits work                       
(N = 11,259) 
Not afraid 
health limits 
work                        




sample                           
(N = 45,384) 
Formal 
volunteering                       
(N = 8,281) 
No formal 
volunteering                        
(N = 37,103) 
Univariate 
analysis 
Afraid health limits work 20.99% 
       
Formal volunteering 
    
18.24% 
   
No formal volunteering     81.76% - -  
Less often than weekly     5.61% 30.15% -  
Weekly     9.05% 51.90% -  
Daily     3.58% 17.95% -  
Diabetes 8.81% 16.45% 6.79% *** 15.14% 10.76% 16.12% *** 
Age categories    ***    *** 
Age 50 to 55 25.74% 23.73% 26.27%      
Age 56 to 60 33.70% 35.03% 33.35%      
Age 61 to 65 40.56% 41.24% 40.38%      
Age 66 to 70     31.30% 39.85% 29.40%  
Age 71 to 75     28.16% 31.78% 27.36%  
Age 76 to 80     20.66% 18.13% 21.22%  
Age 81 to 85     12.67% 7.46% 13.83%  
Age 86 to 90     5.62% 2.38% 6.35%  
                                                          
22 Percentages are presented referring to the mean percentage between waves, unless indicated otherwise. 
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Table 4.1: (continued) 
Variables 
Whole 
sample                                                                   
(N = 53,631) 
Afraid health 
limits work
(N = 11,259) 
Not afraid 
health limits 
work                        








volunteering                       
(N = 8,281) 
No formal 
volunteering                        
(N = 37,103) 
Univariate 
analysis 
Age older than 90     1.57% 0.37% 1.83%  
Female 56.00% 56.66% 55.82% 
 
54.25% 51.25% 54.92% 
 
Education categories    ***    *** 
Low education  31.6% 38.81% 29.25% 
 
45.15% 32.18% 48.04% 
 
Medium education 40.28% 39.00% 40.62% 
 
30.11% 35.55% 28.90% 
 
High education 25.96% 18.28% 28.00% 
 
18.09% 30.67% 15.28% 
 
Marital status categories    ***    *** 
Non-single 75.11% 69.20% 76.68% 
 
64.95% 68.69% 64.11% 
 
Never married 6.90% 8.22% 6.54% 
 
4.01% 4.53% 3.90% 
 
Separated, divorced or 
widowed 
17.12% 21.59% 15.93% 
 




10.33 (1.11) 10.09 (1.09) 10.39 (1.11) *** 10.12 (1.05) 10.42 (0.91) 10.05 (1.07) *** 
Chronic lung disease  5.04% 11.72% 3.27% *** 7.36% 5.59% 7.75% *** 
Cancer 3.92% 8.86% 2.61% *** 6.48% 6.63% 6.45% 
 
Ulcer 3.51% 7.19% 2.54% *** 4.12% 3.67% 4.23% *** 
Heart attack 5.90% 14.15% 3.71% *** 15.96% 13.37% 16.54% *** 
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Table 4.1: (continued) 
Variables 
Whole 
sample                           
(N = 53,631) 
Afraid health 
limits work                       
(N = 11,259) 
Not afraid 
health limits 
work                        








volunteering                       
(N = 8,281) 
No formal 
volunteering                        
(N = 37,103) 
Univariate 
analysis 
Hypertension 29.96% 38.61% 27.66% *** 45.70% 40.45% 46.87% *** 
Stroke 2.09% 6.32% 0.97% *** 4.99% 3.21% 5.38% *** 
Hip fracture 0.96% 2.42% 0.58% *** 2.89% 2.11% 3.07% *** 
Mobility problems     59.57% 47.06% 62.36% *** 
Countries    ***    *** 
Austria 8.74% 6.79% 9.26% 
 
9.36% 9.12% 9.42% 
 
Germany 8.27% 11.16% 7.51% 
 
7.07% 8.21% 6.81% 
 
Sweden 5.91% 5.90% 5.92% 
 
9.16% 9.01% 9.19% 
 
The Netherlands 8.23% 9.06% 8.01% 
 
7.38% 14.79% 5.72% 
 
Spain 9.20% 8.66% 9.35% 
 
12.32% 2.54% 14.51% 
 
Italy  8.72% 5.38% 9.61% 
 
9.83% 5.77% 10.73% 
 
France 10.92% 11.19% 10.85% 
 
9.94% 11.65% 9.56% 
 
Denmark 8.19% 9.83% 7.76% 
 
6.69% 10.34% 5.88% 
 
Switzerland 7.22% 4.09% 8.05% 
 
6.78% 10.84% 5.87% 
 
Belgium 12.87% 13.84% 12.61% 
 
10.54% 13.42% 9.90% 
 
Czech Republic 11.73% 14.10% 11.09% 
 
10.93% 4.31% 12.41% 
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Table 4.1: (continued) 
Variables 
Whole 
sample                           
(N = 53,631) 
Afraid health 
limits work                       
(N = 11,259) 
Not afraid 
health limits 
work                        








volunteering                       
(N = 8,281) 
No formal 
volunteering                        
(N = 37,103) 
Univariate 
analysis 
Waves         
Wave 2 (years 2006/07) 16.39% 16.57% 16.35% 
 
13.58% 12.23% 13.88% 
 
Wave 4 (year 2010) 36.78% 36.33% 36.89% 
 
32.79% 36.00% 32.08% 
 
Wave 5 (year 2013) 46.83% 47.09% 46.76% 
 
53.63% 51.77% 54.04% 
 
*** p<0.01, ** p<0.05, * p<0.1. Comparison of means tests cluster observations at the individual level in case of being afraid health limits work and at the household level in case of 
formal volunteering. 
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Table 4.2: Country specific data, by outcome 
Countries 
 
Whole sample Afraid health limits work                       
Univariate 
analysis 















Austria 8,934 1,030 (11.53%) 4,686 447 (9.54%) *** 4,248 583 (13.72%) ** 
Germany 7,645 1,005 (13.15%) 4,437 434 (9.78%) *** 3,208 571 (17.80%) *** 
Sweden 7,327 766 (10.45%) 3,171 253 (7.98%) *** 4,156 513 (12.34%)  
The Netherlands 7,763 765 (9.85%) 4,414 359 (8.13%) *** 3,349 406 (12.12%) *** 
Spain 10,530 1,674 (15.90%) 4,936 511 (10.35%) ** 5,594 1,163 (20.79%) *** 
Italy  9,136 1,089 (11.92%) 4,676 391 (8.36%) *** 4,460 698 (15.65%) *** 
France 10,366 1,144 (11.04%) 5,856 538 (9.19%) *** 4,510 606 (13.44%) *** 
Denmark 7,433 557 (7.49%) 4,395 229 (5.21%) *** 3,038 328 (10.80%) *** 
Switzerland 6,946 459 (6.61%) 3,870 196 (5.06%) *** 3,076 263 (8.55%) *** 
Belgium 11,684 1,197 (10.24%) 6,901 594 (8.61%) *** 4,783 603 (12.61%) *** 
Czech Republic 11,251 1,912 (16.99%) 6,289 775 (12.32%) *** 4,962 1,137 (22.91%) *** 
Overall sample 99,015 11,575 (11.69%) 53,631 4,344 (8.81%) - 45,384 6,871 (15.14%) - 
*** p<0.01, ** p<0.05.  
Comparison of means tests cluster observations at the individual level in case of being afraid health limits work and at the household level in case of formal 
volunteering. 
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4.4.2 Results from the multivariate regressions 
Being afraid health limits work 
Table 4.3 and Table 4.5 report the results for the overall sample for the outcome “being afraid 
health limits work”, showing the coefficients and the average marginal effects. Having diabetes 
significantly increases the risk of being afraid health limits work, although its coefficient drops 
from 0.902 in Model A to 0.704 in Model B, when the regression is adjusted for clinical 
complications (Columns 1 and 3, Table 4.3). Stroke and hip fracture are the main complications 
increasing the likelihood of reporting being afraid health limits work.  
Looking at the marginal effect of diabetes, I see that having diabetes increases the probability 
of reporting being afraid by 11.6 percentage points in Model B (4th Column, Table 4.3), slightly 
decreasing from Model A (2nd Column, Table 4.3), when its marginal effect without diabetes-
related complications included is 16.2 percentage points. Moreover, the relevance of diabetes and 
its comorbidities is shown in Table 4.5, which shows the average marginal effect of each specific 
complication together with diabetes compared to not suffering from any of them. The greatest 
burden of the listed complications, jointly with diabetes, is given by cancer and heart attack 
(Average Marginal Effect 0.157 in both cases, Model B). 
In addition, regarding the time variables, waves 4 and 5 emerge as significant variables in both 
regression models, A and B (Table 4.3). Being in the year 2010 increases the probability of 
reporting being afraid by 11 percentage points in both regression models (Column 2 and 4, Table 
4.3), whereas living in the year 2013 increases such probability by 10.2 in Model A (2nd Column, 
Table 4.3), but 13.4 percentage points in Model B (4th Column, Table 4.3), with respect to wave 2, 
that is, year 2006/07. Besides, the interaction between diabetes and wave 4 is significant and 
positively associated with the outcome, increasing the probability of the fear by 12.7 percentage 
points (6th  column, Table 4.3). Contrariwise, the interaction between diabetes and wave 5 is not 
significant. Moreover, if one looks at the p-value of the Wald test (Table 4.4) comparing the 
model with interactions to the model B, it lies below the 5% level of significance, meaning that 
the diabetes and time dummies are jointly significant and Model C is the model that better fits the 
data. This results is supported by the AIC coefficient, but not by BIC, which suggests that the 
best model would be Model B. 
Some differences can also be observed across countries. Denmark is the only country 
reporting a positive association with the outcome, meaning that the Danish subsample is more 
afraid health limits the amount or type of work they can do then the German population, which 
is the reference category (average marginal effect, 0.0134 in Model C, Table 4.3). However, the 
effect of Denmark is not significant. On the other hand, living in Italy reduces the risk of being 
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afraid health limits work the most (average marginal effect, -0.168, Model C, Table 4.3), 
compared to Germany.  
In model A, higher education, being non-single and higher income are the set of 
socioeconomic factors that significantly reduce the likelihood of reporting feeling the fear of 
health limiting their work. On the other hand, increasing age is a significant predictor of the 
outcome, but with opposite sign depending on the age group. In the age group closest to 
retirement, the average marginal effect of belonging to such group age is negative, signaling a 
lower probability of being afraid health limits work. A similar trend is followed in model B, being 
a woman also significant. 
 
Formal volunteering: charity work 
Table 4.6 and Table 4.8 report the results for the overall sample for the outcome “formal 
volunteering: charity work”. Having diabetes significantly reduces the probability of being a 
formal volunteer, increasing its marginal effect from – 3.33 in Model A to – 2.69 percentage 
points in Model B, when the regression is adjusted for clinical complications and mobility 
problems (2nd and 4th Column, Table 4.6). Actually, stroke and mobility problems are the main 
complications that significantly reduce the most the probability of doing charity work. Moreover, 
the relevance of diabetes and its comorbidities is shown in Table 4.8. Comorbidities and mobility 
problems reduce its negative marginal effect when, in addition, respondents have diabetes.  
In addition, both time variables are always significant across regression models, increasing the 
magnitude of its coefficient when all clinical and mobility problems are included (coefficient 
0.431 in Model A and 0.406 in Model B in case of wave 4 and 0.362 in Model A and 0.287 in 
Model B in case of wave 5, Table 4.6). Actually, their average marginal effects on the outcome are 
0.0562  and 0.0382 for wave 4 and 5, respectively, in Model B (4th Column, Table 4.6), increasing 
the likelihood of doing charity work. Furthermore, the interactions between diabetes and time are 
negatively associated with the outcome, but not significantly. Moreover, if we look at the p-value 
of the Wald test comparing Model B with Model C (Table 4.7), we see it is far above the 10% 
level of significance, meaning that the interactions are not jointly significant. The test suggests 
that Model B seems to be the best to explain the association between the set of explanatory 
variables and the outcome. Same conclusion is reached when looking at the AIC and BIC values. 
Some differences can also be observed across countries. Southern countries, such as Italy and 
Spain report negative coefficients, signaling that living in any of these countries reduces the 
probability of being a formal volunteer, in comparison to Germany, the reference category, as 
well as in Austria, Sweden or the Czech Republic. The rest of the countries included in the 
analysis report positive coefficients. 
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In model A, increasing age, being woman, lower education and having a couple are the control 
variables that significantly reduce the likelihood of doing charity work. On the other hand, higher 
income is a significant predictors of the outcome, indicating that higher income is associated with 
a higher probability of being a formal volunteer. The same pattern holds in Model B. 
Table 4.A2 in Appendix also shows that diabetes significantly reduces the amount of formal 
volunteering provided. The probability of not doing any amount of formal volunteer is increased 
by 2.50 percentage points if the individual has diabetes and this disease reduces the likelihood of 
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Table 4.3: Results from the logit regressions regarding the fear of health limiting work 

















       
Diabetes 0.902*** 0.162*** 0.704*** 0.116*** 0.643*** 0.101*** 
 (0.0410) (0.00839) (0.0433) (0.00802) (0.0836) (0.00609) 
Diabetes # Wave4     0.158** 0.127** 
     (0.0784) (0.0109) 
Diabetes # Wave5     0.00970 0.111 
     (0.0951) (0.0095) 
Age 55 to 60 0.0982*** 0.0148*** 0.0665** 0.00951** 0.0664** 0.00950** 
 (0.0286) (0.00432) (0.0293) (0.00419) (0.0293) (0.00419) 
Age 60 to 65 -0.0220 -0.00332 -0.119*** -0.0171*** -0.119*** -0.0171*** 
 (0.0317) (0.00478) (0.0326) (0.00467) (0.0326) (0.00466) 
Female 0.0112 0.00168 0.101*** 0.0144*** 0.101*** 0.0144*** 
 (0.0281) (0.00424) (0.0289) (0.00410) (0.0289) (0.00413) 
Low education 0.307*** 0.0477*** 0.277*** 0.0406*** 0.277*** 0.0396*** 
 (0.0335) (0.00535) (0.0341) (0.00515) (0.0341) (0.00488) 
High education -0.465*** -0.0662*** -0.437*** -0.0593*** -0.437*** -0.0625*** 
 (0.0382) (0.00508) (0.0388) (0.00497) (0.0388) (0.00553) 
Non-single -0.273*** -0.0427*** -0.245*** -0.0362*** -0.245*** -0.0351*** 
(0.0359) (0.00580) (0.0368) (0.00560) (0.0368) (0.00526) 
Never married 0.00916 0.00138 0.0413 0.00596 0.0410 0.00587 
 (0.0591) (0.00895) (0.0606) (0.00883) (0.0606) (0.00868) 
Log-household 
income 
-0.170*** -0.0256*** -0.164*** -0.0234*** -0.164*** -0.0234*** 
(0.0194) (0.00292) (0.0196) (0.00280) (0.0196) (0.00280) 
Chronic lung 
disease 
1.209*** 0.232*** 1.093*** 0.195*** 1.094*** 0.156*** 
(0.0505) (0.0112) (0.0528) (0.0110) (0.0528) (0.00741) 
Cancer 1.301*** 0.252*** 1.281*** 0.235*** 1.282*** 0.183*** 
 (0.0551) (0.0123) (0.0577) (0.0123) (0.0577) (0.00808) 
Ulcer   0.828*** 0.141*** 0.828*** 0.118*** 
   (0.0617) (0.0121) (0.0618) (0.00878) 
Heart attack   1.170*** 0.212*** 1.170*** 0.167*** 
   (0.0502) (0.0106) (0.0502) (0.00699) 
Hypertension   0.253*** 0.0373*** 0.253*** 0.0362*** 
   (0.0295) (0.00445) (0.0295) (0.00421) 
Stroke   1.639*** 0.316*** 1.639*** 0.234*** 
   (0.0833) (0.0184) (0.0832) (0.0117) 
Hip fracture   1.378*** 0.257*** 1.379*** 0.197*** 
   (0.112) (0.0243) (0.112) (0.0159) 
Austria -0.787*** -0.0997*** -0.822*** -0.0986*** -0.821*** -0.117*** 
 (0.0650) (0.00674) (0.0676) (0.00663) (0.0676) (0.00964) 
Sweden -0.308*** -0.0433*** -0.283*** -0.0380*** -0.283*** -0.0404*** 
 (0.0722) (0.00939) (0.0744) (0.00935) (0.0743) (0.0106) 
The Netherlands -0.318*** -0.0448*** -0.271*** -0.0366*** -0.270*** -0.0387*** 
 (0.0666) (0.00868) (0.0679) (0.00864) (0.0679) (0.00970) 
Spain -0.747*** -0.0958*** -0.677*** -0.0842*** -0.677*** -0.0968*** 
 (0.0649) (0.00692) (0.0655) (0.00699) (0.0655) (0.00936) 
Italy -1.204*** -0.138*** -1.174*** -0.130*** -1.174*** -0.168*** 
 (0.0707) (0.00585) (0.0716) (0.00590) (0.0715) (0.0102) 
France -0.422*** -0.0584*** -0.389*** -0.0516*** -0.388*** -0.0555*** 
 (0.0603) (0.00760) (0.0616) (0.00753) (0.0616) (0.00881) 
Denmark 0.0633 0.00967 0.0937 0.0137 0.0934 0.0134 
 (0.0642) (0.00994) (0.0654) (0.00973) (0.0654) (0.00936) 
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Switzerland -0.934*** -0.113*** -0.858*** -0.101*** -0.856*** -0.123*** 
 (0.0780) (0.00726) (0.0788) (0.00744) (0.0788) (0.0113) 
Belgium -0.315*** -0.0447*** -0.333*** -0.0447*** -0.332*** -0.0474*** 
 (0.0580) (0.00771) (0.0595) (0.00749) (0.0595) (0.00850) 
Czech Republic -0.567*** -0.0762*** -0.604*** -0.0767*** -0.603*** -0.0863*** 
 (0.0616) (0.00730) (0.0628) (0.00702) (0.0628) (0.00898) 
Wave 4 (2010) 0.0691*** 0.0105*** 0.0770*** 0.0111*** 0.0569** 0.0109*** 
 (0.0245) (0.00373) (0.0252) (0.00363) (0.0268) (0.00359) 
Wave 5 (2013) 0.0678** 0.0102** 0.0933*** 0.0134*** 0.0911*** 0.0132*** 
 (0.0311) (0.00469) (0.0320) (0.00457) (0.0340) (0.00455) 
N (Observations) 53,631 53,631 53,631 53,631 53,631 53,631 
N (Clusters) 34,393 34,393 34,393 34,393 34,393 34,393 
Log 
pseudolikelihood 
-25,349.102  -24,289.654  -24,287.479 
 
Wald chi2 2,773.22  3,627.48  3,634.48  
Prob > chi2 0.000  0.000  0.000  
Clustered standard errors at individual level in parentheses. *** p<0.01, ** p<0.05, * p<0.1.  
Reference categories: age 50 to 55, medium education, being separated/divorced/widowed, Germany and wave 2 (year 
2006/07). 
Model A includes diabetes, sociodemographic characteristics (age, gender, education, marital status and household 
income), and non-diabetes related complications (chronic lung disease and cancer). Model B adds to the previous model 
diabetes-related clinical complications: ulcer, heart attack, hypertension, stroke and hip fracture. Model C includes the 
above variables and the interactions between the main disease of interest, diabetes, and the time variables, wave 4 (year 




Table 4.4: Wald test for the outcome “being afraid health limits work” 
 χ2 Prob > χ2 AIC BIC 
Model B vs Model A 177.29 0.0000 - - 
Model C vs Model B 6.88 0.0321 - - 
Model A - - 50,746.2 50,959.56 
Model B - - 48,637.31 48,895.11 
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Table 4.5: Average marginal effects of clinical and functional complications if individuals 
have diabetes from the logistic regressions 
VARIABLES Average marginal 
effects Model A 
Average marginal 
effects Model B 
Average marginal 
effects Model C 
No chronic lung 
disease 
0.161*** 0.115*** 0.0992*** 
(0.00839) (0.00799) (0.00600) 
Chronic lung 
disease 
0.208*** 0.156*** 0.149*** 
(0.00916) (0.00977) (0.00906) 
No cancer 0.161*** 0.115*** 0.0991*** 
 (0.00838) (0.00798) (0.00600) 
Cancer 0.206*** 0.157*** 0.153*** 
 (0.00898) (0.00963) (0.00930) 
No ulcer  0.116*** 0.0998*** 
  (0.00799) (0.00604) 
Ulcer  0.150*** 0.139*** 
  (0.00973) (0.00867) 
No heart attack  0.115*** 0.0990*** 
  (0.00797) (0.00600) 
Heart attack  0.157*** 0.151*** 
  (0.00972) (0.00911) 
No hypertension  0.113*** 0.0973*** 
  (0.00791) (0.00598) 
Hypertension  0.125*** 0.110*** 
  (0.00840) (0.00654) 
No stroke  0.116*** 0.100*** 
  (0.00803) (0.00608) 
Stroke  0.154*** 0.157*** 
  (0.00919) (0.00947) 
No hip fracture  0.116*** 0.100*** 
  (0.00801) (0.00607) 
Hip fracture  0.156*** 0.154*** 
  (0.00943) (0.00941) 
N (Observations) 53,631 53,631 53,631 
Clustered standard errors at individual level in parentheses. *** p<0.01, ** p<0.05, * p<0.1. 
The coefficient on not having each disease denotes the individual effect of having diabetes 
on the outcome. The coefficient on having each disease represents the jointly effect of 
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Diabetes -0.261*** -0.0333*** -0.209*** -0.0269*** -0.177 -0.0279*** 
 (0.0486) (0.00587) (0.0491) (0.00605) (0.126) (0.00660) 
Diabetes # Wave4     -0.0319 -0.0017 
     (0.129) (0.0083) 
Diabetes # Wave5     -0.0386 -0.0398 
     (0.130) (0.0062) 
Age 70 to 75  -0.106*** -0.0142*** -0.080** -0.011** -0.080** -0.011** 
 (0.0339) (0.0045) (0.0341) (0.0046) (0.0341) (0.0046) 
Age 75 to 80 -0.361*** -0.048*** -0.310*** -0.041*** -0.310*** -0.041*** 
 (0.0435) (0.0058) (0.0443) (0.0059) (0.0443) (0.0059) 
Age 80 to 85 -0.853*** -0.114*** -0.773*** -0.103*** -0.773*** -0.103*** 
 (0.0572) (0.0076) (0.0584) (0.0077) (0.0584) (0.0077) 
Age 85 to 90 -1.199*** -0.161*** -1.094*** -0.146*** -1.094*** -0.146*** 
 (0.2068) (0.0123) (0.0935) (0.0124) (0.0935) (0.0124) 
Age 90+ -1.781*** -0.239*** -1.668*** -0.223*** -1.668*** -0.223*** 
 (0.2068) (0.0277) (0.2076) (0.0277) (0.2076) (0.0277) 
Female -0.0290 -0.00388 0.0125 0.00167 0.0125 0.00167 
 (0.0302) (0.00405) (0.0311) (0.00415) (0.0311) (0.00415) 
Low education -0.278*** -0.0369*** -0.273*** -0.0362*** -0.273*** -0.0365*** 
 (0.0403) (0.00530) (0.0404) (0.00529) (0.0404) (0.00539) 
High education 0.475*** 0.0688*** 0.459*** 0.0660*** 0.459*** 0.0613*** 
 (0.0427) (0.00662) (0.0428) (0.00659) (0.0428) (0.00569) 
Non-single -0.0192 -0.00258 -0.0248 -0.00332 -0.0248 -0.00331 
(0.0404) (0.00544) (0.0405) (0.00543) (0.0405) (0.00541) 
Never married 0.154* 0.0214* 0.163* 0.0226* 0.163* 0.0218* 
 (0.0860) (0.0124) (0.0863) (0.0124) (0.0863) (0.0115) 
Log-household 
income 
0.110*** 0.0147*** 0.104*** 0.0140*** 0.104*** 0.0140*** 
(0.0175) (0.00234) (0.0175) (0.00233) (0.0175) (0.00233) 
Chronic lung 
disease 
-0.299*** -0.0374*** -0.236*** -0.0299*** -0.235*** -0.0315*** 
(0.0604) (0.00704) (0.0609) (0.00730) (0.0609) (0.00814) 
Ulcer   0.0733 0.00996 0.0735 0.00982 
   (0.0737) (0.0102) (0.0737) (0.00984) 
Heart attack   -0.00411 -0.000549 -0.00418 -0.000559 
   (0.0418) (0.00557) (0.0418) (0.00558) 
Hypertension   -0.0345 -0.00460 -0.0345 -0.00461 
   (0.0310) (0.00413) (0.0310) (0.00414) 
Stroke   -0.289*** -0.0360*** -0.289*** -0.0386*** 
   (0.0747) (0.00864) (0.0747) (0.00998) 
Hip fracture   -0.0348 -0.00461 -0.0348 -0.00464 
   (0.0905) (0.0119) (0.0905) (0.0121) 
Mobility problems   -0.255*** -0.0344*** -0.255*** -0.0340*** 
   (0.0352) (0.00481) (0.0352) (0.00470) 
Austria -0.227*** -0.0291*** -0.229*** -0.0292*** -0.229*** -0.0306*** 
 (0.0786) (0.00959) (0.0788) (0.00958) (0.0788) (0.0105) 
Sweden -0.188** -0.0243** -0.207** -0.0265*** -0.207** -0.0277** 
 (0.0820) (0.0102) (0.0823) (0.0101) (0.0824) (0.0110) 
The Netherlands 0.924*** 0.148*** 0.886*** 0.141*** 0.886*** 0.118*** 
 (0.0783) (0.0144) (0.0784) (0.0142) (0.0784) (0.0104) 
Spain -1.571*** -0.144*** -1.588*** -0.145*** -1.588*** -0.212*** 
 (0.108) (0.00611) (0.109) (0.00607) (0.109) (0.0145) 
Italy -0.509*** -0.0612*** -0.506*** -0.0607*** -0.506*** -0.0676*** 
 (0.0912) (0.00969) (0.0912) (0.00969) (0.0912) (0.0122) 
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France 0.197** 0.0274** 0.189** 0.0262** 0.189** 0.0253** 
 (0.0784) (0.0113) (0.0786) (0.0113) (0.0786) (0.0105) 
Denmark 0.353*** 0.0509*** 0.323*** 0.0461*** 0.323*** 0.0431*** 
 (0.0828) (0.0128) (0.0829) (0.0126) (0.0829) (0.0111) 
Switzerland 0.400*** 0.0582*** 0.363*** 0.0522*** 0.362*** 0.0484*** 
 (0.0807) (0.0126) (0.0810) (0.0125) (0.0810) (0.0108) 
Belgium 0.228*** 0.0319*** 0.231*** 0.0322*** 0.231*** 0.0309*** 
 (0.0774) (0.0113) (0.0777) (0.0113) (0.0777) (0.0104) 
Czech Republic -1.067*** -0.113*** -1.057*** -0.111*** -1.057*** -0.141*** 
 (0.0885) (0.00702) (0.0887) (0.00707) (0.0887) (0.0119) 
Wave 4 (2010) 0.431*** 0.0599*** 0.406*** 0.0562*** 0.409*** 0.0542*** 
 (0.0397) (0.00567) (0.0398) (0.00565) (0.0418) (0.00530) 
Wave 5 (2013) 0.362*** 0.0482*** 0.287*** 0.0382*** 0.291*** 0.0382*** 
 (0.0518) (0.00679) (0.0529) (0.00695) (0.0540) (0.00703) 
N (Observations) 45,384 45,384 45,384 45,384 45,384 45,384 
N (Clusters) 18,647 18,647 18,647 18,647 18,647 18,647 
Log 
pseudolikelihood 
-19,224.709  -19,035.365  -19,035.274  
Wald chi2 2,262.79  2,437.11  2,439.53  
Prob > chi2 0.000  0.000  0.000  
Clustered standard errors at household level in parentheses. *** p<0.01, ** p<0.05, * p<0.1. Reference categories: age 65 
to 70, medium education, being separated/divorced/widowed, Germany and wave 2 (year 2006/07). 
Model A includes diabetes, sociodemographic characteristics (age, gender, education, marital status and household 
income), and non-diabetes related complications (chronic lung disease). Model B adds to the previous model diabetes-
related clinical complications: ulcer, heart attack, hypertension, stroke, hip fracture and mobility problems. Model C 
includes the above variables and the interactions between the main disease of interest, diabetes, and the time variables, 





Table 4.7: Wald test for the outcome “formal volunteering: charity work” 
 χ2 Prob > χ2 AIC BIC 
Model B vs Model A 168.73 0.0000 - - 
Model C vs Model B 0.21 0.8998 - - 
Model A - - 38,550.6 38,777.39 
Model B - - 38,439.91 38,719.04 
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Table 4.8: Average marginal effects of clinical and functional complications if individuals 
have diabetes from the logistic regressions 
VARIABLES Average marginal 
effects Model A 
Average marginal 
effects Model B 
Average marginal 
effects Model C 
    
No chronic lung disease -0.0333*** -0.0272*** -0.0281*** 
 (0.00817) (0.00611) (0.00666) 
Chronic lung disease -0.0290*** -0.0238*** -0.0248*** 
 (0.00723) (0.00540) (0.00594) 
No ulcer  -0.0269*** -0.0278*** 
  (0.00604) (0.00659) 
Ulcer  -0.0279*** -0.0289*** 
  (0.00637) (0.00691) 
No heart attack  -0.0269*** -0.0279*** 
  (0.00605) (0.00660) 
Heart attack  -0.0269*** -0.0278*** 
  (0.00607) (0.00662) 
No hypertension  -0.0271*** -0.0281*** 
  (0.00608) (0.00664) 
Hypertension  -0.0266*** -0.0276*** 
  (0.00602) (0.00657) 
No stroke  -0.0271*** -0.0281*** 
  (0.00610) (0.00665) 
Stroke  -0.0230*** -0.0240*** 
  (0.00525) (0.00578) 
No hip fracture  -0.0269*** -0.0279*** 
  (0.00605) (0.00660) 
Hip fracture  -0.0264*** -0.0274*** 
  (0.00609) (0.00663) 
No mobility problems  -0.0291*** -0.0300*** 
  (0.00654) (0.00711) 
Mobility problems  -0.0254*** -0.0263*** 
  (0.00570) (0.00626) 
N (Observations) 45,384 45,384 45,384 
Clustered standard errors at household level in parentheses. *** p<0.01, ** p<0.05, * p<0.1. 
The coefficient on not having each disease denotes the individual effect of having diabetes 
on the outcome. The coefficient on having each disease represents the jointly effect of 
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4.5 DISCUSSION 
In this analysis, I aim to assess the relationship between diabetes and productivity using 
European data for three different periods around the financial crisis. I use two measures of 
productivity, depending on age: for those in their working age, that is, from 50 to 65 years old, I 
have employed being afraid health limited their work as the outcome; and for the individuals 
above 65, I have modelled productivity through volunteering activities.  
This study shows that diabetes increases the likelihood people aged 50 to 65 years old report 
being afraid health limits work by 16 percentage points, falling to 12, after controlling for clinical 
complications, suggesting a positive relationship between diabetes and the fear of health limiting 
work in people still in the working age. In addition, my results suggest that the fear of health 
limiting work increases during the years after the crisis, 2010 and 2013, with respect to the time 
before the crisis, 2006, even after including clinical complications. This could reflect the increased 
uncertainty of the employment situation after the economic crisis. In my third hypothesis, I 
expected that the fear of health limiting work of people in the working age and diabetes was 
higher in the years 2010 and 2013, compared to 2006. My hypothesis is only confirmed in case of 
the interaction between diabetes and year 2010, increasing the probability of being afraid by 13 
percentage points, but no significant results are found for 2013. This result might be driven by 
the combination of the impairing effect of diabetes together with the fact that the economic crisis 
hit stronger in the early years of the crisis, leading to a greater fear of limiting the individual´s 
performance at work. 
Regarding volunteering in people older than 65 years old, it is shown that having diabetes 
reduces the likelihood of performing volunteering work by about 3 percentage points in 
comparison to those people without diabetes, as well as it reduces the frequency of carrying out 
such activity. Year 2010 increases the probability of doing charity work by 6 percentage points, 
which is larger than the average marginal effect of the year 2013, 4 percentage points, even after 
adjusting by clinical complications and mobility problems. The rationale behind such increase 
might be greater solidarity or greater need for charity work rather than the individual willingness 
to be productive. Finally, my results do not support the last hypothesis about the joint effect of 
having diabetes in people aged 65 and above in the year 2010 and 2013 on doing charity work.   
Moreover, some differences have been observed across countries. With regards to the first 
outcome, only Denmark reports to increase the likelihood of being afraid health limits the 
amount or type of work one can do in comparison to Germany, although not significantly, 
whereas a negative association between Italy, Spain, Austria, Sweden and the Czech Republic and 
volunteering is displayed, also compared to the German population. However, these differences 
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should be interpreted with caution in case of both outcomes in addition to the potential 
differences existing in their reporting styles (Jürges, 2007): with regards to the former, a reporting 
bias could be present in this analysis due to the culture and the specific characteristics of each 
country; and also regarding the second outcome, since it has been shown that, especially in 
Southern countries (OECD, 2013), the frequency of volunteering has increased more than in 
other areas, but maybe not the amount of people doing so.  
Therefore, the results about the first outcome support those obtained by Tunceli et al. in 
2005, though I use a different outcome measure. The main driver behind the difference in size of 
the effects can be the subjective feature of the outcome used in this chapter, being afraid health 
limits work, compared to the objective character of the question used by Tunceli et al. (2005), 
whether the individuals had any impairments or health problems that limited work. Hence, latter 
respondents report actual health problems that impair work, whereas former individuals report 
their personal perceptions. Moreover, this variation can also stem from the increase in diabetes 
prevalence or from the difference in the composition of the sample and the time selection. 
Tunceli et al. in 2005 used US data from 7,055 respondents from 1992 to 1994 and the results 
presented here are driven by 34,393 individuals from 2006 to 2013. Another explanation could be 
the different reporting style between the United States and some countries, such as Europe, as 
the literature has already shown (Kapteyn et al., 2007). Moreover, the results regarding 
volunteering activities and diabetes confirm the findings of the American Diabetes Association 
(2008), who included volunteering within the productivity measure of those not in the labour 
force. However, the single analysis between diabetes and volunteering is not available in the 
published document, so I cannot compare the magnitude of my results to theirs. 
Some limitations should also be mentioned. First of all, my measure of productivity for those 
in the workforce does not include the number of days lost due to health or reduced productivity 
at work, which are the most common measures of productivity losses. Such kind of information 
is not available in the dataset used, so I take being afraid health limits work as one of the main 
outcomes in the study, which, as it is subjective, can be very sensitive to changes in individual’s 
situation. Individual perception about his/her ability to perform some activities due to health 
problems has previously been used in the literature (Disney et al., 2006). Authors aimed to assess 
the relationship between health and retirement in the United Kingdom. They built their health 
main measure from two different health-related measures: having certain health problems and 
difficulties, and feeling that their health limits their ability to perform certain daily activities. The 
latter is a close measure to the subjective outcome I use in the analysis, which supports the use of 
individual’s feelings together with other more objective health measures. However, the 
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interpretation of the results in the current analysis could lead to lower or higher productivity. For 
example, it is clear that if individual health gets worse, being diagnosed of diabetes in this case, 
the fear of health limiting work is going to increase and also productivity decreases due to health 
problems. However, when interpreting the association between the time variables and the 
outcome, an increase of the fear could also result in higher productivity so as to prove that the 
individual should not be fired. Second, I could not obtain information on other types of 
volunteering, care for family or informal care, which are available in wave 2, but some changes 
have been made to the question in wave 4. So, I could only stick to the most strict definition of 
volunteering, which refers to charity work (Börsch-Supan et al., 2005). Thirdly, due to data 
restrictions, I exclude seven countries from the analysis from the nineteen countries that SHARE 
provides information from23. However, the results reported in this study are still accurate since I 
include a representative sample of the European population. Finally, the self-reported feature of 
the data, especially health conditions, could bias the results, as it could lead to recall bias and, 
hence, the results here could over or underestimate the true impact of diabetes. Nevertheless, 
there are several findings showing the reliability of data from health conditions collected using 
self-reporting information (Dal Grande et al., 2012; Goebeler et al., 2007). 
The results contribute to the literature in three ways: First, much has been written regarding 
the association between diabetes and number of days lost due to health reasons or reduced 
productivity at work, but little is known about the relationship with being afraid health limits 
work and non-paid productivity measures, such as volunteering. Second, not all the existing 
studies have included diabetes-related clinical and functional complications. Actually, one study 
showed that, by excluding those, one could underestimate the impact of diabetes (Norlund et al., 
2001). Finally, I have also assessed the influence of uncertain economic periods, which has not 
been done before, and its association with both productivity alone and jointly with diabetes. 
While three waves is a relatively modest number, the observed patterns over the years 2006, 2010 
and 2013 are suggestive for the effect of an uncertain economic situation on both subjective (fear 
of health limiting work) and objective (volunteering participation) measures of the impact of 
diabetes on productivity. The results provide evidence that diabetes affects patients, employers, 
and society by contributing to work loss through work limitations and decreases in volunteering 
activities, even in unstable environments, such as the economic crisis that hit Europe recently. 
Moreover, the economic burden associated with diabetes is likely to increase as diabetes becomes 
more prevalent.  
 
                                                          
23 For example, Portugal and Greece, which were deeply hit by the debt crisis during the economic recession, were 
two of the countries excluded from the analysis.  
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APPENDIX CHAPTER 4 
Table 4.A1: List of variables included in the analysis 
Variable Coding 
Being afraid health limits work 
1: respondent has been afraid health limited the kind or amount of 
work s/he did; 0: otherwise 
Formal volunteering 
1: respondent has done voluntary or charity work in the last month; 
0: otherwise 
Age 50 - 55  1: respondent’s age lies between 50 and 55 years old; 0: otherwise 
Age 56 – 60  1: respondent’s age lies between 56 and 60 years old; 0: otherwise 
Age 61 – 65  1: respondent’s age lies between 61 and 65 years old; 0: otherwise 
Age 66 – 70  1: respondent’s age lies between 66 and 70 years old; 0: otherwise 
Age 71 - 75  1: respondent’s age lies between 71 and 75 years old; 0: otherwise 
Age 76 – 80  1: respondent’s age lies between 76 and 80 years old; 0: otherwise 
Age 81 – 85  1: respondent’s age lies between 81 and 85 years old; 0: otherwise 
Age 86 - 90  1: respondent’s age lies between 86 and 90 years old; 0: otherwise 
Age 90+  1: respondent is older than 90; 0: otherwise 
Female 1: female; 0: male 
Low education 
1: respondent had completed primary education or first stage of 
basic education and lower secondary or second stage of basic 
education; 0: otherwise 
Medium education 
1: respondent had completed (upper) secondary education and post-
secondary non-tertiary education; 0: otherwise 
High education 
1: respondent had completed first and second stage of tertiary 
education; 0: otherwise 
Non-single 1: married or with a registered partner; 0: otheriwse 
Never married 1: never married; 0: otherwise 
Separated, divorced or 
widowed 
1: separated, divorced or widowed; 0: otherwise 
Log household income 1: respondent’s income is in the lowest quintile group; 0: otherwise 
Chronic lung disease  1: respondent has any chronic lung disease; 0: otherwise 
Cancer   1: respondent has cancer; 0: otherwise 
Ulcer  1: respondent has an ulcer; 0: otherwise 
Heart attack  1: respondent has had a heart attack; 0: otherwise 
Hypertension  1: respondent has hypertension; 0: otherwise 
Stroke  1: respondent has had a stroke; 0: otherwise 
Hip fracture 1: respondent has had a hip fracture; 0: otherwise 
Mobility problems 
1: any number of mobility problems had been reported by the 
respondent; 0: otherwise 
Austria  1: respondent lives in Austria; 0: otherwise 
Germany  1: respondent lives in Germany; 0: otherwise 
Sweden  1: respondent lives in Sweden; 0: otherwise 
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Table 4.A1: (continued) 
Variable Coding 
The Netherlands  1: respondent lives in The Netherlands; 0: otherwise 
Spain  1: respondent lives in Spain; 0: otherwise 
Italy   1: respondent lives in Italy; 0: otherwise 
France  1: respondent lives in France; 0: otherwise 
Denmark  1: respondent lives in Denmark; 0: otherwise 
Greece  1: respondent lives in Greece; 0: otherwise 
Switzerland  1: respondent lives in Switzerland; 0: otherwise 
Belgium  1: respondent lives in Belgium; 0: otherwise 
Czech Republic  1: respondent lives in Czech Republic; 0: otherwise 
Wave 2 (years 2006/07)  1: data was collected from wave 1; 0: otherwise 
Wave 4 (year 2010)  1: data was collected from wave 2; 0: otherwise 
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Table 4.A2: Average marginal effects from the ordered logit regression regarding frequency of 
formal volunteering for the overall sample 
VARIABLES 
Average marginal 












Diabetes 0.0250*** -0.00602*** -0.0133*** -0.00568*** 
 (0.00645) (0.00155) (0.00344) (0.00147) 
Age 70 to 75 0.0069 -0.0017 -0.0037 -0.0016 
 (0.0043) (0.0010) (0.0023) (0.0010) 
Age 75 to 80 0.0384*** -0.0093*** -0.0205*** -0.0087*** 
 (0.0056) (0.0013) (0.0030) (0.0013) 
Age 80 to 85 0.0979*** -0.0236*** -0.0522*** -0.0222*** 
 (0.0075) (0.0019) (0.0040) (0.0018) 
Age 85 to 90 0.1411*** -0.0340*** -0.0752*** 0.0319*** 
 (0.0123) (0.0030) (0.0067) (0.0029) 
Age 90+ 0.2419*** -0.0583*** -0.1289*** -0.0547*** 
 (0.0301) (0.0074) (0.0161) (0.0071) 
Female -0.00187 0.000450 0.000996 0.000423 
 (0.00397) (0.000956) (0.00212) (0.000899) 
Low education 0.0353*** -0.00850*** -0.0188*** -0.00799*** 
 (0.00525) (0.00127) (0.00281) (0.00122) 
High education -0.0549*** 0.0132*** 0.0292*** 0.0124*** 
 (0.00544) (0.00133) (0.00292) (0.00130) 
Non-single 0.00400 -0.000962 -0.00213 -0.000905 
(0.00521) (0.00125) (0.00278) (0.00118) 
Never married -0.0180 0.00433 0.00957 0.00407 
 (0.0115) (0.00276) (0.00611) (0.00261) 
Log-household income -0.0121*** 0.00291*** 0.00645*** 0.00274*** 
 (0.00223) (0.000540) (0.00119) (0.000515) 
Chronic lung disease 0.0276*** -0.00664*** -0.0147*** -0.00624*** 
 (0.00797) (0.00193) (0.00425) (0.00182) 
Ulcer -0.00757 0.00182 0.00403 0.00171 
 (0.00981) (0.00236) (0.00523) (0.00222) 
Heart attack 0.000967 -0.000233 -0.000515 -0.000219 
 (0.00533) (0.00128) (0.00284) (0.00121) 
Hypertension 0.00723* -0.00174* -0.00385* -0.00164* 
 (0.00398) (0.000959) (0.00212) (0.000904) 
Stroke 0.0358*** -0.00862*** -0.0191*** -0.00811*** 
 (0.00974) (0.00235) (0.00520) (0.00222) 
Hip fracture 0.00756 -0.00182 -0.00403 -0.00171 
 (0.0117) (0.00282) (0.00624) (0.00265) 
Mobility problems 0.0327*** -0.00788*** -0.0174*** -0.00741*** 
 (0.00452) (0.00110) (0.00242) (0.00105) 
Austria 0.0454*** -0.0109*** -0.0242*** -0.0103*** 
 (0.0101) (0.00242) (0.00536) (0.00231) 
Sweden 0.0289*** -0.00695*** -0.0154*** -0.00654*** 
 (0.0103) (0.00248) (0.00549) (0.00234) 
The Netherlands -0.110*** 0.0264*** 0.0584*** 0.0248*** 
 (0.00957) (0.00234) (0.00519) (0.00229) 
Spain 0.211*** -0.0507*** -0.112*** -0.0477*** 
 (0.0149) (0.00373) (0.00816) (0.00362) 
Italy 0.0622*** -0.0150*** -0.0332*** -0.0141*** 
 (0.0119) (0.00288) (0.00635) (0.00269) 
France -0.0188* 0.00452* 0.01000* 0.00425* 
 (0.0100) (0.00242) (0.00535) (0.00228) 
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Table 4A2: (continued) 
VARIABLES 
Average marginal 












Denmark -0.0364*** 0.00875*** 0.0194*** 0.00823*** 
 (0.0102) (0.00247) (0.00547) (0.00233) 
Switzerland -0.0357*** 0.00860*** 0.0190*** 0.00809*** 
 (0.0101) (0.00243) (0.00537) (0.00228) 
Belgium -0.0257*** 0.00619*** 0.0137*** 0.00582*** 
 (0.00990) (0.00238) (0.00527) (0.00226) 
Czech Republic 0.171*** -0.0412*** -0.0911*** -0.0387*** 
 (0.0124) (0.00304) (0.00675) (0.00306) 
Wave 4 (year 2010) -0.0286*** 0.00687*** 0.0153*** 0.00651*** 
 (0.00482) (0.00117) (0.00257) (0.00111) 
Wave 5 (year 2013) -0.0130** 0.00312** 0.00694** 0.00296** 
 (0.00652) (0.00158) (0.00347) (0.00148) 
Observations 45,384 45,384 45,384 45,384 
Clustered standard errors at household level in parentheses. *** p<0.01, ** p<0.05, * p<0.1. 
Reference categories: age 65 to 70, medium education, being separated/divorced/widowed, Germany and wave 2 
(year 2006/07). 
Model includes diabetes, sociodemographic characteristics (age, gender, education, marital status and household 
income), non-diabetes related complications (chronic lung disease), a list of diabetes-related clinical complications 
(ulcer, heart attack, hypertension, stroke, hip fracture and mobility problems), dummy variables for countries and 



















































HEALTH-RELATED QUALITY OF LIFE AND DIABETES AMONG 
OLDER PEOPLE: THE KEY INFLUENCE OF CLINICAL 
COMPLICATIONS AND FRAILTY24 
 
 
5.1 INTRODUCTION AND BACKGROUND 
The number of adults suffering from diabetes mellitus (DM) has nearly doubled in the last 
thirty years, from 4.7% in 1980 to 8.5% in 2014 (OECD/EU, 2016) and these figures will keep 
increasing until 2030 (O’Shea et al., 2013; Wild et al., 2004). Especially relevant is the rise in the 
prevalence of type 2 DM (T2DM), which represents more than 90% of the diabetes diagnoses 
and mainly affects people aged 65 and older, whose diabetes prevalence is around 25% (Wild et 
al., 2004).  
The existing literature has provided evidence on the negative impact that diabetes has on 
quality of life (Vadyia et al., 2015; Schunck et al., 2012; Papadopoulos et al., 2007; Rubin and 
Peyrot, 1999), being consistent across health-related quality of life (HRQoL) instruments 
(Kontodimopoulos et al., 2012; Fu et al., 2011).  
Furthermore, people with diabetes are at greater risk of additionally suffering from 
cardiovascular diseases, such as heart attack or stroke (OECD/EU, 2016; Engelmann et al., 2016; 
Constantino et al., 2013); kidney failure (OECD/EU, 2016); foot ulcers that might lead to 
amputation (Lombardo et al., 2014; Chand et al., 2012; Group, 2000); and functional impairment, 
which is actually the main consequence of worse individuals’ autonomy and quality of life among 
old people with diabetes (Sinclair et al., 2015). In this regard, Burden of Diabetes has been ranked 
as the seventh and eighth cause of years of life lost and Disability-Adjusted Life Years (DALYs) 
                                                          
24 Parts of this study have been presented in the 2017 International Health Economics Association Congress in 
Boston, United States, July 9 – 11, 2017; and at the XXXVII Jornadas Economía de la Salud in Barcelona, Spain, 
September 4-8, 2017. I thank the conference attendees for their contribution made to the manuscript. 
This chapter uses data from the Toledo Study of Healthy Ageing (TSHA) Waves 1 (years 2006 – 2009) and 2 
(years 2011 – 2013). The author would like to thank Francisco Jose García-García and Jose Antonio Carnicero-
Carreño for their help with the data.  
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respectively in Western Societies (Murray and López, 2013) and the 14th cause all over the world 
in the ranking of causes of DALYs (Murray et al., 2012), accounting for 1.9% of total DALYs. 
So, when analysing the burden of diabetes in the elderly, disability should be taken into account. 
Given the association between diabetes and the consequent development of the 
aforementioned complications, knowing the burden of diabetes and diabetes-related 
complications on health-related quality of life should be of great interest not only for those 
suffering from the disease, but also for policymakers and the society as a whole. Using data from 
the Toledo Study on Health Ageing (TSHA), a representative sample of Spanish old adults 
(Appendix, Table 5.A1), I analyse the impact that diabetes-related and non-related complications 
have on HRQoL of old people with diabetes, adding to the existing literature the inclusion of the 
frailty syndrome (FS). This syndrome has been found to worsen as age increases and to increase 
the risks of disability, hospitalization and mortality (Ensrud et al., 2009; Avila-Funes et al., 2008; 
Cawthon et al., 2007; Fried et al., 2001). Moreover, the joint burden of these complications on 
quality of life will be assessed.  
The literature has widely analysed the impact of micro and macrovascular diseases in people 
with diabetes quality of life (Javanbakht et al., 2012; Redekop et al., 2002), concluding that the 
quality of life in people with diabetes is affected by complications and not by diabetes itself 
(Venkataraman et al., 2013). Within 1,348 T2DM European patients from the CODE-2 study 
whose most participants were older than 65 years old, suffering from micro or macrovascular 
diseases significantly reduced HRQoL, increasing its impact when the individual had both 
(Redekop et al., 2002). Using data from 2,601 individuals with mean age equal to 48 years old 
from Singapore, Venkataraman et al. (2013) concluded that people with diabetes and any of the 
micro or macrovascular complications included had lower HRQoL than the individuals solely 
with diabetes, being peripheral neuropathy the complication showing the greatest impact on 
quality of life. Other authors found that, within 356 Norwegians with T2DM and a mean age of 
64 years old, neuropathy and stroke were the main complications reducing HRQoL (Solli et al., 
2010). Another study including 1,141 US participants initially aged 13 to 39 years old reported 
that, after 23.5 years of follow-up, the clinical conditions that reported lower HRQoL scores were 
retinopathy, nephropathy and neuropathy (Jacobson et al., 2013). In a population of 6,317 US 
individuals with type 2 or type 1 diabetes aged 60 to 75 years old, congestive heart failure and 
myocardial infarction were the complications reducing the most physical HRQoL, whereas 
hypoglycaemia and congestive heart failure were associated with lower mental HRQoL 
(Laiteerapong et al., 2011).  
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However, little is known about the influence of chronic conditions, including functional 
impairment, on quality of life of people with diabetes when being evaluated together. Taking into 
account that older people have several diseases simultaneously, which is known as comorbidity, 
knowing how chronic conditions and frailty interact with respect to quality of life and other 
outcomes, such as disability (Verbrugge et al., 1989) or life expectancy (van Baal et al., 2006), 
would be of special relevance in the elderly. By doing so, I could assess whether diseases and 
conditions work independently or whether they interact synergistically to increase or reduce 
HRQoL. Some authors have already analysed the joint impact of suffering from diabetes and 
additional diseases on HRQoL (Banegas et al., 2007; Wee et al., 2005; Gaynes et al., 2002), but 
still, they do not estimate the joint effect of chronic diseases on people with diabetes, compared 
to people without diabetes.  
In this study, the aim is to build on the existing literature by analysing the relationship between 
some factors that could determine the differences in HRQoL among people with and without 
diabetes, adding not only the clinical complications, but also the frailty syndrome as a measure of 
functional impairment. Moreover, their joint effect will be quantified.  
The structure of the chapter is as follows. In Section 5.2, the data that has been used to run 
the analyses is presented, as well as the variables selected and the empirical methods used for the 
estimation of the determinants of HRQoL associated with diabetes and the clinical complications 
and the frailty syndrome. The results that have been obtained are presented in Section 5.3. 
Finally, a discussion of the results and the derived implications for policymakers are presented in 
Section 5.4, besides the limitations of the analysis.  
 
5.2 DATA AND METHODS 
5.2.1 Sample data 
The analysis is run using data from the Toledo Study on Healthy Ageing (TSHA). TSHA is a 
population-based longitudinal study containing information of both institutionalized and 
community-dwelling people aged 65 and above living in the province of Toledo, Spain, 
composed by two cohorts. The first one includes the survivors of a previous study (the Toledo 
Study), which contained data among people aged 77 and older. The second cohort collected data 
from individuals 65-76 years of age who just joined the study. Subjects from both cohorts were 
randomly selected by a two-stage random sampling from the Toledo census, according to gender, 
age and town-size groups. The study sample included 24% of the population aged 65 and older 
living in Toledo. Selection of study participants (Figure 5.1) and data collection at baseline were 
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conducted from June 2006 to September 2009. Signed informed consent was obtained from all 
participants25.  
 
Figure 5.1: Participants flow of the Toledo Study of Healthy Ageing, first wave (García-
García et al., 2011) 
 
 
A second collection of data took place between 2011 and 2013, including 2,360 participants, 
from which 847 were new in the study. From the 2,488 participants in wave 1 (years 2006 – 
2009), 1,513 took part in the second cohort, 452 died before the second interview took place, 193 
did not want to participate in the second wave, 68 were not possible to contact and additional 40 
individuals did want to be part of the study but did not finally do so.  
Data was collected in three stages. In the first one, six psychologists conducted computed 
assisted interviews at the subjects’ home. The questionnaires referred to background 
characteristics, social support, activities of daily living, HRQoL, clinical history, physical activity, 
and healthy lifestyle information, such as smoking and drinking habits, and depressive symptoms 
and an extensive neuropsychology assessment. 
In the second stage, three nurses performed a physical examination and some clinical tests, 
also at the survey respondent’s home. Nurses measured heart rate, blood pressure and 
anthropometry. They also made an electrocardiogram, a spirometry test, determined the ankle-
brachial index, and evaluated physical performance (extremity strength, walking speed, balance 
and a sit-and-stand from chair). Nurses also evaluated cognition skills and inquired about urinary 
incontinence. Both the psychologists and nurses were trained specifically for this study. 
                                                          
25 The study was approved by the Clinical Research Ethics Committee of the Toledo Hospital. 
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In the third stage, study participants went to their health center to provide a fasting blood 
sample.  
The study includes information about socioeconomic status (age, gender, country, marital 
status, education, etc.), family networks, health and functional status (self-perceived health, 
diagnoses, number of limitations in Activities of Daily Living (ADL) and Instrumental Activities 
of Daily Living (IADL); and frailty syndrome), quality of life and use of healthcare resources 
(being admitted to hospital, drugs use, etc.).   
The data used for the purpose of this chapter includes 2933 observations, with information on 
2156 individuals from the first two waves that are currently available: wave 1, whose data was 
collected from the years 2006 to 2009; and wave 2, which corresponds to the time period from 
2011 to 2013. 
 
5.2.2 Selection of variables 
Outcome measure: Health-Related Quality of Life  
Health-Related Quality of Life (HRQoL) is measured using the multi-attribute utility 
questionnaire known as EQ-5D-3L, which refers to five different dimensions: mobility, self-care, 
usual activities, pain or discomfort and anxiety or depression. Respondents answer whether they 
have experienced any problems in any of these dimensions according to three different levels: no 
problems; moderate or some problems; and severe or many problems.  
The EQ-5D is a generic tool to measure HRQoL for both healthy individuals and for patients 
with several pathologies. The different health states as respondents indicate them on the EQ-5D 
questionnaire are given different values using country specific tariffs that have been previously 
obtained in separate studies in the general population using a valuation technique as it is the time 
trade-off (Herdman et al., 2001). Values range between 1 (best possible health state) and 0 
(death), although negative values can be found, signalling health states worse than death.  
Although there are some other instruments (Quality of Wellbeing Scale, Health Utilities 
Index), the EQ-5D is the only one that has been adapted and validated in Spain (Herdman et al., 
2001). For the TSHA dataset, EQ-5D answers were translated into EQ-5D index utilities using 
the Spanish Time-Trade Off (TTO) tariffs (Herdman et al., 2001). 
 
Independent variables 
Diabetes is self-reported, but also checked with medical records and drugs use. So, in order to 
be classified as having diabetes, the first step is to having answered affirmatively to “Have you 
ever been told by a doctor that you suffer from diabetes?”. Then, those answers are double 
checked with people who reported taking drugs for diabetes, which is also contained in the 
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dataset. If an individual has not responded affirmatively to having been diagnosed of diabetes, 
but takes any drug for diabetes, that person is also classified as suffering from diabetes. Finally, 
information is verified using medical records provided by the hospital.  
Clinical complications are also self-reported and later checked with medical records.  These 
are classified as: i) non-diabetes related, which include chronic lung disease, asthma, cancer and 
gastric ulcer; ii) diabetes-related complications, which refer to hypertension, microvascular 
(nephropathy, retinopathy) and macrovascular diseases (heart attack, stroke and peripheral arterial 
disease).  
Frailty is measured according to the Fried criteria (Fried et al., 2001), whose test was 
performed by trained nurses at the survey participant’s home. The criteria that have been used to 
determine whether the individual is frail, pre-frail or robust are: 
• Weakness, defined as the lowest quintile (20%) of maximum strength on the dominant 
hand by gender and body mass index  
• Low energy, meaning by “low energy” when individuals answered affirmatively to any of 
the following two questions: “I felt that anything I did was a big effort” and “I felt that I 
could not keep on doing things” at least 3 to 4 days a week. 
• Slowness, referring to the lowest quintile (20%) in the three-meter walking speed test, by 
gender and height. 
• Low physical activity, according to Physical Activity Scale for the Elderly (PASE) score, 
which is a weighted score referring to the kilocalories expended per week. Low physical 
activity is defined as having an score in the lowest quintile (20%), which, by gender, are  
less than 383 Kcals/week for males and less than 270 Kcals/week for women   
• Weight loss, as unintentional weight loss of 4.5 kg or more in the last year. 
Then, one point is assigned to each of these categories if the individuals meet the above 
criteria and a final score is built as the sum of the five criteria. According to this score, subjects 
are classified as non-frail (0 points), pre-frail (1-2 points) and frail (3-5 points) (García-García et 
al., 2011). The Fried phenotype of frailty has extensively been used in the literature and validated 
(Bieniek et al., 2016; Chen et al., 2015; Drey et al., 2011), signaling the good applicability of the 
Fried criteria to identify frail individuals in older people, as it is the case in my study.  
Sociodemographic factors are also included, such as age and the quadratic form of age in 
order to control for its potential decreasing marginal effect, which are actually my only 
continuous demographic variables in the model. Dummy variables for gender, marital and 
employment status, and education categories are also part of the analyses. 
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A detailed description of the variables included in the analysis can be found in Appendix, 
Table 5.A2.  
 
5.2.3 Statistical analyses 
Given the panel nature of the data, I am able to take into account individual heterogeneity 
across time. Two main estimation techniques are used when having panel data: fixed-effects and 
random-effects models (Berrington et al., 2006; Heij et al., 2004). Fixed-effects models explore 
the relationship between variables that vary over time (for example, age, marital status, disease 
diagnosis) within an individual; the impact of the time-invariant variables cannot be identified (i.e. 
gender, date of birth). Hence, fixed-effects models are aimed to analyze the causes of changes 
within an individual. On the other hand, random-effects models allow time-invariant factors to 
be associated with the outcome and, hence, the variation across individuals is assumed to be 
random, exogeneous and uncorrelated with the independent variables. A random-effects linear 
regression model will be used so as to take into account individual variation between the two 
waves included in the analysis.     
The baseline model with random-effects is as follows: 
𝐻𝑅𝑄𝑜𝐿𝑠𝑐𝑜𝑟𝑒𝑖𝑡 =  𝛽′1𝑆𝐸𝑖𝑡 + 𝛽2𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖𝑡 +  𝜑𝑡 + 𝑐𝑖 + 𝑢𝑖𝑡      (1) 
where 𝐻𝑅𝑄𝑜𝐿𝑠𝑐𝑜𝑟𝑒𝑖𝑡 is a continuous variable that represents the HRQoL score from 
individual i in time t  year; 𝑆𝐸𝑖𝑡 is a vector of explanatory variables referring to age, gender, 
marital and employment status, and education;  𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖𝑡 denotes a dummy variable with value 
1 indicating that the individual suffers from diabetes, and 0 otherwise; 𝜑𝑡denotes the fixed time 
effects and 𝑐𝑖 represents the random effects term, where 𝐸(𝑐𝑖|𝑠𝑖, 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠𝑖) = 0, signaling that 
the conditional mean of the random-effects is independent of the right-hand side variables. 𝑢𝑖𝑡 
denotes the idiosyncratic error term.  
In the above regression model, diabetes non-related and related complications have been 
excluded. These will be added in subsequent models. Model 2 will also take into account the 
diabetes non-related clinical conditions, such as chronic obstructive pulmonary disease (COPD), 
asthma, cancer and gastric ulcer. In a third regression model, the diabetes-related diseases will be 
added to Model 2: hypertension, micro (retinopathy and neuropathy) and macrovascular diseases 
(heart attack, stroke and peripheral arterial disease). Finally, in a fourth model the diagnosis of 
frailty syndrome (pre-frail and frail) will be included.  
It has already been mentioned in the literature that the greater the prevalence of comorbidities 
in addition to diabetes, the greater the reduction in HRQoL. However, little is known about the 
joint impact that suffering from more than one complication has on quality of life in people with 
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diabetes, constituting an empirical challenge. Moreover, it is not known how big this reduction is 
compared to the population without diabetes. Hence, the following regression model is proposed 
to be run for both subsamples, those with diabetes and those without, separately: 
𝐻𝑅𝑄𝑜𝐿𝑠𝑐𝑜𝑟𝑒𝑖𝑡 = 𝛽′1𝑆𝐸𝑖𝑡 +  𝛾1𝑛𝑜𝑛𝑑𝑖𝑎𝑟𝑒𝑙𝑖𝑡 + 𝛾2𝑑𝑖𝑎𝑟𝑒𝑙𝑖𝑡 +  𝛾3𝑓𝑟𝑎𝑖𝑙𝑡𝑦𝑖𝑡 +  𝜑𝑡 + 𝑐𝑖 + 𝑢𝑖𝑡(2) 
where 𝑛𝑜𝑛𝑑𝑖𝑎𝑟𝑒𝑙𝑖𝑡 denotes the number of non-diabetes related clinical complications; 
𝑑𝑖𝑎𝑟𝑒𝑙𝑖𝑡 refers to the number of diabetes-related chronic complications; and 
𝑓𝑟𝑎𝑖𝑙𝑡𝑦𝑖𝑡 represents the two categories of the frailty syndrome, being pre-frail and frail. 
Finally, the interactions between the number of non-diabetes related complications and frailty 
and between the number of diabetes-related chronic conditions and frailty, for both subsamples, 
will be added to the regression model specified in equation (2). 
All the statistical analyses have been performed using STATA 14.0 software (Stata 
Corporation, College Station, TX). 
 
5.3 RESULTS 
5.3.1 Summary statistics 
Characteristics of the general study population and by diabetes status are shown in Table 5.1, 
as well as a comparison of means test between people with and without diabetes.  
The overall prevalence of diabetes is 20% and mean EQ-5D utilities equal to 0.83. The mean 
age is 75.02 years old and 56% of the sample are women, 71% are married, 61% are retired and 
38% are homemakers, and 56% have no education degree. With respect to health conditions, the 
most prevalent ones are hypertension, pre-frailty and peripheral arterial disease, which affect 
59%, 36% and 33% of the whole sample, respectively. The average number of non-diabetes 
related conditions suffered in the whole sample is 0.21, whereas the number, on average, of 
diabetes-related complications increases to 1.02. 
Table 5.1 also shows that there are some differences between the general sample and the 
individuals with and without diabetes. Those with diabetes show lower utilities scores than the 
ones without diabetes (0.81 vs 0.84, respectively). Moreover, people with diabetes are older (75.49 
vs 74.90), with a lower percentage of women (52% vs 57%) and more likely to be retired (64% vs 
61%).  
When talking about health status, the most prevalent diagnoses are equal to the ones in the 
whole sample, although the prevalence varies. Within people with diabetes, 71% and 40% suffer 
from hypertension and pre-frailty; whereas in case of those without diabetes, these percentages 
are 56% and 35%, respectively. Significant differences between both subsamples can be observed 
in the number of the so-called diabetes-related conditions prevalent in each subsample, as the 
average number is 1.33 in the group with diabetes and 0.95 in those without diabetes.     
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Table 5.1: Descriptive statistics26  
Variables 
Whole sample                           
(N = 2,933) 
Diabetes                       
(N = 589) 
Without 
diabetes                        




Mean (SD) EQ-5D Time Trade Off score 0.83 (0.18)  0.81 (0.18)  0.84 (0.18) 0.000*** 
Diabetes  0.2 - - - 
Mean (SD) Age  75.02 (5.92) 75.49 (5.55)  74.90 (6.00)  0.034** 
Female   0.56 0.52 0.57 0.052* 
Marital status     0.233 
Married  0.71 0.68 0.72  
Widowed  0.23 0.26 0.22  
Never married 0.06 0.06 0.06  
Employment status     
Retired 0.61 0.64 0.61 0.094* 
Homemaker 0.38 0.35 0.38  
Employed 0.01 0.02 0.01  
Education    0.297 
No education   0.56 0.58 0.56  
Low education   0.32 0.32 0.32  
Medium or high education   0.12 0.11 0.12  
Chronic lung disease   0.04 0.06 0.04 0.155 
Asthma  0.04 0.04 0.04 0.913 
Cancer   0.07 0.06 0.07 0.295 
Ulcer   0.06 0.07 0.05 0.112 
Mean (SD) Number of non-diabetes-
related conditions 
0.21 (0.49) 0.23 (0.42) 0.21 (0.48) 0.317 
Hypertension 0.59 0.71 0.56 0.000*** 
Microvascular complications   0.03 0.15 - - 
Nephropathy  0.01 0.03 - - 
Retinopathy  0.03 0.13 - - 
Macrovascular complications  0.35 0.38 0.34 0.082* 
Heart attack   0.05 0.07 0.04 0.012** 
Stroke   0.02 0.04 0.02 0.113 
Peripheral arterial disease   0.33 0.35 0.32 0.189 
Both micro and macrovascular   0.01 0.06 - - 
Mean (SD) Number of diabetes-related 
conditions 
1.02 (0.81) 1.33 (0.91) 0.95 (0.76) 0.000*** 
Frailty Syndrome    0.000*** 
Non-frail 0.58 0.52 0.60  
Pre-frail   0.36 0.40 0.35  
Frail   0.06 0.08 0.05  
Wave 1 (years 2006/09)  0.43 0.37 0.45 0.000*** 
Wave 2 (years 2011/13)  0.57 0.63 0.55 0.000*** 
*** p<0.01, ** p<0.05, * p<0.1. Comparison of means tests cluster observations at the individual level  
                                                          
26 Percentages are presented referring to the mean percentage between waves, unless indicated otherwise. 
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5.3.2 Regression results 
Table 5.2 shows the results for the overall sample obtained in the four regression models. 
Model 1 shows that having diabetes significantly decreases HRQoL (Coefficient = -0.034, 
p<0.01), compared to people without diabetes. Being a woman (Coeff. = -0.121, p<0.01) also 
decreases HRQoL scores. On the contrary, having low and medium or high education increase 
health-related quality of life by 0.0408 (p<0.01) and 0.0575 (p<0.01), respectively, compared to 
those with no education.   
When non-related clinical diseases are included in the analysis (Model 2, Table 5.2) diabetes is 
still significant and negatively related to the outcome (Coeff. = -0.0331, p<0.01). All the clinical 
complications are also significant in reducing HRQoL scores, having asthma the greatest impact 
on reducing quality of life (Coeff. = -0.0465, p<0.05). Moreover, when diabetes-related 
complications are part of the regression model (Model 3, Table 5.2), diabetes still reduces health-
related quality of life significantly, but its coefficient drops to -0.0159 (p<0.1). Within the clinical 
complications, nephropathy (Coeff. = -0.120, p<0.05) and stroke (Coeff. = -0.0659, p<0.01) bear 
the greatest effect in decreasing quality of life. Finally, a fourth model adding two categories of 
the frailty syndrome, being pre-frail and frail, show that it is being frail and pre-frail the 
complications with the greatest impact on HRQoL score, reducing it by 0.267 (p<0.01) and by 
0.0815 points (p<0.01), respectively. Diabetes is no longer significantly related to HRQoL in 
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Table 5.2: Results from the random-effects linear regression models regarding Health-
related Quality of Life score for the overall sample 








Diabetes -0.0340*** -0.0331*** -0.0159* -0.00716 
 (0.00812) (0.00806) (0.00839) (0.00760) 
Age 0.0119 0.0117 0.0133 -0.00115 
 (0.0105) (0.0104) (0.0104) (0.00892) 
Age2 -0.000120* -0.000119* -0.000127* -8.64e-06 
 (6.89e-05) (6.81e-05) (6.79e-05) (5.81e-05) 
Female -0.121*** -0.125*** -0.123*** -0.107*** 
(0.00807) (0.00808) (0.00815) (0.00738) 
Married 0.0189 0.0202 0.0204 0.0172 
 (0.0137) (0.0136) (0.0138) (0.0124) 
Widowed 0.0172 0.0190 0.0190 0.0120 
 (0.0157) (0.0157) (0.0157) (0.0141) 
Retired -0.0278 -0.0268 -0.0317 -0.0139 
 (0.0210) (0.0213) (0.0214) (0.0202) 
Homemaker -3.37e-06 -0.000599 -0.00759 -0.00947 
 (0.0217) (0.0220) (0.0221) (0.0208) 
Low education  0.0408*** 0.0396*** 0.0378*** 0.0290*** 
 (0.00745) (0.00743) (0.00738) (0.00667) 
Medium or high education   0.0575*** 0.0559*** 0.0540*** 0.0420*** 
 (0.00902) (0.00901) (0.00900) (0.00826) 
Chronic lung disease  -0.0380** -0.0340** -0.0234* 
  (0.0160) (0.0155) (0.0140) 
Asthma  -0.0465*** -0.0465*** -0.0263* 
  (0.0154) (0.0153) (0.0136) 
Cancer  -0.0246** -0.0232* -0.0139 
  (0.0123) (0.0121) (0.0109) 
Ulcer  -0.0380*** -0.0382*** -0.0241* 
  (0.0147) (0.0145) (0.0134) 
Hypertension   -0.0179*** -0.0200*** 
   (0.00626) (0.00571) 
Nephropathy   -0.120** -0.103*** 
   (0.0473) (0.0387) 
Retinopathy   -0.0645*** -0.0721*** 
   (0.0220) (0.0206) 
Heart attack   -0.0361** -0.0212 
   (0.0148) (0.0131) 
Stroke   -0.0659*** -0.0472** 
   (0.0247) (0.0223) 
Peripheral arterial disease   0.0133** 0.00800 
   (0.00640) (0.00588) 
Both micro and macrovascular 
complications 
  -0.0396 -0.00229 
  (0.0369) (0.0317) 
Pre-frail 
 
   -0.0815*** 
   (0.00624) 
Frail    -0.267*** 
    (0.0147) 
Constant 0.657 0.670* 0.613 1.068*** 
 (0.402) (0.397) (0.396) (0.341) 
N (Observations) 2,933 2,933 2,933 2,933 
N (Individuals) 2,156 2,156 2,156 2,156 
Year FE YES YES YES YES 
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Table 5.2: (continued) 








σu 0.0830 0.0813 0.0788 0.0566 
σe 0.1356 0.1356 0.1354 0.1317 
ρ 0.2726 0.2643 0.2531 0.1562 
χ2-test value for the joint 
significance of the new 
variables  
 31.30*** 66.91*** 433.59*** 
Clustered standard errors at the individual level in parentheses. *** p<0.01, ** p<0.05, * p<0.1. 
Model 1 includes diabetes and sociodemographic characteristics: age, gender, marital and employment 
status, and education. Model 2 adds to the previous model non-related diabetes complications, such as 
chronic obstructive pulmonary disease (COPD), asthma, cancer and gastric ulcer. Model 3 includes the 
above variables and diabetes-related clinical complications, like hypertension and micro (nephropathy and 
retinopathy) and macrovascular diseases (heart attack, stroke and peripheral arterial disease). Model 4 adds 

























Health-related quality of life and diabetes among older people: The key influence of clinical complications and frailty 
 
Page | 155  
 
Comparing people with and without diabetes 
Table 5.3 reports the results from the regression models with the number of diabetes-related 
and non-related chronic diseases as well as the frailty syndrome categories by diabetes status and 
the interactions between the number of clinical complications and frailty.  
Model 1 shows that females have significantly lower HRQoL scores than males in both 
groups, with and without diabetes. The gender effect is larger in people without diabetes (Coeff. 
= -0.103, p<0.01 in people with diabetes; Coeff. = -0.108, p<0.01 in people without diabetes). 
Being married (Coeff. = 0.0247, p<0.1), having low (Coeff. = 0.0316, p<0.01) and medium or 
high education (Coeff. = 0.0526, p<0.01) are positively associated with HRQoL scores only in 
the individuals without diabetes.  
With respect to the health variables, within the sub-population with diabetes, not suffering 
from any of the diabetes-related complications increases HRQoL scores by 0.115 (p<0.01). 
When any of them is present, its effect on quality of life depends on the number of conditions 
suffered: if the person suffers from one single diabetes-related complication, quality of life is 
reduced by 0.0856 (p<0.01); and if two diabetes-related conditions are given, HRQoL scores 
decrease by 0.0921 (p<0.01). Moreover, being pre-frail and frail also reduce quality of life in 
people with diabetes, by 0.0851 (p<0.01) and 0.271 (p<0.01) points, respectively.  
On the other hand, for the group of people without diabetes, having one non-diabetes related 
disease reduces quality of life by 0.0333 (p<0.01) and by 0.0325 points (p<0.1) if the person has 
two non-diabetes related diseases. Moreover, if the individual suffers from two diabetes-related 
complication, quality of life is reduced by 0.0248 (p<0.01). In addition, pre-frailty and frailty also 
reduce quality of life in people without diabetes, by 0.0831 (p<0.01) and 0.262 (p<0.01) points, 
respectively. Differences between both subgroups are statistically significant according to the 
Chow test value (39.61, p<0.01). 
When the interactions between the number of chronic conditions and the frailty syndrome are 
included, some differences, which are significant according to the Chow test (45.43, p<0.05), can 
also be observed between both subsamples. In case of people with diabetes, suffering from two 
diabetes-related complications and pre-frailty reduce quality of life by 0.0199 points (p<0.1) and 
by 0.0841 (p<0.05) points if the individual has four diabetes-related conditions and pre-frailty. 
Being frail and having one diabetes-related disease decreased HRQoL scores by 0.0932 (p<0.1); 
by 0.116 (p<0.05) points if three diabetes-related conditions are additionally suffered to frailty; 
and by 0.187 (p<0.01) points if four conditions. On the contrary, quality of life in people without 
diabetes is reduced when individuals have three non-diabetes-related chronic conditions and are 
pre-frail by 0.192 points (p<0.05).  
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Table 5.3: Results from the random-effects linear regression models with the number 
of chronic conditions and interaction terms regarding Health-related Quality of Life 


















Age -0.0151 -0.000770 -0.0168 -0.000501 
 (0.0256) (0.00967) (0.0256) (0.00977) 
Age2 8.05e-05 -1.07e-05 9.03e-05 -1.24e-05 
 (0.000168) (6.30e-05) (0.000168) (6.36e-05) 
Female -0.103*** -0.108*** -0.103*** -0.108*** 
(0.0184) (0.00804) (0.0184) (0.00807) 
Married -0.0109 0.0247* -0.0155 0.0260* 
 (0.0252) (0.0140) (0.0253) (0.0141) 
Widowed -0.0103 0.0171 -0.00962 0.0184 
 (0.0281) (0.0160) (0.0281) (0.0160) 
Retired -0.0544 0.00246 -0.0516 0.00260 
 (0.0375) (0.0238) (0.0378) (0.0243) 
Homemaker -0.0456 0.00440 -0.0462 0.00466 
 (0.0387) (0.0244) (0.0392) (0.0249) 
Low education  0.0237 0.0316*** 0.0232 0.0318*** 
 (0.0146) (0.00760) (0.0149) (0.00762) 
Medium or high education   0.00266 0.0526*** -0.00134 0.0526*** 
 (0.0219) (0.00900) (0.0220) (0.00904) 
Number of non-diabetes related 
complications 
    
    
0 0.514 - 0.659 - 
 (1.038)  (1.037)  
1 0.504 -0.0333*** 0.651 -0.0315*** 
 (1.036) (0.00910) (1.037) (0.00975) 
2 0.431 -0.0325* 0.637 -0.0305 
 (1.039) (0.0190) (1.039) (0.0231) 
3 0.490 0.0289 0.640 -0.105 
 (1.040) (0.0410) (1.040) (0.0856) 
Number of diabetes-related 
complications  
    
    
0 0.115*** - 0.0496 - 
 (0.0297)  (0.0435)  
1 -0.0856*** -0.0104 0.0255 -0.00302 
 (0.0289) (0.00720) (0.0409) (0.00799) 
2 -0.0921*** -0.0248*** 0.0404 -0.0161 
 (0.0293) (0.00927) (0.0409) (0.00995) 
3 0.0321 -0.0399 0.0150 -0.0220 
 (0.0372) (0.0255) (0.0517) (0.0264) 
4 - 0.00632 - 0.0118 
 (0.00839)  (0.00864) 
Pre-frail -0.0851*** -0.0831*** -0.0712** -0.0670*** 
 (0.0139) (0.00710) (0.0304) (0.0122) 
Frail -0.271*** -0.262*** -0.242*** -0.249*** 
 (0.0295) (0.0169) (0.0345) (0.0359) 
Number of non-diabetes related 
complications # Pre-frail 
    
1   -0.0159 0.00448 
   (0.0315) (0.0207) 
 
Health-related quality of life and diabetes among older people: The key influence of clinical complications and frailty 
 
Page | 157  
 
Table 5.3: (continued) 
VARIABLES 
















2   -0.0320 -0.00998 
   (0.0929) (0.0399) 
3   - -0.192** 
    (0.0943) 
Number of non-diabetes related 
complications # Frail 
    
     
1   0.0399 -0.0480 
   (0.0684) (0.0460) 
2   -0.144 0.0160 
   (0.109) (0.0441) 
3   - 0.134 
    (0.112) 
Number of diabetes-related 
complications # Pre-frail 
    
     
1   0.00597 -0.0212 
   (0.0362) (0.0155) 
2   -0.0199* -0.0308 
   (0.0369) (0.0190) 
3   -0.0812 -0.0387 
   (0.0625) (0.0635) 
4   -0.0841** - 
   (0.0615)  
Number of diabetes-related 
complications # Frail 
    
     
1   -0.0932* 0.00119 
   (0.0544) (0.0393) 
2   -0.0531 0.0291 
   (0.0659) (0.0498) 
3   -0.116** -0.0332 
   (0.0739) (0.0571) 
4   -0.187*** - 
   (0.0499)  
N (Observations) 589 2,344 589 2,344 
N (Individuals) 474 1,753 474 1,753 
Year FE YES YES YES YES 
Chow test value 39.61*** 45.43** 
Clustered standard errors at the individual level in parentheses. *** p<0.01, ** p<0.05, * p<0.1. 
Model 1 includes sociodemographic characteristics (age, gender, marital and employment status, and 
education); the number of non-related diabetes complications (chronic obstructive pulmonary disease 
(COPD), asthma, cancer and gastric ulcer); the number of diabetes-related clinical complications 
(hypertension, nephropathy, retinopathy, heart attack, stroke and peripheral arterial disease) and two 
categories of the frailty syndrome (pre-frailty and frailty). Model 2 adds the interaction between the 
number of non-related and diabetes-related clinical complications and the two categories of the frailty 
syndrome. 
Each of the interactions measures the effect of jointly having the number of chronic diseases (non-related 
and diabetes-related) and frailty categories compared with robust individuals (non-frail). 
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5.4 DISCUSSION 
This analysis aims to assess the main drivers of (higher/lower) quality of life among a 
representative sample of the Spanish population older than 65 years old. The focus is placed on 
one disease, diabetes, and a set of clinical complications, both non-related and diabetes-related 
chronic conditions, plus frailty/pre-frailty status. Moreover, I estimate their joint impact on 
HRQoL scores by diabetes status: with and without diabetes.  
The results confirm that diabetes is a predictor of lower quality of life in older people, 
compared to people with diabetes. Diabetes reduces HRQoL scores in the overall sample by 
0.034 and 0.033 points (within a range variable of 0 – 1) in both scenarios when it is the only 
clinical variable and when only non-related diabetes clinical complications, respectively, are part 
of the regression model. These results support the literature in which a negative association 
between HRQoL scores and diabetes has already been suggested (Schunk et al., 2012; 
Papadopoulos et al., 2007; Rubin and Peyrot, 1999), showing a similar effect of diabetes on 
HRQoL than another study using data from 229 old Greek adults with a mean age of 70 years 
old (Wee et al., 2005). Authors concluded that when diabetes is measured alone, HRQoL was 
reduced by 0.03 points. However, they used a different instrument to evaluate HRQoL, so the 
comparison between studies should be interpreted with caution.  
However, when diabetes-related chronic conditions are included in the regression, diabetes is 
still significant, but its coefficient decreases till 0.016 points. This detrimental effect would show 
that the variables remaining in the model explain part of the effect of diabetes as a risk factor for 
lower quality of life. More remarkably, in case the two categories of the frailty syndrome, being 
pre-frail and frail, enter to the analysis, diabetes is no longer significant. Actually, it is the frailty 
syndrome what reduces quality of life the most. Hence, it could be concluded that the effect of 
diabetes is mediated by the clinical complications, but more importantly by frailty, reducing its 
impact on HRQoL. This is one of the main findings from the current research, as the mediation 
effect of clinical and functional complications on diabetes and healthcare resources has already 
been stated in the literature (Rodriguez-Sanchez et al., 2017), but never on quality of life. 
When I compare the population with diabetes with those without diabetes, the findings show 
that frailty bears the greatest impact in both subsamples and differences between groups are 
significant. Within the sub-population with diabetes, being pre-frail and frail reduce quality of life 
by 0.0851 and 0.271 points (within a range variable of 0 – 1), respectively. When any diabetes-
related disease is present, its effect on quality of life increases with the number of conditions 
suffered: in case of one single diabetes-related complication, quality of life is reduced by 0.0856; 
and if two diabetes-related conditions, HRQoL scores decrease by 0.0921. In case of people 
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without diabetes, the effect of these conditions is still negative, but lower than in the subgroup 
with diabetes. If the individual suffers from two diabetes-related complications, quality of life is 
reduced by 0.0248. Pre-frailty and frailty also reduce quality of life in people without diabetes by 
0.0831 and 0.262 points, respectively. Non-diabetes related complications do reduce quality of 
life in people without diabetes, as having one of them reduces quality of life by 0.0333 points and 
by 0.0325 if the individual suffers from two non-diabetes related conditions. 
Within the determinants of lower HRQoL in people with diabetes, both micro and 
macrovascular diseases, as they have been included in the analysis, can be widely found in the 
literature (Javanbakht et al., 2012; Papadopoulos et al., 2007; Redekop et al., 2002). More 
specifically, Jacobson et al. (2013) found that within people with diabetes, microvascular 
complications reduce HRQoL the most. However, they did not include frailty in their analysis as 
in here. It can be seen from the results that, after frailty, the number of diabetes-related 
conditions lead to greater reductions in quality of life in people with diabetes. The results would 
then confirm the detrimental effect of single and multiple complications on HRQoL scores 
among individuals with diabetes that has already been reported in the literature (Laiteerapong et 
al., 2011; Solli et al., 2010; Morgan et al., 2006). 
When looking at the joint effect of chronic conditions and frailty, in case of people with 
diabetes, having two diabetes-related complications and pre-frailty reduces quality of life by 
0.0199 and by 0.0841 points if the individual has four diabetes-related conditions together with 
pre-frailty. In case of being frail, additionally having one diabetes-related disease decreases 
HRQoL scores by 0.0932; and by 0.187 points if four conditions. Quality of life in people 
without diabetes is reduced when three non-diabetes-related chronic conditions are given jointly 
to pre-frailty by 0.192 points.  
Although no other previous study has been found assessing the joint impact of chronic 
conditions on HRQoL in people with and without diabetes, the literature has already established 
that, for example, the effect of micro and macrovascular diseases in individuals with diabetes 
increases when these are suffered together (Morgan et al., 2006; Redekop et al., 2002), but the 
combination of these conditions with the frailty syndrome, as it is done in this analysis, has not 
been assessed before.  
Some limitations should also be mentioned. Although I have been able to run a longitudinal 
analysis with the current data, only two waves are available. So, little variation could be expected 
within individuals between time periods. A longer follow-up period would allow for a more in-
depth knowledge of potential changes in HRQoL when survey respondents are newly-diagnosed 
of any of the chronic conditions included in the analysis and the frailty syndrome. Further 
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analysis could include more survey-years data. Moreover, in order to construct the HRQoL 
values, the EQ-5D-3L questionnaire is used and its corresponding tariffs for the Spanish 
population. However, the discriminatory power of the 3 level version has been a matter of debate 
in the literature (Janssen et al., 2012), being the 5-level version more preferred. In the present 
cohort, only the 3-level version has been provided to survey respondents. Finally, the self-
reported feature of the data, especially about health conditions, could bias the results, since it 
could lead to recall bias and, hence, the results here could over or underestimate the true impact 
of diabetes. Nevertheless, this possibility looks unlikely as the data comes from two different 
waves of the study, showing a strong consistency among them. Furthermore, the self-reported 
information was checked with the drugs use and the medical records, so it is not self-reported 
information only.  
These figures could provide a valuable contribution to the existing literature since it is the first 
analysis looking at the burden of diabetes on quality of life in older people, compared to people 
without diabetes, analyzing the impact of a list of chronic conditions by subgroup using a 
representative wide sample of the Spanish elderly population. It is also pioneer in including the 
frailty syndrome as one of the factors involved in predicting HRQoL scores in both sub-
populations, with and without diabetes. It is noteworthy that this factor not only helps to explain 
part of the effect of diabetes on quality of life, but it is the main one, emerging as the main 
mediator of the negative burden of diabetes on the outcome. Moreover, I also contribute to the 
literature by measuring the joint impact of chronic conditions and frailty on HRQoL in people 
with and without diabetes. This input would be of special relevance given the raise in diabetes 
prevalence (O’Shea et al., 2013) and its associated high risk of multimorbidity in people with 
diabetes (OECD/EU, 2016) and development of disability (Sinclair et al., 2015; Murray and 
López, 2013; Murray et al., 2012). My results could be of great utility for policymakers when 
informing diabetes prevention and management programs. Given that the loss in HRQoL at 
individual level varies by the number of chronic conditions suffered and, especially, by frailty 
status, these should be then the focus in this particular aged group. Running appropriate 
preventive programs for the onset of diabetes and its complications, especially frailty, would help 
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APPENDIX CHAPTER 5 
Table 5.A1: Health statistics comparing Spanish population and the Toledo Study on Healthy Ageing 
sample 
 








Diabetes Stroke Cancer 
Age 65 – 74 44.4 1.5 4.4 7.8 17.6 1.2 3.0 
Age 75 – 84 49.4 2.5 4.9 11.8 21.9 2.2 3.4 
Age 85+ 51.1 3.3 7.1 14.1 18.3 5.3 4.0 
Total 48.3 2.5 5.5 11.2 19.2 2.9 3.4 
 








Diabetes Stroke Cancer 
Age 65 – 74 56.6 3.15 4.5 3.8 17.9 1.9 7.9 
Age 75 – 84 60.6 6.32 3.8 4.7 22.7 2.8 6.9 
Age 85+ 64.6 8.59 4.5 5.6 17.2 4.5 2.5 
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Table 5.A2: List of variables included in the analysis 
Variable Coding 
EQ-5D Time Trade Off 
(TTO) score 
HRQoL score, which goes from 0 (death) to 1 (best possible health 
status), although negative values are possible, signaling health states 
worse than death  
Age  Age of respondent 
Female 1: female; 0: male 
Marital status 
 
Married 1: married; 0: otheriwse 
Widowed 1: widowed; 0: otherwise 
Never married 1: never married; 0: otherwise  
Employment status 
 
Retired 1: retired; 0: otheriwse 
Homemaker 1: homemaker; 0: otherwise 




1: respondent had not completed primary or first stage of basic 
education; 0: otheriwse 
Low education 
1: respondent had completed primary education or first stage of 
basic education and lower secondary or second stage of basic 
education; 0: otherwise  
Medium or high education 
1: respondent had completed (upper) secondary education and post-
secondary non-tertiary education or respondent had completed first 
and second stage of tertiary education; 0: otherwise  
Chronic lung disease 
1: respondent has ever been diagnosed of chronic obstructive 
pulmonary disease; 0: otherwise 
Asthma 1: respondent has ever been diagnosed of asthma; 0: otherwise 
Cancer 
1: respondent has ever been diagnosed of malignant tumor or 
cancer; 0: otherwise 
Ulcer 1: respondent has ever been diagnosed of gastric ulcer; 0: otherwise 
Number of non-diabetes-
related conditions 
Number of non-diabetes-related conditions suffered from the ones 
included in the analysis (chronic lung disease, asthma, cancer and 
gastric ulcer). Values range from 0 to 4 
Hypertension 1: respondent has ever been diagnosed of hypertension; 0: otherwise 
Microvascular complications  
Nephropathy 1: respondent has ever been diagnosed of nephropathy; 0: otherwise 
Retinopathy 1: respondent has ever been diagnosed of retinopathy; 0: otherwise 
Macrovascular complications  
Heart attack 1: respondent has ever had a heart attack; 0: otherwise 
Stroke 1: respondent has ever had a stroke; 0: otherwise 
Peripheral vascular disease 
1: respondent has ever been diagnosed of peripheral vascular disease; 
0: otherwise 
Both micro and 
macrovascular disease 
1: respondent has ever been diagnosed of both micro and 
macrovascular complications included in the analysis; 0: otherwise 
Number of diabetes-related 
conditions 
Number of diabetes-related conditions suffered from the ones 
included in the analysis (hypertension, nephropathy, retinopathy, 
heart attack, stroke and peripheral vascular disease). Values range 
from 0 to 6 
Frailty syndrome  
Non-frail 
1: respondent does not meet any of the Fried criteria of frailty; 0: 
otherwise 
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Table 5.A2: (continued) 
Variables Coding 
Pre-frail 
1: respondent meets 1 to 2 of the Fried criteria of frailty; 0: 
otherwise 
Frail 
1: respondent meets more than 2 of the Fried criteria of frailty; 0: 
otherwise 
Wave 1 (years 2006/09) 1: data was collected from wave 1; 0: otherwise 
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SAMENVATTING IN NEDERLANDS 
 
Alhoewel het al is vastgesteld dat de economische last van diabetes voor de nationale 
gezondheidszorg en overheidsuitgaven vrij groot is (OECD/EU, 2016; Alva et al., 2015; ADA, 
2013), zijn er, voor zover ik weet, geen relevante en uitgebreide studies over de bredere 
economische impact van diabetes onder oudere volwassenen, waarbij de speciale aandacht 
schenken aan de rol van functionele status. De huidige uitdaging omarmt methodologische 
kwesties aangaande het analyseren van gezondheidskosten (Wu et al, 2012), of het gewicht van 
functionele beperkingen ten opzichte van co morbiditeit en complicaties in het bepalen van de 
kosten.  
Het scenario voor de volgende decennia laat een toename in de kosten geassocieerd met het 
beheer van diabetici door de vergrijzing van de bevolking  en de hogere kosten per inwoner 
onder oudere volwassenen (Waldeyer et al, 2013). Deze toename in de kosten vormt een nieuwe 
uitdaging voor de Health Systems dat modellen zou moeten uitvoeren die zijn toegespitst op de 
behoeften van deze bevolkingsgroep (Sinclair et al, 2011). 
Dit proefschrift streeft ernaar om bij te dragen aan de bestaande literatuur door een nieuw en 
breder inzicht op de lasten van diabetes onder de oudere bevolking aan te dragen door niet alleen 
het gebruik van en de kosten van de traditionele gezondheidszorgmiddelen voor diabetes onder 
oudere volwassenen (de kosten van zorg voor mensen met diabetes) mee te nemen, maar ook 
andere, minder vaak geëvalueerde, kosten, zoals uitgaven voor een verzorgingstehuis, en de 
impact van diabetes op de levenskwaliteit en productieve activiteiten. Tevens bouw ik voort op 
de bestaande literatuur door in mijn analyse niet alleen klinische complicaties die mogelijk 
ontstaan door diabetes mee te nemen, maar ook functionele beperkingen. Diabetes heeft een 
toenemend negatief effect op de functionele autonomie naarmate mensen ouder worden (Kalyani 
et al., 2010; Wong et al., 2013), en het is de achtste oorzaak van DALYs in westerse 
maatschappijen (Murray en López, 2013). Bovendien gebruik ik een verscheidenheid aan datasets 
in dit proefschrift: administratief (Vektis en ZODIAC data in Hoofdstuk 2) en enquête datasets 
(the Survey of Health, Ageing and Retirement in Europe, SHARE, in Hoofdstukken 3 en 4; en 
de Toledo Study on Healthy Ageing, TSHA, in Hoofdstuk 5), waardoor ik in staat ben om 
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verschillende informatiebronnen (vorderingen, klinische en zelf-gerapporteerde data) over 
individuen die leven in verschillende institutionele instellingen te onderzoeken. 
In de volgende sectie beschrijf ik de hoofdstukken die onderdeel zijn van mijn proefschrift en 
de specifieke doelstellingen die ik wil analyseren.  
 
SAMENVATTING EN BELANGRIJKSTE BEVINDINGEN 
In Hoofdstuk 2 gebruik ik Nederlandse vorderingen data (Vektis), gecombineerd met 
Nederlandse huisartsenregister data (ZODIAC) om de associatie tussen gemiddelde glucose 
controle en zorgkosten voor mensen met diabetes, maar niet noodzakelijk dankzij diabetes, te 
onderzoeken. Bovendien onderzoek ik de cohorteffecten van diabetes diagnoses en 
behandelingsmodaliteit. Ik maak een onderscheiding tussen het type kosten (totale zorg, huisarts, 
medicijnen, ziekenhuis en specialist, en kosten voor de apparaten). De data is samengesteld uit 
deze twee gekoppelde datasets, waardoor ik in staat ben om over een vierjarige periode (2008 – 
2011) administratieve data te gebruiken van alle medische behandelingen die vergoed worden 
door Nederlandse verzekeringsmaatschappijen binnen het wettelijk verplichte verzekeringspakket 
en klinische metingen.  
De resultaten laten zien dat gemiddelde glucose controle significant geassocieerd wordt met 
hogere zorgkosten voor mensen met diabetes, alhoewel het effect op de kosten gemedieerd 
worden door diabetes behandelingsmodaliteit. Wanneer ik orale medicatie en insuline als 
diabetesbehandelingsvariabelen toevoeg, wordt een 1% hogere HbA1c alleen significant 
geassocieerd met een verhoging van de totale zorgkosten, als de persoon niet behandeld wordt, 
noch met insuline, noch met orale medicatie; er wordt geen significante associatie tussen HbA1c  
en hogere zorgkosten gerapporteerd wanneer de persoon orale medicatie tot zich neemt of 
insuline gebruikt. Echter, insuline wordt significant geassocieerd met hogere zorgkosten, 
ongeacht de covariaten in de analyse. Een andere belangrijke bevinding is dat de positieve 
effecten van de diabetesduur op de zorgkosten toenemen wanneer ik controleer voor cohort 
effecten van het jaar van aanvang van diabetes. Zonder toevoeging van de cohort effecten nemen 
de totale kosten toe voor een diabetesduur tot 25 jaar en nemen ze daarna af, maar wanneer ik de 
jaar van aanvang categorieën meeneem, is de drempelwaarde vanaf waar zorgkosten beginnen af 
te nemen een diabetesduur van 35 jaar. McBrien et al. (2012) concludeerden dat zorgkosten voor 
mensen met diabetes altijd toenemen met de tijd sinds de diagnose na de eerste vijf jaar, net zoals 
ik vind, maar ik vind ook dat de stijging van de kosten een afnemend effect hebben nadat mensen 
35 jaar met diabetes geleefd hebben, iets wat eerder nog niet is gerapporteerd in de literatuur. 
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Tenslotte, corrigeren voor behandelingsmodaliteit, diabetesduur en jaar van aanvang cohorten, 
heeft geleid tot een ander innovatieve bevinding: leeftijd is niet significant gerelateerd met 
zorgkosten, terwijl het wel is gelinkt aan stijgende zorgkosten (Trogdon en Hylands, 2008; 
Nichols en Brown, 2002). Niet alleen kijk ik naar de impact van gemiddelde glucose controle op 
zorgkosten voor mensen met diabetes, maar ook naar behandelingsmodaliteit, diabetesduur, en 
jaar van aanvang effecten, welke niet eerder gezamenlijk zijn beoordeeld. Het uitsluiten van deze 
factoren kan leiden tot vertekende schattingen.  
Hoofdstuk 3 richt zich op de rol van diabetes en een lijst met klinische en functionele 
complicaties op de waarschijnlijkheid van opname in een verpleeghuis voor mensen ouder dan 50 
jaar, waarbij gebruik wordt gemaakt van data van de Survey of Health, Ageing and Retirement in 
Europe (SHARE). Ik gebruik data van drie verschillende golven: golf 1 (2004), golf 2 (2006-07) 
en golf 4 (2010); en van twaalf landen (België, Denemarken, Duitsland, Frankrijk, Griekenland, 
Italië, Nederland, Oostenrijk, Spanje, Tsjechië, Zweden en Zwitserland). Bovendien streef ik 
ernaar om te analyseren of er verschillen zijn tussen Europese landen en andere subgroepen die 
onderdeel zijn van de analyse (naar leeftijd of geslacht en naar verblijfsduur) in de relatie tussen 
plaatsing in een verpleeghuis en de belangrijkste variabelen waarin we geïnteresseerd zijn. Nadat 
ik deze resultaten heb verkregen, gebruik ik de schattingen om de uitgaven van verpleeghuizen te 
bepalen die te wijten zijn aan diabetes en de complicaties ervan in Europa en om mogelijke 
verschillen tussen Europese landen te onderzoeken.  
Mijn resultaten bevestigen dat diabetes positief en significant geassocieerd wordt met plaatsing 
in een verpleeghuis. Diabetes verhoogt het risico op institutionalisering, hoewel het effect ervan 
afneemt wanneer diabetes gerelateerde klinische complicaties worden meegenomen en met name 
wanneer functionele status wordt geïntroduceerd. Het effect van diabetes wordt zodoende 
gemedieerd door klinische en functionele complicaties, waardoor de impact van diabetes op de 
kans op opname in een verpleeghuis wordt verminderd. Bovendien is het effect van functionele 
beperkingen op het risico van institutionalisering leeftijdsafhankelijk, waardoor het risico op 
plaatsing in een verpleeghuis groter wordt naarmate mensen ouder worden. De totale gemiddelde 
kosten van verpleeghuizen bedroegen $12.66 per hoofd van de bevolking over alle landen, wat 
neerkomt op de verschillende gradaties van functionele beperkingen 78%.  
 Hoewel in de totale steekproef de interactie tussen diabetes en complicaties niet significant is, 
worden sommige verschillen tussen landen wel gemeld. In België, Griekenland en Frankrijk zijn 
diabetes en een beroerte significant gerelateerd aan het risico van institutionalisering, terwijl 
diabetes samen met functionele beperkingen de kans verhoogt op toelating tot een verpleeghuis 
in Spanje. Nederland is het land met de hoogste uitgaven voor verpleeghuizen voor mensen met 
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diabetes, waarvan 25% van de uitgaven te wijten zijn aan gematigde functionele beperkingen. Het 
substantiële karakter van functionele beperkingen wordt ook bevestigd wanneer we kijken tussen 
landen, en het vertegenwoordigt het grootste deel van de kosten, voornamelijk in Duitsland, 
Nederland en Spanje, meestal gevolgd door beroertes. Bovendien, wanneer de kosten van 
institutionalisering worden geïnterpreteerd als percentage van het Bruto Binnenlands Product 
(BBP) per hoofd van de bevolking, is Spanje het land waar de kosten die strikt te wijten zijn aan 
diabetes complicaties de grootste waarde vertegenwoordigen als percentage van het BBP per 
hoofd van de bevolking, waarvan functionele beperkingen de grootste last draagt. De resultaten 
dragen bij aan de literatuur door aan te tonen dan functionele beperkingen niet alleen een deel 
van de kosten helpen te verklaren, maar ook door aan te tonen dat ze de belangrijkste oorzaak 
zijn van hogere kosten voor verpleeghuizen. Bovendien is het de eerste tussen-landen-analyse die 
de last van diabetes op het gebruik van en kosten voor verpleeghuizen voor oudere Europeanen 
bekijkt.  
Hoofdstuk 4 richt zich op de relatie tussen diabetes en twee maten van productieve 
activiteiten, het bang zijn dat hun werk beperkt wordt door hun gezondheid voor oudere mensen 
die nog in de werkende leeftijd zijn (50 tot 65 jaar oud), en het zijn van een formele vrijwilliger 
voor mensen van 65 en ouder die al gepensioneerd zijn. Voor deze analyse gebruik ik data van 
golven 2, 4 en 5, wat overeenkomt met respectievelijk de jaren 2006/07, 2010 en 2013, en elf 
Europese landen (België, Denemarken, Duitsland, Frankrijk, Italië, Nederland, Oostenrijk, 
Spanje, Tsjechië, Zweden en Zwitserland) van SHARE. Het observeren van trends in deze 
periode zou meer licht kunnen werpen op de vraag hoe relevant gezondheid is met betrekking tot 
de productiviteit in periodes van economische onzekerheid. Bovendien controleer ik voor 
klinische en functionele complicaties, omdat het effect van diabetes in het algemeen gemedieerd 
wordt door comorbiditeiten.  
Ik laat zien dat diabetes geassocieerd wordt met productieve activiteiten bij oudere 
volwassenen, zowel betaald als onbetaald. Diabetes verhoogt de kans dat mensen tussen 50 en 65 
jaar oud rapporteren dat ze bang zijn dat hun werk beperkt wordt door hun gezondheid, wat een 
positieve relatie suggereert tussen diabetes en de angst dat hun werk beperkt wordt door hun 
gezondheid voor mensen die nog in de werkende leeftijd zijn. De angst dat gezondheid een 
beperking voor het werk kan zijn neemt toe in de jaren na de crisis, 2010 en 2013, zelfs na het 
meenemen van klinische complicaties. Dit zou de toegenomen onzekerheid over de 
werkgelegenheid na de economische crisis kunnen reflecteren. Bovendien neemt de kans dat 
mensen bang zijn dat hun gezondheid het werk beperkt significant toe met de interactie tussen 
diabetes en het jaar 2010, maar geen er zijn geen significante effecten gevonden voor de interactie 
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met het jaar 2013. Dit resultaat kan worden gedreven door de combinatie van het verstorende 
effect van diabetes en het feit dat de economische crisis sterker toesloeg in de eerste jaren van de 
crisis, wat leidt tot een grotere angst voor individuele prestaties op het werk die lijden onder de 
gezondheid. Met betrekking tot vrijwilligerswerk bij mensen ouder dan 65 jaar, vermindert 
diabetes de kans op het doen van liefdadigheidswerk in vergelijking met mensen zonder diabetes, 
evenals de frequentie van het uitvoeren van dergelijke activiteiten. Het jaar 2010 verhoogt de kans 
op het doen van liefdadigheid in grotere mate dan het geval is in het jaar 2013. De beweegreden 
voor een dergelijke toename kan een grotere solidariteit zijn of een grotere behoefte aan 
liefdadigheidswerk in plaats van de individuele bereidheid om productief te zijn. De interacties 
tussen het hebben van diabetes en de jaren 2010 en 2013 zijn geen significante voorspellers van 
het doen van vrijwilligerswerk. Bovendien worden er verschillen tussen landen waargenomen. 
Alleen in Denemarken wordt een positief, maar insignificant, effect gerapporteerd in de associatie 
met de kans op de angst voor dat het werk lijdt onder de gezondheid, terwijl een significant en 
negatieve relatie wordt aangetoond tussen Italië, Oostenrijk, Spanje, Tsjechië en Zweden en het 
doen van vrijwilligerswerk. De resultaten zouden op verschillende manieren kunnen bijdragen 
aan de bestaande literatuur. Ten eerste door het opvullen van het hiaat in de literatuur over 
onbetaalde activiteiten van oudere mensen, daar veel is geschreven over productiviteitsverlies en 
de lonen die mensen met diabetes ontvangen, maar er is weinig bekend over de relatie met het 
doen van vrijwilligerswerk. Ten tweede heb ik bovendien gecontroleerd voor klinische 
complicaties en mobiliteitsproblemen, en niet alleen voor diabetes als de belangrijkste klinische 
factor. Ten slotte heb ik ook de invloed van onzekere economische periodes beoordeeld, wat nog 
niet eerder is gedaan, suggererend dat er een effect kan zijn van onzekere economische situaties 
op zowel subjectieve (angst dat de gezondheid het werk beperkt) en objectieve (deelname aan 
vrijwilligerswerk) productiviteitsmaten.  
In Hoofdstuk 5 is het doel om voort te bouwen op de bestaande literatuur over gezondheids-
gerelateerde kwaliteit van leven (HRQoL/GKvL) en diabetes door de relatie tussen sommige 
factoren te analyseren die de verschillen in HRQoL tussen oudere mensen met en zonder 
diabetes kunnen bepalen. We voegen niet alleen klinische complicaties toe, maar ook het 
kwetsbaarheidssymdroom, dat verslechtert naarmate de leeftijd toeneemt en leidt tot een hoger 
risico op invaliditeit, ziekenhuisopname en sterfte, als een maat voor functionele beperkingen. In 
de analyse maken we gebruik van data uit de eerste twee golven, wat overeenkomt met de jaren 
2006/07 (golf 1) en 2011-2013 (golf 2) van de Toledo Study on Healthy Ageing (TSHA). 
Bovendien zal de associatie tussen kwetsbaarheid en het aantal comorbiditeiten gezamenlijk 
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worden geanalyseerd, waarbij ik onderscheid maak tussen diabetesstatus om de bestaande 
verschillen tussen mensen met en zonder diabetes te onderzoeken.  
De resultaten bevestigen dat diabetes wordt geassocieerd met een lagere kwaliteit van leven bij 
oudere mensen in vergelijking met mensen zonder diabetes, hoewel het effect afneemt wanneer 
diabetes-gerelateerde klinische complicaties worden meegenomen. Maar als de verschillende 
categorieën van het kwetsbaarheidssyndroom (zijnde pre-zwak en zwak) deel uitmaken van de 
analyse, dan wordt diabetes niet langer significant geassocieerd met kwaliteit van leven. De last 
van diabetes op de kwaliteit van leven bij oudere mensen wordt dus gemedieerd door klinische 
complicaties, maar nog belangrijker, door kwetsbaarheid. Wanneer ik de bevolking met diabetes 
vergelijk met diegenen zonder diabetes, heeft kwetsbaarheid de grootste en een meer negatieve 
impact op de kwaliteit van leven in beide deelsteekproeven. De verschillen tussen beide groepen 
zijn significant, waarbij de voorwaarden die worden meegenomen in de analyse een groter 
negatief effect hebben op de kwaliteit van leven van mensen met diabetes dan van diegenen 
zonder diabetes. De resultaten tonen aan dat, na kwetsbaarheid, het aantal diabetes-gerelateerde 
aandoeningen leiden tot een grotere afname van de kwaliteit van leven van mensen met diabetes, 
wat de nadelige gevolgen van enkele en meerdere complicaties op de kwaliteit van leven 
bevestigt. Wanneer we kijken naar het gezamenlijke effect van chronische aandoeningen en 
kwetsbaarheid, in het geval van mensen met diabetes en die kwetsbaar zijn, heeft het hebben van 
vier diabetes-gerelateerde aandoeningen de meeste negatieve invloed op de kwaliteit van leven. 
De kwaliteit van leven van mensen zonder diabetes neemt het meest af wanneer drie niet-
diabetes-gerelateerde chronische aandoeningen.  Deze cijfers kunnen een waardevolle bijdrage 
leveren aan de bestaande literatuur, aangezien het de eerste analyse is die kijkt naar de last van 
diabetes op de kwaliteit van leven van oude mensen, waarbij de impact van een lijst van 
chronische aandoeningen wordt geanalyseerd, waarbij bovendien mensen met en zonder diabetes 
worden vergeleken. Het is ook de eerste analyse dat het kwetsbaarheidssyndroom meeneemt als 
één van de factoren die betrokken zijn bij het voorspellen van HRQoL scores, wat naar voren 
komt als de belangrijkste mediator van de negatieve last van diabetes op de uitkomst.  
  
 
 
 
 
 
  
 
 
 
 
 
 
